<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput xmlns:ns2="local" id="10388"><DrugName>cetuximab</DrugName><DrugNamesKey><Name id="42748858">Erbitux</Name><Name id="42748857">cetuximab</Name></DrugNamesKey><DrugSynonyms><Name><Value>C225</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>cetuximab</Value><Types><Type>INN</Type></Types></Name><Name><Value>Erbitux</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>IMC-C 22</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>IMC-C225</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>EMR-62202</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>EMD-271786</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>MAb225, ImClone</Value></Name><Name><Value>NSC-714692</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>LY-2939777</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>BMS-564717</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="17193">Imclone LLC</CompanyOriginator><CompaniesPrimary><Company id="19862">Merck Serono SA</Company><Company id="17193">Imclone LLC</Company></CompaniesPrimary><CompaniesSecondary><Company id="1062214">Inven2</Company><Company id="15065">Bristol-Myers Squibb Co</Company><Company id="18101">Merck KGaA</Company></CompaniesSecondary><CrossReferences><SourceEntity id="10388" type="Drug"><TargetEntity id="230562" type="siDrug">Cetuximab</TargetEntity></SourceEntity><SourceEntity id="1062214" type="Company"><TargetEntity id="5035553633" type="organizationId">Inven2 AS</TargetEntity></SourceEntity><SourceEntity id="15065" type="Company"><TargetEntity id="4295903619" type="organizationId">Bristol-Myers Squibb Co</TargetEntity></SourceEntity><SourceEntity id="17193" type="Company"><TargetEntity id="4295906769" type="organizationId">ImClone LLC</TargetEntity></SourceEntity><SourceEntity id="18101" type="Company"><TargetEntity id="4295869098" type="organizationId">Merck KGaA</TargetEntity></SourceEntity><SourceEntity id="19862" type="Company"><TargetEntity id="4295890498" type="organizationId">Merck Serono SA</TargetEntity></SourceEntity><SourceEntity id="1108" type="ciIndication"><TargetEntity id="10018338" type="MEDDRA"></TargetEntity><TargetEntity id="D005910" type="MeSH"></TargetEntity><TargetEntity id="-1503483999" type="omicsDisease"></TargetEntity><TargetEntity id="680" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1240" type="ciIndication"><TargetEntity id="C45" type="ICD10"></TargetEntity><TargetEntity id="163" type="ICD9"></TargetEntity><TargetEntity id="10027406" type="MEDDRA"></TargetEntity><TargetEntity id="D008654" type="MeSH"></TargetEntity><TargetEntity id="50251" type="ORPHANET"></TargetEntity><TargetEntity id="-666440137" type="omicsDisease"></TargetEntity><TargetEntity id="2015" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="127" type="ciIndication"><TargetEntity id="C16" type="ICD10"></TargetEntity><TargetEntity id="151" type="ICD9"></TargetEntity><TargetEntity id="10017758" type="MEDDRA"></TargetEntity><TargetEntity id="D013274" type="MeSH"></TargetEntity><TargetEntity id="-2031094615" type="omicsDisease"></TargetEntity><TargetEntity id="646" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1295" type="ciIndication"><TargetEntity id="10029223" type="MEDDRA"></TargetEntity><TargetEntity id="D009437" type="MeSH"></TargetEntity><TargetEntity id="-533466818" type="omicsDisease"></TargetEntity><TargetEntity id="14" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1516" type="ciIndication"><TargetEntity id="10055111" type="MEDDRA"></TargetEntity><TargetEntity id="D001661" type="MeSH"></TargetEntity><TargetEntity id="-1032913655" type="omicsDisease"></TargetEntity><TargetEntity id="577" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1705" type="ciIndication"><TargetEntity id="10014733" type="MEDDRA"></TargetEntity><TargetEntity id="D016889" type="MeSH"></TargetEntity><TargetEntity id="-49801714" type="omicsDisease"></TargetEntity><TargetEntity id="597" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1767" type="ciIndication"><TargetEntity id="D006528" type="MeSH"></TargetEntity><TargetEntity id="88673" type="ORPHANET"></TargetEntity><TargetEntity id="-1116061312" type="omicsDisease"></TargetEntity><TargetEntity id="1973" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="194" type="ciIndication"><TargetEntity id="10039491" type="MEDDRA"></TargetEntity><TargetEntity id="D012509" type="MeSH"></TargetEntity><TargetEntity id="-172901782" type="omicsDisease"></TargetEntity><TargetEntity id="714" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2193" type="ciIndication"><TargetEntity id="C21" type="ICD10"></TargetEntity><TargetEntity id="230.5" type="ICD9"></TargetEntity><TargetEntity id="10061424" type="MEDDRA"></TargetEntity><TargetEntity id="D001005" type="MeSH"></TargetEntity><TargetEntity id="-1699935608" type="omicsDisease"></TargetEntity><TargetEntity id="1335" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2380" type="ciIndication"><TargetEntity id="C67" type="ICD10"></TargetEntity><TargetEntity id="188.9" type="ICD9"></TargetEntity><TargetEntity id="10005003" type="MEDDRA"></TargetEntity><TargetEntity id="-2101107804" type="omicsDisease"></TargetEntity><TargetEntity id="578" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2939" type="ciIndication"><TargetEntity id="10043670" type="MEDDRA"></TargetEntity><TargetEntity id="D013945" type="MeSH"></TargetEntity><TargetEntity id="99867" type="ORPHANET"></TargetEntity><TargetEntity id="-2144850506" type="omicsDisease"></TargetEntity><TargetEntity id="2566" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3246" type="ciIndication"><TargetEntity id="3031" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3658" type="ciIndication"><TargetEntity id="10052358" type="MEDDRA"></TargetEntity><TargetEntity id="595" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3665" type="ciIndication"><TargetEntity id="10059515" type="MEDDRA"></TargetEntity><TargetEntity id="613" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3666" type="ciIndication"><TargetEntity id="10063916" type="MEDDRA"></TargetEntity><TargetEntity id="647" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3669" type="ciIndication"><TargetEntity id="631" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3673" type="ciIndication"><TargetEntity id="5572" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="4250" type="ciIndication"><TargetEntity id="10050513" type="MEDDRA"></TargetEntity><TargetEntity id="3229" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="427" type="ciIndication"><TargetEntity id="C53" type="ICD10"></TargetEntity><TargetEntity id="10008342" type="MEDDRA"></TargetEntity><TargetEntity id="D002583" type="MeSH"></TargetEntity><TargetEntity id="-837567682" type="omicsDisease"></TargetEntity><TargetEntity id="590" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="49" type="ciIndication"><TargetEntity id="C50" type="ICD10"></TargetEntity><TargetEntity id="10006279" type="MEDDRA"></TargetEntity><TargetEntity id="D001943" type="MeSH"></TargetEntity><TargetEntity id="-436099203" type="omicsDisease"></TargetEntity><TargetEntity id="588" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="623" type="ciIndication"><TargetEntity id="C76.0" type="ICD10"></TargetEntity><TargetEntity id="10067821" type="MEDDRA"></TargetEntity><TargetEntity id="D006258" type="MeSH"></TargetEntity><TargetEntity id="-545944758" type="omicsDisease"></TargetEntity><TargetEntity id="1148" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="799" type="ciIndication"><TargetEntity id="C56" type="ICD10"></TargetEntity><TargetEntity id="10033128" type="MEDDRA"></TargetEntity><TargetEntity id="D010051" type="MeSH"></TargetEntity><TargetEntity id="-1370909262" type="omicsDisease"></TargetEntity><TargetEntity id="626" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="989" type="ciIndication"><TargetEntity id="10061451" type="MEDDRA"></TargetEntity><TargetEntity id="D015179" type="MeSH"></TargetEntity><TargetEntity id="-1280257855" type="omicsDisease"></TargetEntity><TargetEntity id="594" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="740" type="Action"><TargetEntity id="4345" type="Mechanism">EGFR (Thr790Met Mutant) Inhibitors</TargetEntity><TargetEntity id="4344" type="Mechanism">EGFR (HER1; erbB1) (Mutant) Inhibitors</TargetEntity><TargetEntity id="1071" type="Mechanism">EGFR (HER1; erbB1) Inhibitors</TargetEntity><TargetEntity id="1613" type="Mechanism">Anti-EGFR</TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity><SourceEntity id="PTGT-00682" type="ciTarget"><TargetEntity id="201985772919563" type="siTarget">Epidermal growth factor receptor</TargetEntity><TargetEntity id="233" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Metastatic colorectal cancer - Switzerland - Dec-2003</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="5">Accelerated Approval</RegulatoryDesignation><RegulatoryDesignation id="3">Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="2193">Anal tumor</Indication><Indication id="2939">Thymoma</Indication><Indication id="3658">Metastatic colorectal cancer</Indication><Indication id="3673">Metastatic head and neck cancer</Indication><Indication id="623">Head and neck tumor</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1108">Glioma</Indication><Indication id="1240">Mesothelioma</Indication><Indication id="127">Stomach tumor</Indication><Indication id="1295">Neuropathic pain</Indication><Indication id="1516">Biliary cancer</Indication><Indication id="1705">Endometrioid carcinoma</Indication><Indication id="1767">Hepatocellular carcinoma</Indication><Indication id="194">Sarcoma</Indication><Indication id="2380">Bladder cancer</Indication><Indication id="3246">Hormone refractory prostate cancer</Indication><Indication id="3665">Metastatic non small cell lung cancer</Indication><Indication id="3666">Metastatic stomach cancer</Indication><Indication id="3669">Metastatic pancreas cancer</Indication><Indication id="4250">Metastatic renal cell carcinoma</Indication><Indication id="427">Uterine cervix tumor</Indication><Indication id="49">Breast tumor</Indication><Indication id="799">Ovary tumor</Indication><Indication id="989">Colorectal tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="740">Epidermal growth factor receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="2946">Analgesic</Action><Action id="55685">Anticancer monoclonal antibody</Action><Action id="62255">Anticancer protein kinase inhibitor</Action><Action id="7293">Synergist</Action></ActionsSecondary><Technologies><Technology id="166">Chimeric monoclonal antibody</Technology><Technology id="167">Monoclonal antibody murine</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="740">Infusion</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="85">Protein recombinant</Technology></Technologies><EphmraCodes><Ephmra><Code>N2</Code><Name>ANALGESICS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-06-11T16:36:52.000Z</LastModificationDate><ChangeDateLast>2019-07-01T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Cetuximab (Erbitux) is a human-murine chimeric anti-EGFR mAb, developed and launched by &lt;ulink linkID="17193" linkType="Company"&gt;ImClone Systems&lt;/ulink&gt; (a subsidiary of &lt;ulink linkID="17810" linkType="Company"&gt;Eli Lilly&lt;/ulink&gt;) in collaboration with   &lt;ulink linkID="18101" linkType="Company"&gt;Merck KGaA&lt;/ulink&gt; (the parent company of &lt;ulink linkID="18101" linkType="Company"&gt;&lt;/ulink&gt;&lt;ulink linkID="19862" linkType="Company"&gt;Merck Serono&lt;/ulink&gt;) and former licensee  &lt;ulink linkID="15065" linkType="Company"&gt;Bristol-Myers Squibb&lt;/ulink&gt; (BMS). The product is indicated in the US: for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy, recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with 5-FU, and recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing after platinum-based therapy; and for the treatment of K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer (mCRC)as determined by FDA-approved tests, in combination with FOLFIRI for first-line treatment, in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy, and as a single agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan [&lt;ulink linkID="1663406" linkType="Reference"&gt;1663406&lt;/ulink&gt;]. In the EU, the drug is indicated for the treatment of patients with EGFR-expressing, RAS wild-type mCRC in combination with irinotecan-based chemotherapy, in first-line in combination with FOLFOX, and as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan, and for the treatment of patients with SCCHN in combination with radiation therapy for locally advanced disease, and in combination with platinum-based chemotherapy for recurrent and/or metastatic disease [&lt;ulink linkID="1663422" linkType="Reference"&gt;1663422&lt;/ulink&gt;]. In Japan the drug is indicated for  unresectable advanced or recurrent EGFR-positivecolorectal cancer, and for head and neck cancer [&lt;ulink linkID="1663441" linkType="Reference"&gt;1663441&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2004, cetuximab, in combination with &lt;ulink linkID="2871" linkType="Drug"&gt;irinotecan&lt;/ulink&gt;, had been launched in all EU countries that did not require specific reimbursement negotiations prior to launch, including the UK, for the treatment of EGFR-expressing irinotecan-refractory mCRC [&lt;ulink linkID="552368" linkType="Reference"&gt;552368&lt;/ulink&gt;], [&lt;ulink linkID="567293" linkType="Reference"&gt;567293&lt;/ulink&gt;]. By March 2005, cetuximab had been launched in the US for second-line mCRC [&lt;ulink linkID="591298" linkType="Reference"&gt;591298&lt;/ulink&gt;]. The drug was launched for the treatment of advanced mCRC in Japan in September 2008 [&lt;ulink linkID="944606" linkType="Reference"&gt;944606&lt;/ulink&gt;]. Cetuximab was approved for first-line mCRC in Europe in July 2008 [&lt;ulink linkID="927584" linkType="Reference"&gt;927584&lt;/ulink&gt;]. Japanese approval for the first-line treatment of mCRC in combination with chemotherapy was granted in March 2010 [&lt;ulink linkID="1086084" linkType="Reference"&gt;1086084&lt;/ulink&gt;]. In July 2012, the FDA approved the drug for the first-line treatment of KRAS wild-type EGFR-expressing mCRC [&lt;ulink linkID="1306857" linkType="Reference"&gt;1306857&lt;/ulink&gt;]. In December 2013, the EC approved the drug for patients with EGFR-expressing, RAS wild-type mCRC in combination with irinotecan, in the first-line setting in combination with FOLFOX or as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan [&lt;ulink linkID="1510961" linkType="Reference"&gt;1510961&lt;/ulink&gt;].   In June 2016, a global, registrational phase III trial (BEACON CRC) began in patients with BRAF-mutant mCRC who previously received first-line systemic therapy to assess a triplet  therapy composed of cetixumab and &lt;ulink linkID="25902" linkType="Company"&gt;Array&lt;/ulink&gt;'s  &lt;ulink linkID="55305" linkType="Drug"&gt;binimetinib&lt;/ulink&gt; and &lt;ulink linkID="73843" linkType="Drug"&gt;encorafenib&lt;/ulink&gt; versus cetixumab and irinotecan-based therapy [&lt;ulink linkID="1769245" linkType="Reference"&gt;1769245&lt;/ulink&gt;], [&lt;ulink linkID="1769248" linkType="Reference"&gt;1769248&lt;/ulink&gt;]; in September 2016, Array reached a Special Protocol Assessment (SPA) agreement with the FDA for the BEACON CRC trial [&lt;ulink linkID="1795998" linkType="Reference"&gt;1795998&lt;/ulink&gt;]; in May 2019, positive topline data were reported. At that time, the company planned to file for approval for the combination treatment in 2H19 [&lt;ulink linkID="2153883" linkType="Reference"&gt;2153883&lt;/ulink&gt;]. In February 2004, a phase III trial for adjuvant CRC began [&lt;ulink linkID="1106380" linkType="Reference"&gt;1106380&lt;/ulink&gt;]; however, development in this setting had been discontinued by March 2013 [&lt;ulink linkID="1389621" linkType="Reference"&gt;1389621&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2006,  FDA approval was granted for first-line use in combination with radiation therapy for the treatment of locally or regionally advanced SCCHN and for second-line use as a single agent in recurrent or metastatic SCCHN [&lt;ulink linkID="653235" linkType="Reference"&gt;653235&lt;/ulink&gt;]; in November 2011, US approval was granted for first-line use  for recurrent and/or metastatic SCCHN in combination with platinum-based therapy [&lt;ulink linkID="1237149" linkType="Reference"&gt;1237149&lt;/ulink&gt;]. In April 2006, the EMA approved first-line use in combination with radiotherapy for locally advanced, non-metastatic SCCHN [&lt;ulink linkID="660930" linkType="Reference"&gt;660930&lt;/ulink&gt;]; in December 2008, the EMA approved first-line use in combination with platinum-based chemotherapy in patients with recurrent and/or metastatic SCCHN [&lt;ulink linkID="967526" linkType="Reference"&gt;967526&lt;/ulink&gt;]. By June 2013, the product had been launched in Japan for locally advanced and/or metastatic SCCHN [&lt;ulink linkID="1461669" linkType="Reference"&gt;1461669&lt;/ulink&gt;]. In March 2017, a phase II trial was initiated in combination with &lt;ulink linkID="CP312688" linkType="Compound"&gt;pembrolizumab&lt;/ulink&gt; in patients with recurrent/metastatic SCCHN [&lt;ulink linkID="1915298" linkType="Reference"&gt;1915298&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Development in other cancer indications  is ongoing. In December 2009, a  phase II, investigator-led, company-sponsored study was initiated for   thymoma or thymic carcinoma in the US; in April 2018, the trial was ongoing and expected to complete in December 2019 [&lt;ulink linkID="1636894" linkType="Reference"&gt;1636894&lt;/ulink&gt;]. In June 2012, a phase I, investigator-led, company-sponsored study in locally advanced anal cancer patients was started; in March 2018, the trial was ongoing  and expected to complete in January 2019 [&lt;ulink linkID="1446832" linkType="Reference"&gt;1446832&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The drug was previously also developed for other cancer indications. In December 1997, a phase II trial began in metastatic renal cell carcinoma [&lt;ulink linkID="271226" linkType="Reference"&gt;271226&lt;/ulink&gt;]; however, no development has been reported since that time. In September 2003, a phase II combination trial in ovarian and peritoneal cancer began  [&lt;ulink linkID="1271105" linkType="Reference"&gt;1271105&lt;/ulink&gt;], with a monotherapy trial starting in November 2004; however the monotherapy trial was terminated due to lack of efficacy [&lt;ulink linkID="1271110" linkType="Reference"&gt;1271110&lt;/ulink&gt;], and no further development has been reported. In March 2005, a phase II trial in sarcoma was initiated [&lt;ulink linkID="1025518" linkType="Reference"&gt;1025518&lt;/ulink&gt;]; however the drug did not demonstrate efficacy in this setting [&lt;ulink linkID="1270842" linkType="Reference"&gt;1270842&lt;/ulink&gt;], and no development has been reported.   In February 2006, a phase II trial for advanced cervical carcinoma began; however, no further development has been reported since May 2011 [&lt;ulink linkID="1025513" linkType="Reference"&gt;1025513&lt;/ulink&gt;]. By February 2006, phase II trials had been conducted in hepatocellular carcinoma [&lt;ulink linkID="796228" linkType="Reference"&gt;796228&lt;/ulink&gt;]; however, no further development in this indication has been reported. In October 2006, a phase II study for endometrial cancer began [&lt;ulink linkID="1025523" linkType="Reference"&gt;1025523&lt;/ulink&gt;]; however, no further development has been reported. Phase III combination trials in advanced/metastatic pancreatic cancer were also conducted. The drug failed to meet its primary endpoint in combination with &lt;ulink linkID="3199" linkType="Drug"&gt;gemcitabine&lt;/ulink&gt; in the first-line setting; by April 2007, the companies were working to interpret the results and intended to pursue additional evaluations with the drug, including a pilot study in combination with &lt;ulink linkID="8047" linkType="Drug"&gt;bevacizumab&lt;/ulink&gt; with or without gemcitabine [&lt;ulink linkID="782188" linkType="Reference"&gt;782188&lt;/ulink&gt;]; final data from the trial were reported in June 2007, confirming no effect on overall survival (OS)   [&lt;ulink linkID="805121" linkType="Reference"&gt;805121&lt;/ulink&gt;], and no further development has been reported in this indication. In June 2007, Merck Serono initiated a phase II trial in triple-negative breast cancer [&lt;ulink linkID="886347" linkType="Reference"&gt;886347&lt;/ulink&gt;]; first results were presented in October 2010 [&lt;ulink linkID="1138405" linkType="Reference"&gt;1138405&lt;/ulink&gt;], and phase II trials were ongoing in March 2011 [&lt;ulink linkID="1170782" linkType="Reference"&gt;1170782&lt;/ulink&gt;]; however, by March 2012, Merck had discontinued development in breast cancer [&lt;ulink linkID="1268927" linkType="Reference"&gt;1268927&lt;/ulink&gt;]. A phase II trial in advanced biliary cancer began in October 2007 [&lt;ulink linkID="981857" linkType="Reference"&gt;981857&lt;/ulink&gt;], with another trial starting in September 2008 [&lt;ulink linkID="1271067" linkType="Reference"&gt;1271067&lt;/ulink&gt;]; however both trials completed in 2010 and no further development has been reported. In May 2008, a phase II trial in metastatic androgen-independent prostate cancer was initiated;  however, no further development has been reported since April 2010  [&lt;ulink linkID="1025499" linkType="Reference"&gt;1025499&lt;/ulink&gt;]. In June 2008, phase II data in recurrent high-grade glioma were reported   [&lt;ulink linkID="911055" linkType="Reference"&gt;911055&lt;/ulink&gt;]; however, no further development has been reported. In July 2008, Merck  initiated EXPAND, a phase III trial in advanced/metastatic gastric cancer [&lt;ulink linkID="923604" linkType="Reference"&gt;923604&lt;/ulink&gt;]; however in July 2012, it was reported that the trial did not achieve the primary endpoint [&lt;ulink linkID="1306313" linkType="Reference"&gt;1306313&lt;/ulink&gt;]; a phase II trial for adjuvant gastric cancer began in March 2009 and completed in October 2015 [&lt;ulink linkID="1642851" linkType="Reference"&gt;1642851&lt;/ulink&gt;]; development in gastric cancer was discontinued by Merck by March 2013;  BMS is also presumed to have halted development for that indication [&lt;ulink linkID="1389621" linkType="Reference"&gt;1389621&lt;/ulink&gt;]. The companies had filed for European and US approval for EGFR-expressing, advanced or metastatic NSCLC [&lt;ulink linkID="942513" linkType="Reference"&gt;942513&lt;/ulink&gt;], [&lt;ulink linkID="1180162" linkType="Reference"&gt;1180162&lt;/ulink&gt;], [&lt;ulink linkID="969409" linkType="Reference"&gt;969409&lt;/ulink&gt;],  [&lt;ulink linkID="1211987" linkType="Reference"&gt;1211987&lt;/ulink&gt;], but by April 2012, following a negative opinion from  the FDA, US development in NSCLC had been halted [&lt;ulink linkID="1283502" linkType="Reference"&gt;1283502&lt;/ulink&gt;]; the filing was withdrawn in the EU [&lt;ulink linkID="1389621" linkType="Reference"&gt;1389621&lt;/ulink&gt;], and in November 2012, discontinuation of development for this indication was confirmed [&lt;ulink linkID="1340957" linkType="Reference"&gt;1340957&lt;/ulink&gt;]. In May 2008, a phase II trial for first-line bladder cancer was initiated;  in June 2012 and May 2014, data were reported and the trial completed in June 2015 [&lt;ulink linkID="1025510" linkType="Reference"&gt;1025510&lt;/ulink&gt;], [&lt;ulink linkID="1607314" linkType="Reference"&gt;1607314&lt;/ulink&gt;], [&lt;ulink linkID="1629623" linkType="Reference"&gt;1629623&lt;/ulink&gt;]. A phase II trial in mesothelioma began in October 2009, which was ongoing in December 2014 [&lt;ulink linkID="1657523" linkType="Reference"&gt;1657523&lt;/ulink&gt;]; however, no further development has been reported. Merck KGaA, under license from researchers at &lt;ulink linkID="1037439" linkType="Company"&gt;Sorlandet Hospital&lt;/ulink&gt; via the technology transfer company &lt;ulink linkID="1062214" linkType="Company"&gt;Inven2&lt;/ulink&gt;,    was also developing the drug for the potential treatment of  neuropathic pain [&lt;ulink linkID="1541914" linkType="Reference"&gt;1541914&lt;/ulink&gt;], [&lt;ulink linkID="1684233" linkType="Reference"&gt;1684233&lt;/ulink&gt;]. In October 2015, a   phase II trial was  initiated; in October 2016, the trial was completed [&lt;ulink linkID="1676056" linkType="Reference"&gt;1676056&lt;/ulink&gt;]; however, no further development has been reported.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;As a biologic there is no composition of matter patent that specifically claims cetuximab in the US, and no use patent in monotherapy. In April 2001, ImClone received &lt;ulink linkID="PA3107669" linkType="Patent"&gt;US-06217866&lt;/ulink&gt; (expiry April 2018), which covers a composition of matter of any EGFR mAb that inhibits the binding of EGF to its receptor, in combination with any antineoplastic agent, as well as the therapeutic use of such combinations [&lt;ulink linkID="404319" linkType="Reference"&gt;404319&lt;/ulink&gt;]. In September 2006, a US Court granted &lt;ulink linkID="15489" linkType="Company"&gt;Yeda Research and Development Company Ltd&lt;/ulink&gt; ownership of the use patent for combination therapy with cytotoxic treatments relating to cetuximab; ImClone and Yeda had been in litigation over ownership [&lt;ulink linkID="800896" linkType="Reference"&gt;800896&lt;/ulink&gt;]. In December 2007, all outstanding patent litigation with Yeda was settled. Yeda became the sole owner of the '866 patent in the US and was mandated to receive a cash payment plus a single-digit royalty on worldwide sales [&lt;ulink linkID="862359" linkType="Reference"&gt;862359&lt;/ulink&gt;]. In February 2013, BMS stated that US data exclusivity expired in 2016 [&lt;ulink linkID="1392809" linkType="Reference"&gt;1392809&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2007, &lt;ulink linkID="13601" linkType="Company"&gt;Abbott Laboratories&lt;/ulink&gt; filed a  patent infringement lawsuit against ImClone relating to &lt;ulink linkID="IN2398627" linkType="Patent"&gt;US-05665578&lt;/ulink&gt;. In September 2008, a settlement deal was agreed between the two companies,  with ImClone paying Abbott $17.5 million for  all claims and counterclaims, ending the litigation [&lt;ulink linkID="996069" linkType="Reference"&gt;996069&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Biosimilars are in development, including those from &lt;ulink linkID="83051" linkType="Drug"&gt;Amgen/Abgenix&lt;/ulink&gt;, &lt;ulink linkID="79610" linkType="Drug"&gt;Bioexpress&lt;/ulink&gt; and &lt;ulink linkID="83533" linkType="Drug"&gt;Oncobiologics/Virorpo&lt;/ulink&gt;.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;&lt;ulink linkID="IN2266651" linkType="Patent"&gt;EP-00667165&lt;/ulink&gt; expired in countries where the SPC was rejected or withdrawn (including the UK, Germany) in September 2009, and in September 2014 in countries where an SPC was granted (including France and Belgium).&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;In February 2012, BMS stated that regulatory data protection expired in Japan in 2016 [&lt;ulink linkID="1264186" linkType="Reference"&gt;1264186&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;In March 2015, &lt;ulink linkID="1073079" linkType="Company"&gt;Shanghai Henlius&lt;/ulink&gt; was developing JZB-28 (HLX-05) as a class 2 therapeutic biologic in China  [&lt;ulink linkID="1637411" linkType="Reference"&gt;1637411&lt;/ulink&gt;], [&lt;ulink linkID="1639919" linkType="Reference"&gt;1639919&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;In February 2012, BMS stated that regulatory data protection expired in Canada in 2016 [&lt;ulink linkID="1264186" linkType="Reference"&gt;1264186&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;&lt;subtitle&gt;Colorectal cancer&lt;/subtitle&gt;&lt;subtitle&gt;Second-line treatment&lt;/subtitle&gt;In August 2018, the FDA granted Breakthrough Therapy Designation for  &lt;ulink linkID="73843" linkType="Drug"&gt;encorafenib&lt;/ulink&gt; in combination with &lt;ulink linkID="55305" linkType="Drug"&gt;binimetinib&lt;/ulink&gt; and cetuximab for the treatment of patients with BRAF-mutant metastatic CRC after failure of one to two prior lines of therapy for metastatic disease [&lt;ulink linkID="2060639" linkType="Reference"&gt;2060639&lt;/ulink&gt;], [&lt;ulink linkID="2069795" linkType="Reference"&gt;2069795&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By the end of 2000, Merck had been planning to launch the product in the US in 2002 [&lt;ulink linkID="395423" linkType="Reference"&gt;395423&lt;/ulink&gt;], [&lt;ulink linkID="397901" linkType="Reference"&gt;397901&lt;/ulink&gt;], [&lt;ulink linkID="387074" linkType="Reference"&gt;387074&lt;/ulink&gt;]. In February 2001, cetuximab received Fast Track status for refractory CRC [&lt;ulink linkID="397656" linkType="Reference"&gt;397656&lt;/ulink&gt;], [&lt;ulink linkID="436303" linkType="Reference"&gt;436303&lt;/ulink&gt;]. In November 2001, ImClone completed the filing of a rolling BLA with the FDA for cetuximab in combination with irinotecan to treat irinotecan-refractory CRC [&lt;ulink linkID="427710" linkType="Reference"&gt;427710&lt;/ulink&gt;]. However, in December 2001, the FDA advised ImClone that its BLA for cetuximab was not acceptable for filing [&lt;ulink linkID="434579" linkType="Reference"&gt;434579&lt;/ulink&gt;]. In February 2002, the companies met with the FDA to discuss resubmission of the BLA with additional European clinical data [&lt;ulink linkID="441606" linkType="Reference"&gt;441606&lt;/ulink&gt;], [&lt;ulink linkID="441634" linkType="Reference"&gt;441634&lt;/ulink&gt;]. By June 2003, ImClone had  discussions with the FDA over additional data, including data from Merck's 007 study [&lt;ulink linkID="492514" linkType="Reference"&gt;492514&lt;/ulink&gt;]. In August 2003, ImClone submitted a BLA for cetuximab in combination with irinotecan for EGFR-expressing mCRC. ImClone also requested Priority Review status and accelerated approval  [&lt;ulink linkID="501075" linkType="Reference"&gt;501075&lt;/ulink&gt;]. In October 2003, the FDA granted Priority Review [&lt;ulink linkID="508435" linkType="Reference"&gt;508435&lt;/ulink&gt;]. In February 2004, the FDA granted accelerated approval  for use in combination with irinotecan to treat EGFR-expressing mCRC refractory to irinotecan-based chemotherapy, and as a single agent in the treatment of patients with EGFR-expressing mCRC who are intolerant to irinotecan-based chemotherapy [&lt;ulink linkID="523128" linkType="Reference"&gt;523128&lt;/ulink&gt;]. By March 2005, cetuximab had been launched in the US for second-line mCRC [&lt;ulink linkID="591298" linkType="Reference"&gt;591298&lt;/ulink&gt;].  In October 2007, the US label was extended to include OS data as a single agent in EGFR-expressing mCRC after failure of both irinotecan- and oxaliplatin-based regimens [&lt;ulink linkID="835796" linkType="Reference"&gt;835796&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;First-line treatment&lt;/subtitle&gt;In April 2011, a US filing for cetuximab for the first-line treatment of mCRC was planned for 2011 [&lt;ulink linkID="1197941" linkType="Reference"&gt;1197941&lt;/ulink&gt;]. In July 2012, the FDA approved the drug for the first-line treatment of KRAS wild-type EGFR-expressing mCRC [&lt;ulink linkID="1306857" linkType="Reference"&gt;1306857&lt;/ulink&gt;], [&lt;ulink linkID="1306866" linkType="Reference"&gt;1306866&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Head and neck cancer&lt;/subtitle&gt;&lt;subtitle&gt;Second-line treatment&lt;/subtitle&gt;By August 2005, an sBLA for cetuximab for second-line use as a single agent in recurrent or metastatic SCCHN had been submitted; in March 2006,  approval was granted [&lt;ulink linkID="653235" linkType="Reference"&gt;653235&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;First-line treatment&lt;/subtitle&gt;In August 2008, ImClone and BMS filed for FDA approval of cetuximab for use in combination with platinum-based therapy for the first-line treatment of patients with recurrent and/or metastatic SCCHN. Priority Review, which the company felt was supported by data from the EXTREME trial, was requested [&lt;ulink linkID="940430" linkType="Reference"&gt;940430&lt;/ulink&gt;]. The FDA accepted the filing for review in October 2008, and granted Priority Review  [&lt;ulink linkID="957959" linkType="Reference"&gt;957959&lt;/ulink&gt;]. In March 2009, the FDA issued a complete response letter, requesting an additional pharmacokinetic study to demonstrate that the drug substance used in the submission was that same as the drug available in the US; the study was initiated in July 2010 [&lt;ulink linkID="988557" linkType="Reference"&gt;988557&lt;/ulink&gt;], [&lt;ulink linkID="1330233" linkType="Reference"&gt;1330233&lt;/ulink&gt;]. By April 2011, Lilly had responded to the  Complete Response letter [&lt;ulink linkID="1197941" linkType="Reference"&gt;1197941&lt;/ulink&gt;]. In November 2011, approval was granted for this indication [&lt;ulink linkID="1237149" linkType="Reference"&gt;1237149&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By August 2005, an sBLA for cetuximab for first-line use in combination with radiation therapy for the treatment of locally or regionally advanced SCCHN had been submitted; in March 2006,  approval was granted [&lt;ulink linkID="653235" linkType="Reference"&gt;653235&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Non-small-cell lung cancer&lt;/subtitle&gt;In December 2008, an sBLA for the first-line treatment of advanced NSCLC was filed [&lt;ulink linkID="969409" linkType="Reference"&gt;969409&lt;/ulink&gt;]. However, in January 2009, following discussions with the FDA, ImClone and BMS withdrew the sBLA for advanced NSCLC based on a CMC issue related to the preclinical pharmacokinetics comparability of the US version of cetuximab  with the clinical supplies used by Serono [&lt;ulink linkID="978967" linkType="Reference"&gt;978967&lt;/ulink&gt;]. By July 2011, Lilly and BMS had resubmitted the sBLA [&lt;ulink linkID="1211987" linkType="Reference"&gt;1211987&lt;/ulink&gt;]. By April 2012, the FDA had issued a complete response letter for the first-line NSCLC filing, which was based on the FLEX study. At that time, Lilly and BMS were not planning to resubmit the FLEX filing and development had been halted [&lt;ulink linkID="1283502" linkType="Reference"&gt;1283502&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By August 2005, an sBLA for cetuximab as monotherapy and in combination with radiotherapy had been submitted for the second-line treatment of non-metastatic  SCCHN, and in March 2006,  approval irst-line use in combination with radiation therapy for the treatment of locally or regionally advanced SCCHN and for second-line use as a single agent in recurrent or metastatic SCCHNwas granted [&lt;ulink linkID="653235" linkType="Reference"&gt;653235&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;&lt;subtitle&gt;Colorectal cancer&lt;/subtitle&gt;&lt;subtitle&gt;Second-line treatment&lt;/subtitle&gt;In November 2013, the CHMP recommended approval of the drug for patients with EGFR-expressing, RAS wild-type mCRC in combination with &lt;ulink linkID="2871" linkType="Drug"&gt;irinotecan&lt;/ulink&gt; or as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan based on biomarker data from the OPUS study [&lt;ulink linkID="1502230" linkType="Reference"&gt;1502230&lt;/ulink&gt;]. In December 2013, the EC approved the updated indication [&lt;ulink linkID="1510961" linkType="Reference"&gt;1510961&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2003, Merck filed an MAA with Swissmedic for cetuximab as a monotherapy and in combination with irinotecan for mCRC [&lt;ulink linkID="496093" linkType="Reference"&gt;496093&lt;/ulink&gt;].  In November 2003, it received notice from Swissmedic of its intention to approve cetuximab for CRC [&lt;ulink linkID="513128" linkType="Reference"&gt;513128&lt;/ulink&gt;], [&lt;ulink linkID="513127" linkType="Reference"&gt;513127&lt;/ulink&gt;]. In December 2003, cetuximab was approved in Switzerland, for use in patients with CRC who no longer respond to chemotherapy treatment with irinotecan; Merck immediately launched the drug [&lt;ulink linkID="515543" linkType="Reference"&gt;515543&lt;/ulink&gt;], [&lt;ulink linkID="515542" linkType="Reference"&gt;515542&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2002, Merck delayed its application to the EMEA so  it could include primarily its own CRC data rather than ImClone's [&lt;ulink linkID="449226" linkType="Reference"&gt;449226&lt;/ulink&gt;]. By December 2002, the company was analyzing results from the pivotal European trial (EMR 62202-007)  [&lt;ulink linkID="474512" linkType="Reference"&gt;474512&lt;/ulink&gt;]. In June 2003, Merck filed an MAA with the EMEA for cetuximab as a monotherapy and in combination with irinotecan for mCRC [&lt;ulink linkID="496093" linkType="Reference"&gt;496093&lt;/ulink&gt;]. In March 2004, the CHMP recommended approval of cetuximab for use in combination with irinotecan [&lt;ulink linkID="528889" linkType="Reference"&gt;528889&lt;/ulink&gt;], [&lt;ulink linkID="528914" linkType="Reference"&gt;528914&lt;/ulink&gt;]; in June 2004, the EC granted approval. It was to be launched in all 25 member states of the EU as well as Iceland and Norway [&lt;ulink linkID="547104" linkType="Reference"&gt;547104&lt;/ulink&gt;]. By July 2004, launch had taken place in Germany, the UK, Austria, Ireland, Finland, Sweden, and the Netherlands.  By October 2004, launch had taken place in Norway, Denmark and Portugal [&lt;ulink linkID="579610" linkType="Reference"&gt;579610&lt;/ulink&gt;], [&lt;ulink linkID="591970" linkType="Reference"&gt;591970&lt;/ulink&gt;]. In January 2005, it was launched in Spain [&lt;ulink linkID="616326" linkType="Reference"&gt;616326&lt;/ulink&gt;], [&lt;ulink linkID="585802" linkType="Reference"&gt;585802&lt;/ulink&gt;]. By February 2007, the drug had been launched in Iceland [&lt;ulink linkID="1450717" linkType="Reference"&gt;1450717&lt;/ulink&gt;].  By March 2007, the drug had been launched in Belgium [&lt;ulink linkID="772792" linkType="Reference"&gt;772792&lt;/ulink&gt;]. In January 2008, it was launched in France [&lt;ulink linkID="1348676" linkType="Reference"&gt;1348676&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;First-line treatment&lt;/subtitle&gt;In November 2013, the CHMP recommended approval of the drug in the first-line setting in combination with FOLFOX for patients with EGFR-expressing, RAS wild-type mCRC based on biomarker data from the OPUS study [&lt;ulink linkID="1502230" linkType="Reference"&gt;1502230&lt;/ulink&gt;]. In December 2013, the EC approved the updated indication [&lt;ulink linkID="1510961" linkType="Reference"&gt;1510961&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;In November 2011, the CHMP recommended approval of the drug for EGFR-expressing, KRAS wild-type mCRC in the first-line setting in combination with FOLFOX [&lt;ulink linkID="1241438" linkType="Reference"&gt;1241438&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2007, Merck filed for approval in Europe for the use of cetuximab in first-line mCRC and in May 2008, the CHMP issued a positive opinion, recommending approval for the treatment of patients with EGFR-expressing, KRAS wild-type mCRC, in combination with chemotherapy and as a monotherapy [&lt;ulink linkID="827155" linkType="Reference"&gt;827155&lt;/ulink&gt;], [&lt;ulink linkID="912064" linkType="Reference"&gt;912064&lt;/ulink&gt;]. The drug was approved in this setting in July 2008 [&lt;ulink linkID="927584" linkType="Reference"&gt;927584&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Head and neck cancer&lt;/subtitle&gt;&lt;subtitle&gt;First-line treatment&lt;/subtitle&gt;In June 2008, Merck submitted an application to the EMEA to extend the use of cetuximab for the first-line treatment of recurrent and/or metastatic SCCHN in combination with platinum-based chemotherapy [&lt;ulink linkID="918824" linkType="Reference"&gt;918824&lt;/ulink&gt;]. The EU's CHMP recommended approval in this setting in October 2008 [&lt;ulink linkID="956208" linkType="Reference"&gt;956208&lt;/ulink&gt;]; the filing was approved in December 2008 [&lt;ulink linkID="967526" linkType="Reference"&gt;967526&lt;/ulink&gt;], and the drug was launched in this setting in January 2009 [&lt;ulink linkID="1079607" linkType="Reference"&gt;1079607&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In August 2005,  cetuximab was filed for locally advanced head and neck cancer in Switzerland [&lt;ulink linkID="646378" linkType="Reference"&gt;646378&lt;/ulink&gt;], [&lt;ulink linkID="734111" linkType="Reference"&gt;734111&lt;/ulink&gt;]. In December 2005, the drug was approved by the Swiss regulatory authorities, and was presumed to have been immediately launched [&lt;ulink linkID="734112" linkType="Reference"&gt;734112&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In August 2005,  cetuximab was filed for  first-line treatment in combination with radiotherapy for locally advanced  in the EU   [&lt;ulink linkID="646378" linkType="Reference"&gt;646378&lt;/ulink&gt;], [&lt;ulink linkID="734111" linkType="Reference"&gt;734111&lt;/ulink&gt;]. In February 2006, Merck received a positive opinion from the EU CHMP for the second-line treatment of locally advanced head and neck cancer, and the EMEA approved cetuximab for this indication in April 2006 [&lt;ulink linkID="652221" linkType="Reference"&gt;652221&lt;/ulink&gt;], [&lt;ulink linkID="660930" linkType="Reference"&gt;660930&lt;/ulink&gt;], [&lt;ulink linkID="733057" linkType="Reference"&gt;733057&lt;/ulink&gt;].                                                            By  March 2007, it was available in all 27 EU states, as well as Iceland and Norway [&lt;ulink linkID="772792" linkType="Reference"&gt;772792&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Non-small-cell lung cancer&lt;/subtitle&gt;In September 2008, Merck submitted an application to the EMEA for the use of cetuximab in the first-line treatment of EGFR-expressing, advanced or metastatic NSCLC [&lt;ulink linkID="942513" linkType="Reference"&gt;942513&lt;/ulink&gt;]. In July 2009, the CHMP issued a negative opinion regarding the use of cetuximab for NSCLC treatment [&lt;ulink linkID="1028138" linkType="Reference"&gt;1028138&lt;/ulink&gt;], [&lt;ulink linkID="1028135" linkType="Reference"&gt;1028135&lt;/ulink&gt;]; later that month, Merck requested a re-examination of the CHMP negative opinion [&lt;ulink linkID="1030093" linkType="Reference"&gt;1030093&lt;/ulink&gt;]. Following re-examination, the CHMP again issued a negative opinion for the use of cetuximab in NSCLC in November 2009 [&lt;ulink linkID="1059208" linkType="Reference"&gt;1059208&lt;/ulink&gt;]; in August 2010, the company was evaluating the next steps for the drug in this indication [&lt;ulink linkID="1124183" linkType="Reference"&gt;1124183&lt;/ulink&gt;]. In March 2011, Merck submitted a further application for first-line NSCLC treatment in combination with platinum-based therapies [&lt;ulink linkID="1180162" linkType="Reference"&gt;1180162&lt;/ulink&gt;]. In September 2012, Merck withdrew the MAA after the European regulator indicated additional data would be required [&lt;ulink linkID="1324154" linkType="Reference"&gt;1324154&lt;/ulink&gt;], [&lt;ulink linkID="1324668" linkType="Reference"&gt;1324668&lt;/ulink&gt;]. In November 2012, it was confirmed that  development for lung cancer had been discontinued [&lt;ulink linkID="1340957" linkType="Reference"&gt;1340957&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;&lt;subtitle&gt;Colorectal cancer&lt;/subtitle&gt;&lt;subtitle&gt;Second-line treatment&lt;/subtitle&gt;In September 2003, Merck had expected a Japanese CRC launch in 2006 [&lt;ulink linkID="504447" linkType="Reference"&gt;504447&lt;/ulink&gt;]. Cetuximab was submitted in Japan for mCRC in January 2007, based on Japanese and European data, and in May 2008, the CDFS's Second Committee on Drugs recommended approval of the drug [&lt;ulink linkID="763073" linkType="Reference"&gt;763073&lt;/ulink&gt;], [&lt;ulink linkID="915660" linkType="Reference"&gt;915660&lt;/ulink&gt;]. Approval was granted in July 2008 and in  September 2008, cetuximab was launched in Japan for the treatment of advanced or mCRC [&lt;ulink linkID="925595" linkType="Reference"&gt;925595&lt;/ulink&gt;], [&lt;ulink linkID="944606" linkType="Reference"&gt;944606&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;First-line treatment&lt;/subtitle&gt;In March 2010, the drug was approved in combination with chemotherapy for the first-line treatment of curatively unresectable, advanced or recurrent EGFR-expressing, KRAS wild-type  mCRC [&lt;ulink linkID="1086084" linkType="Reference"&gt;1086084&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Head and neck cancer&lt;/subtitle&gt;In June 2012, Japan's Ministry of Health, Labour and Welfare granted priority review designation for an application to expand cetuximab use for the treatment of locally-advanced and recurrent metastatic SCCHN [&lt;ulink linkID="1311084" linkType="Reference"&gt;1311084&lt;/ulink&gt;]. In December 2012, cetuximab was approved in Japan for head and neck cancer [&lt;ulink linkID="1352207" linkType="Reference"&gt;1352207&lt;/ulink&gt;]. By June 2013, the product had been launched in Japan for this indication [&lt;ulink linkID="1461669" linkType="Reference"&gt;1461669&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;&lt;subtitle&gt;Colorectal cancer&lt;/subtitle&gt;&lt;subtitle&gt;Second-line treatment&lt;/subtitle&gt;In December 2005, cetuximab was approved in China [&lt;ulink linkID="1264140" linkType="Reference"&gt;1264140&lt;/ulink&gt;]; by March 2007, the product had been launched in that region [&lt;ulink linkID="772792" linkType="Reference"&gt;772792&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Colorectal cancer&lt;/subtitle&gt;&lt;subtitle&gt;First-line treatment&lt;/subtitle&gt;In April 2016, based on  positive data from a phase III TAILOR  trial, Merck planned to work with the Chinese authorities to make the drug available as a first-line treatment in that region as soon as possible  [&lt;ulink linkID="1755019" linkType="Reference"&gt;1755019&lt;/ulink&gt;]; in March 2018, Merck KGaA noted that advanced had been occurred in China following the positive phase III trial as a first-line treatment for colorectal cancer [&lt;ulink linkID="2011632" linkType="Reference"&gt;2011632&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Head and neck cancer&lt;/subtitle&gt;In November 2018, positive topline data were presented for the phase III trial CHANGE II in Chinese patients with recurrent and/or metastatic SCCHN. At that time, Merck was planning to discuss the results with the Chinese National Medical Products Administration (NMPA) and planned to file for approval for the additional indication in China [&lt;ulink linkID="2097906" linkType="Reference"&gt;2097906&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;&lt;subtitle&gt;Colorectal cancer&lt;/subtitle&gt;In November 2003, ImClone and BMS filed a Priority Review NDS in Canada for mCRC [&lt;ulink linkID="514622" linkType="Reference"&gt;514622&lt;/ulink&gt;]. In September 2005, the drug was approved in Canada in combination with irinotecan; launch was expected within the coming weeks  [&lt;ulink linkID="885914" linkType="Reference"&gt;885914&lt;/ulink&gt;]; however, by April 2008, cetuximab had not been launched in Canada [&lt;ulink linkID="893149" linkType="Reference"&gt;893149&lt;/ulink&gt;]. Canadian launch took place in October 2008 [&lt;ulink linkID="957229" linkType="Reference"&gt;957229&lt;/ulink&gt;], [&lt;ulink linkID="957490" linkType="Reference"&gt;957490&lt;/ulink&gt;]. In January 2013, cetuximab was additionally approved in Canada in combination with FOLFIRI for first-line mCRC patients with non-mutated (wild-type) KRAS [&lt;ulink linkID="1356640" linkType="Reference"&gt;1356640&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Head and neck cancer&lt;/subtitle&gt;In October 2008, the drug was  approved for SCCHN in Canada [&lt;ulink linkID="957490" linkType="Reference"&gt;957490&lt;/ulink&gt;], [&lt;ulink linkID="957229" linkType="Reference"&gt;957229&lt;/ulink&gt;]; it is presumed launch occurred shortly following approval.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Latin America&lt;/subtitle&gt;&lt;subtitle&gt;Colorectal cancer&lt;/subtitle&gt;By September 2008, the drug was approved for CRC in  South America  [&lt;ulink linkID="943610" linkType="Reference"&gt;943610&lt;/ulink&gt;]; it is presumed launch occurred shortly following approval.&lt;/para&gt;&lt;para&gt;By September 2008, the drug was approved for CRC in   Central America  [&lt;ulink linkID="943610" linkType="Reference"&gt;943610&lt;/ulink&gt;]; it is presumed launch occurred shortly following approval.&lt;/para&gt;&lt;para&gt;By October 2006, the drug was available in Brazil [&lt;ulink linkID="738760" linkType="Reference"&gt;738760&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;in September 2005, it was approved in Ecuador [&lt;ulink linkID="734111" linkType="Reference"&gt;734111&lt;/ulink&gt;]; it is presumed launch occurred shortly following approval.&lt;/para&gt;&lt;para&gt;In July 2005, the drug was approved in Guatemala  [&lt;ulink linkID="734111" linkType="Reference"&gt;734111&lt;/ulink&gt;]; it is presumed launch occurred shortly following approval.&lt;/para&gt;&lt;para&gt;In July 2005, the drug was approved in Panama  [&lt;ulink linkID="734111" linkType="Reference"&gt;734111&lt;/ulink&gt;]; it is presumed launch occurred shortly following approval.&lt;/para&gt;&lt;para&gt;By April 2005, it was submitted for approval in Peru [&lt;ulink linkID="616326" linkType="Reference"&gt;616326&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2004, the drug was approved in Argentina [&lt;ulink linkID="542377" linkType="Reference"&gt;542377&lt;/ulink&gt;], and  by July 2004, was launched in this country [&lt;ulink linkID="591970" linkType="Reference"&gt;591970&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2004, Merck filed for approval in Mexico  [&lt;ulink linkID="591967" linkType="Reference"&gt;591967&lt;/ulink&gt;]. In May 2004, the drug was approved in Mexico for mCRC [&lt;ulink linkID="542377" linkType="Reference"&gt;542377&lt;/ulink&gt;], and  by July 2004, was launched in this country [&lt;ulink linkID="591970" linkType="Reference"&gt;591970&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2004, Merck filed for approval in Chile [&lt;ulink linkID="591967" linkType="Reference"&gt;591967&lt;/ulink&gt;], and  by July 2004, the drug was launched in this country [&lt;ulink linkID="591970" linkType="Reference"&gt;591970&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Head and neck cancer&lt;/subtitle&gt;By October 2006, approval had been obtained in Chile [&lt;ulink linkID="738760" linkType="Reference"&gt;738760&lt;/ulink&gt;]; it is presumed launch occurred shortly following approval.&lt;/para&gt;&lt;para&gt;By October 2006, approval had been obtained in Mexico [&lt;ulink linkID="738760" linkType="Reference"&gt;738760&lt;/ulink&gt;]; it is presumed launch occurred shortly following approval.&lt;/para&gt;&lt;para&gt;In February 2006, the drug was approved in Argentina [&lt;ulink linkID="734112" linkType="Reference"&gt;734112&lt;/ulink&gt;]; it is presumed launch occurred shortly following approval.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Middle East and Africa&lt;/subtitle&gt;&lt;subtitle&gt;Colorectal cancer&lt;/subtitle&gt;By September 2008, the drug was approved, and presumably launched, for CRC in  Middle East [&lt;ulink linkID="943610" linkType="Reference"&gt;943610&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Head and neck cancer&lt;/subtitle&gt;In February 2006, the drug was approved in Israel [&lt;ulink linkID="734112" linkType="Reference"&gt;734112&lt;/ulink&gt;]; it is presumed launch occurred shortly following approval.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;South Asia&lt;/subtitle&gt;&lt;subtitle&gt;Colorectal cancer&lt;/subtitle&gt;By February 2006, the drug was approved In India [&lt;ulink linkID="734112" linkType="Reference"&gt;734112&lt;/ulink&gt;]. By March 2007, the product had been launched in India [&lt;ulink linkID="772792" linkType="Reference"&gt;772792&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Head and neck cancer&lt;/subtitle&gt;In February 2006, the drug was approved in India [&lt;ulink linkID="734112" linkType="Reference"&gt;734112&lt;/ulink&gt;]. By March 2007, the product had been launched in India  [&lt;ulink linkID="772792" linkType="Reference"&gt;772792&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;&lt;subtitle&gt;Colorectal cancer&lt;/subtitle&gt;By September 2008, the drug was approved for CRC in  Asia [&lt;ulink linkID="943610" linkType="Reference"&gt;943610&lt;/ulink&gt;]; it is presumed launch occurred shortly following approval.&lt;/para&gt;&lt;para&gt;By September 2008, the drug was approved for CRC in  New Zealand [&lt;ulink linkID="943610" linkType="Reference"&gt;943610&lt;/ulink&gt;]; it is presumed launch occurred shortly following approval.&lt;/para&gt;&lt;para&gt;By March 2007, the product had been launched in Korea [&lt;ulink linkID="772792" linkType="Reference"&gt;772792&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2005, the drug was approved as Eribitux in Taiwan for the use in combination with FOLFIRI (folinic acid/5-FU/irinotecan) as the first-line treatment for EGFR expressing, KRAS wild-type mCRC.The product was assumed to be launched in Taiwan by Merck shortly after its approval there [&lt;ulink linkID="1517763" linkType="Reference"&gt;1517763&lt;/ulink&gt;]. By February 2006, the drug was approved in Taiwan (November 2005)  [&lt;ulink linkID="734112" linkType="Reference"&gt;734112&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2005, it was approved in Philippines [&lt;ulink linkID="734111" linkType="Reference"&gt;734111&lt;/ulink&gt;]; it is presumed launch occurred shortly following approval.&lt;/para&gt;&lt;para&gt;In September 2005, it was approved in Malaysia [&lt;ulink linkID="734111" linkType="Reference"&gt;734111&lt;/ulink&gt;]; it is presumed launch occurred shortly following approval.&lt;/para&gt;&lt;para&gt;By April 2005, it was submitted for approval in Singapore [&lt;ulink linkID="616326" linkType="Reference"&gt;616326&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2003, Merck's Australian pharmaceuticals subsidiary, &lt;ulink linkID="1003707" linkType="Company"&gt;Alphapharm&lt;/ulink&gt;, filed an MAA for CRC [&lt;ulink linkID="511321" linkType="Reference"&gt;511321&lt;/ulink&gt;]. By September 2008, the drug was approved for CRC in  Australia [&lt;ulink linkID="943610" linkType="Reference"&gt;943610&lt;/ulink&gt;]. By February 2010, the drug had been launched in Australia [&lt;ulink linkID="2063803" linkType="Reference"&gt;2063803&lt;/ulink&gt;]. It was approved for first-line CRC in Australia in March 2010 [&lt;ulink linkID="1170782" linkType="Reference"&gt;1170782&lt;/ulink&gt;]. In May 2013, approval was granted in Australia for the treatment of patients with EGFR-expressing, K-RAS wild-type metastatic CRC in combination with chemotherapy plus irinotecan, in combination with irinotecan in patients who are refractory to first-line chemotherapy, in first-line in combination with FOLFOX, and as a single agent in patients who have failed or are intolerant to oxaliplatin-based therapy and irinotecan-based therapy [&lt;ulink linkID="1635078" linkType="Reference"&gt;1635078&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Head and neck cancer&lt;/subtitle&gt;In November 2005, the drug was approved as Eribitux in Taiwan for the use in combination with chemotherapy containing platinum to treat recurrent or metastatic SCCHN. The product was assumed to be launched  shortly after its approval there [&lt;ulink linkID="1517763" linkType="Reference"&gt;1517763&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;SAFETY INFORMATION&lt;/subtitle&gt;The drug's label carries a black box warning regarding the risk of serious infusion reactions and cardiopulmonary arrest [&lt;ulink linkID="1663406" linkType="Reference"&gt;1663406&lt;/ulink&gt;]. In July 2009, the FDA approved revisions to the label stating that analyses of CRC trials had not shown  treatment benefit  in patients whose tumors had KRAS mutations in codon 12 or 13, and that the use of cetuximab was not recommended for the treatment of CRC with these mutations [&lt;ulink linkID="1026907" linkType="Reference"&gt;1026907&lt;/ulink&gt;]. In May 2011, the EMA's CHMP recommended that the EU label for cetuximab for mCRC should be restricted to use in combination with irinotecan-based chemotherapy or FOLFOX-4 only; this was as a result of data from a study showing lack of efficacy of cetuximab in combination with oxaliplatin-based regimens [&lt;ulink linkID="1196166" linkType="Reference"&gt;1196166&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;&lt;subtitle&gt;Head and neck cancer&lt;/subtitle&gt;In October 2016, clinical data from a prospective, non-interventional, phase IV study (SOCCER; EMR062202-542) which evaluated the safety and efficacy of cetuximab in patients (n = 219) with recurrent and/or metastatic sSCCHN were presented at the ESMO 2016 Congress in Copenhagen, Denmark. Of 219 patients enrolled, 82 and 76 patients received cisplatin or carboplatin + cetuximab, and 38 patients received radiotherapy + cetuximab, respectively. Tumor progression (44%), death (14%) and patients wish (12%) were the main reasons for cetuximab treatment. A total of 7% of patients discontinued treatment due to toxicities [&lt;ulink linkID="1805895" linkType="Reference"&gt;1805895&lt;/ulink&gt;] [&lt;ulink linkID="1801032" linkType="Reference"&gt;1801032&lt;/ulink&gt;]. In October 2018, updated interim results were presented at 2018 ESMO Congress in Munich, Germany. Overall response rate (complete response + partial response) and disease control rates were 63.8 and 88.8% in the radiotherapy group; 48.5 and 80.8% in the cisplatin-based chemotherapy group and 37.9 and 74.7% in the carboplatin-based chemotherapy group, respectively. In the chemotherapy and radiotherapy groups, median progression-free survival was 5.2 and 8.7 months and median overall survival was 9.3 and 9.3 months, respectively [&lt;ulink linkID="2084902" linkType="Reference"&gt;2084902&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;I nOctober 2016, clinical data from first observational, prospective, national, multicenter study (DIRECT) which evaluated the efficacy of cetuximab in patients (n = 157) with recurrent and/or metastatic SCCHN were presented at the ESMO 2016 Congress in Copenhagen, Denmark. During maintenance, 54.2 and 45.8% of patients received cetuximab (q2w and qw; n = 39 and 33, respectively). 12-month-progression-free survival rate of 23.1% and 12-month OS rate of 70.1% was observed with cetuximab treatment. While 12-month-OS rate of 41.2% was observed in patients (n = 55) with disease free interval &amp;lt; 6 months [&lt;ulink linkID="1806805" linkType="Reference"&gt;1806805&lt;/ulink&gt;] [&lt;ulink linkID="1801032" linkType="Reference"&gt;1801032&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2009, a prospective, observational, postmarketing trial (&lt;ulink linkID="67246" linkType="Protocol"&gt;NCT01142869&lt;/ulink&gt;; EMR 062202-514) evaluating the safety and efficacy of first-line cetuximab in combination with platinum-based chemotherapy began in patients (expected n = 100) in India with recurrent or metastatic SCCHN. The primary endpoint was incidence and type of adverse drug reactions, serious adverse drug reactions, incidence of withdrawals due to intolerability of cetuximab and severity of adverse events from first infusion of cetuximab until 28 days after the last infusion. At that time, the trial was estimated to complete in July 2013, however the trial was terminated due to slow recruitment [&lt;ulink linkID="1330287" linkType="Reference"&gt;1330287&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Colorectal cancer&lt;/subtitle&gt;In January 2016, interim analysis data were presented from a multicenter, observational, German non-interventional study (ERBITAG) which evaluated the impact of prophylactic treatments of cetuximab-based skin reactions in 497 patients with mCRC were presented at the 2016 Gastrointestinal Cancers Symposium in San Francisco, CA. Patients received cetuximab (400 mg/m2 in week 1 followed by 250 g/m2 weekly). Overall, 299 patients had prophylactic skin management (P). Patients received oral systemic antibiotics (SA; n = 92), skin care without systemic antibiotics (SC; n = 37) and treated with other topical treatment (OT; n = 170). Overall, 198 patients had no prophylactic treatment (NP), of which 15.7% of patients shwed grade 3 or 4 skin reactions, while these reactions occurred in 7.6, 11.3, 18.9 and 11.8% of patients who received SA, P, SC and OT, respectively. Overall, 297, 89 and 146 skin reactions were treated with topical, systemic and combination of topical and systemic treatment, respectively. Complete remission or significant improvement was reported in 73.1, 69.7 and 68.5% of patients in topical, systemic and combination of topical and systemic treatment groups, respectively [&lt;ulink linkID="1729959" linkType="Reference"&gt;1729959&lt;/ulink&gt;]. In January 2016, clinical data were presented at the 2016 Gastrointestinal Cancers Symposium in San Francisco, CA.  PFS did not differ significantly between the age groups, irrespective of CCl. Median PFS was 11,5, 12.9, 10.2 and 8.1 months for all KRAS-wild type, &amp;lt;/= 65 years, &amp;gt; 65 to 75 and &amp;gt; 75 years patients, respectively. TTF was found to be longer than other age groups with a median of 6.0 in comparison to 4.1 and 2.8 months for &amp;gt; 65 to 75 and &amp;gt; 75 years patient groups. No remarkable difference was observed for patients with &amp;lt;/= 65 years and patients between &amp;gt; 65 to 75 and &amp;gt; 75 years with median of 5.3, 5.2 and 5.5 months, respectively [&lt;ulink linkID="1729956" linkType="Reference"&gt;1729956&lt;/ulink&gt;]. In October 2016, further data were presented at the ESMO 2016 Congress in Copenhagen, Denmark. For patients with and without resection of liver metastases, median PFS  was 20.3 and 9.5 months, respectively, and median OS was 42.0 and 18.2 months, respectively. For liver-limited disease-patients with and without resection of liver metastases, median PFS was 20.5 and 11.9 months, respectively, and median OS was 42.0 and 18.7 months, respectively [&lt;ulink linkID="1806804" linkType="Reference"&gt;1806804&lt;/ulink&gt;], [&lt;ulink linkID="1801032" linkType="Reference"&gt;1801032&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;EGFR-expressing KRAS wildtype colorectal cancer&lt;/subtitle&gt;&lt;subtitle&gt;Third-line therapyPhase II&lt;/subtitle&gt;In April 2018, data from a multicenter, phase II, single-arm study (CRICKET; &lt;ulink linkID="216384" linkType="Protocol"&gt;NCT02296203&lt;/ulink&gt;) which evaluated the efficacy of third line cetuximab plus irinotecan in metastatic colorectal cancer (mCRC) patients (n = 28) who became resistant to first line cetuximab + irinotecan were presented at the 109th AACR Annual Meeting in Chicago, IL. Of 28 patients, 6 patients showed partial response with a response rate (primary endpoint) of 21.4%; 9 patients achieved stable disease (disease control rate of 53.6%) and 13 patients showed disease progression [&lt;ulink linkID="2022499" linkType="Reference"&gt;2022499&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2016, data from a multicenter (Japan), prospective phase II study (JACCRO CC-08; UMIN000010638), which evaluated the efficacy and safety of third-line cetuximab re-challenge, in patients with metastatic wild-type K-RAS colorectal cancer who achieved a clinical benefit in response to first-line cetuximab plus chemotherapy,  were presented at the ESMO 2016 Congress in Copenhagen, Denmark. Of 36 patients, 34 received q2w irinotecan (150 mg/m2) + cetuximab (400 mg/m2 as an initial dose followed by 250 mg/m2 weekly). The 3-month progression-free rate (primary endpoint) was 44.1%, with a median progression-free survival and an overall survival time of 2.4 and 8.1 months, respectively. The overall response rate was 2.9% and disease-control rate was 55.9% [&lt;ulink linkID="1805992" linkType="Reference"&gt;1805992&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Second-line monotherapy&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;The phase III study NCIC CTG CO.17 was designed to compare cetuximab plus best standard care to standard care alone in patients with EGFR-expressing mCRC whose disease had progressed through treatment with all approved chemotherapy, including irinotecan, oxaliplatin, and fluoropyrimidines [&lt;ulink linkID="955026" linkType="Reference"&gt;955026&lt;/ulink&gt;]. In November 2006, results of the 572-patient study indicated that monotherapy with cetuximab met the primary efficacy endpoint of significant improvement in OS compared with best supportive care [&lt;ulink linkID="739247" linkType="Reference"&gt;739247&lt;/ulink&gt;]. In November 2007, data were published from the trial. Cetuximab produced a significant improvement in progression-free survival (PFS) with median survival of 6.1 months compared with 4.6 months for patients receiving BSC alone [&lt;ulink linkID="851326" linkType="Reference"&gt;851326&lt;/ulink&gt;]. In October 2008, further results from the trial were published. Patients whose tumors expressed the normal K-ras gene (n = 230) displayed almost two-fold improvement in OS. In patients with normal K-ras, median OS and PFS was 9.5 months and 3.7 months, respectively, in the cetuximab plus BSC group, compared with 4.8 months and 1.9 months in the group treated with BSC alone. In patients with mutated K-ras (n = 164), no significant difference in OS or PFS was observed [&lt;ulink linkID="955026" linkType="Reference"&gt;955026&lt;/ulink&gt;], [&lt;ulink linkID="955369" linkType="Reference"&gt;955369&lt;/ulink&gt;]. Further data were reported in May 2009, at the 45th ASCO meeting in Orlando, FL. Patients with greater comorbidities had superior OS. This was unexpected and studies investigating this phenomenon were planned [&lt;ulink linkID="1010041" linkType="Reference"&gt;1010041&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In June 2008, data from a phase II trial in previously treated EGFR-negative mCRC patients were presented at the 44th ASCO meeting. The drug was active in this patient group, and the efficacy rate suggested that EGFR immunohistochemistry is a poor indicator of cetuximab activity [&lt;ulink linkID="913210" linkType="Reference"&gt;913210&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2003, a randomized, open-label, multicenter, phase III study (&lt;ulink linkID="42202" linkType="Protocol"&gt;NCT00063141&lt;/ulink&gt;; obsolete identifier NCT00065598; CA225-006) began in the US, Australia, Hongkong and Europe in patients (n = 1302) with metastatic, EGFR-positive colorectal cancer. The trial completed in October 2007 [&lt;ulink linkID="2100182" linkType="Reference"&gt;2100182&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In August 2002, an open-label phase II trial was initiated to evaluate cetuximab in 250 patients with EGFR-positive mCRC who had failed previous chemotherapy [&lt;ulink linkID="468726" linkType="Reference"&gt;468726&lt;/ulink&gt;], [&lt;ulink linkID="475946" linkType="Reference"&gt;475946&lt;/ulink&gt;]. As of February 2003, the trial ((IMC 0144, EMR 62202-027), being carried out in the US and Belgium, had enrolled 142 of 250 patients with mCRC who had been previously treated with fluoropyrimidine, oxaliplatin and irinotecan. The endpoint was survival [&lt;ulink linkID="479208" linkType="Reference"&gt;479208&lt;/ulink&gt;]. By July 2003, enrollment was complete, with 346 patients enrolled [&lt;ulink linkID="499057" linkType="Reference"&gt;499057&lt;/ulink&gt;]. Data were presented in May 2009 at ASCO. K-ras lcs6 polymorphism was significantly associated with tumor response in patients with wild-type K-ras. The 12 patients harboring a G allele had a 42% partial response rate compared to 55 patients with TT genotype with only 9% partial response rate [&lt;ulink linkID="1010022" linkType="Reference"&gt;1010022&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A phase II study presented at the 38th ASCO meeting in 2002 compared cetuximab monotherapy with 5-flourouracil (FU) and irinotecan in patients with irinotecan-refractory CRC. Single-agent cetuximab was well tolerated and produced major objective responses. Six of 57 patients achieved a partial response [&lt;ulink linkID="453834" linkType="Reference"&gt;453834&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;As of July 2003, EMR 62202-028, a phase I pharmacodynamics trial, was enrolling mCRC patients failing standard therapy in the Netherlands, Belgium and Switzerland. The trial would involve a loading dose of 400 mg/m2 followed by weekly dosing at 250 mg/m2 in most patients, although initial/weekly cetuximab doses of 250/250 and 350/350 mg/m² were also used [&lt;ulink linkID="499057" linkType="Reference"&gt;499057&lt;/ulink&gt;]. By February 2004, enrollment in EMR 62202-028 was complete at 49 patients; data demonstrated a Cmax of 158 microg/l and half-life of 97 h. Pharmacokinetics were linear [&lt;ulink linkID="1270108" linkType="Reference"&gt;1270108&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Second-line combination therapy&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;IIn October 2018, retrospective RAS analysis data from a multicenter, open-label, randomized, phase III EPIC study (EMR 062202-025) conducted to confirm the increased benefit of cetuximab-based therapy as a standard, second-line treatment for patients with RAS wildtype mCRC were presented at the 2018 ESMO Congress in Munich, Germany. Patients were administered cetuximab (400 mg/m2 day 1 followed by 250 mg/m2 weekly) + irinotecan (350 mg/m2 q3w) (n = 231) and the same regimen of irinotecan alone (n = 221). In irinotecan and cetuximab + irinotecan arms, median OS was 12 and 12.3 months (HR 0.91), respectively, and median PFS was 5.4 versus 2.6 months (HR 0.57, p &amp;lt; 0.0001), respectively. In irinotecan and cetuximab + irinotecan arms, ORR was 29.4 versus 5%, respectively. On addition of second-line cetuximab to irinotecan, ORR and PFS were doubled in RAS wt mCRC patients while compared with the same treatment in the RAS- unselected patients. Overall, 47.1% patients in the irinotecan arm received cetuximab-based treatment in a subsequent line of therapy versus 11.3% of patients in cetuximab and irinotecan regimen. Febrile neutropenia and diarrhea were the most commonly reported grade &amp;gt;/=3 treatment-related serious adverse events reported in &amp;gt;/= 5% patients in both arms [&lt;ulink linkID="2084497" linkType="Reference"&gt;2084497&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;n March 2003, the phase III BMS CA225-014 (EXPLORE) trial began to evaluate cetuximab plus oxaliplatin, 5-FU and leucovorin (FOLFOX4) vs FOLFOX4; a planned 1100 mCRC patients previously treated with irinotecan would be enrolled in the US [&lt;ulink linkID="479208" linkType="Reference"&gt;479208&lt;/ulink&gt;]. Enrollment in EXPLORE was due to be completed by 4Q06 [&lt;ulink linkID="524620" linkType="Reference"&gt;524620&lt;/ulink&gt;]. However, due to a change in standard of care, recruitment became difficult, and in December 2004 the trial was terminated having enrolled 102 patients. As a result, no conclusion regarding differences in efficacy could be made (median OS was 12.3 and 13.5 months for cetuximab + FOLFOX4 and FLOFOX4, respectively) [&lt;ulink linkID="1270160" linkType="Reference"&gt;1270160&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In October 2018, data from a multicenter, phase II study (&lt;ulink linkID="222540" linkType="Protocol"&gt;UMIN000016439&lt;/ulink&gt;) which evaluated the efficacy and safety of cetuximab rechallenge as a salvage chemotherapy in patients with RAS wild-type mCRC were presented at the 2018 ESMO Congress in Munich, Germany. Patients (n = 33) received cetuximab (weekly) + CPT-11 (biw). The response rates (primary endpoint) of partial response, stable disease and progressive disease (PD) were 15.2, 39.4 and 42.4%, respectively. Median PFS and OS (secondary endpoints) were 88 and 262 days, respectively. Overall response rate, disease control rate and PD were 12.5, 50 and 37.5%, respectively, by any mutation of liquid biopsy; and 25, 50 and 25%, respectively, by wild type mutation. Overall, cetuximab rechallenge showed some activity in the salvage setting in patients for whom cetuximab was previously effective [&lt;ulink linkID="2084718" linkType="Reference"&gt;2084718&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2017, data from a randomized trial (SWOG-1406; &lt;ulink linkID="197307" linkType="Protocol"&gt;NCT02164916&lt;/ulink&gt;) which evaluated the safety and efficacy of irinotecan and cetuximab with or without vemurafenib, in patients with BRAF-mutant mCRC, were presented at the 53rd ASCO meeting in Chicago, IL. Patients (n = 106) were randomized to irinotecan (180 mg/m2 iv, q2w) and cetuximab (500 mg/m2 iv q2w) without or with vemurafenib (960 mg po, bid continuous) (arm 1 and 2; n = 50 and 49, respectively). In arm 1 and 2, median PFS (primary endpoint) was 2.0 and 4.3 months, respectively (p = 0.001); median and overall survival was 5.9 and 9.6 months, respectively (p = 0.19). A total of 48% of patients in arm 1 had disease progression and crossed over to arm 2. In crossover patients (n = 24), median PFS was 5.8 months, median overall survival was 12.1 months, partial response was archived by 17% of patients, stable disease was observed in 55%, and disease control rate was 72% [&lt;ulink linkID="1932117" linkType="Reference"&gt;1932117&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2014, non-randomized, open-label, single-arm, phase I/II trial (&lt;ulink linkID="217478" linkType="Protocol"&gt;UMIN000015835&lt;/ulink&gt;, KSCC1401) began in Japan in patients (expected n = 57) with RAS wild type metastatic colorectal cancer [&lt;ulink linkID="2100275" linkType="Reference"&gt;2100275&lt;/ulink&gt;]. In October 2018, results were presented at ESMO Congress in Munich, Germany. The treatment response with confirmation in phase II part was complete response(CR), partial response(PR), stable disease(SD), progressive disease(PD), not evaluated(NE) in (n = 1, n = 28, n = 15, n = 6, n = 1) and objective reaction rate(ORR) and disease control rate(DCR) was 56.9 and 86.3% of patients, respectively. The best response with CR, PR, SD, PD, NE in (n = 1, n = 37, n = 11, n = 1, n = 1) and ORR and DCR was 74.5 and 86.3% of patients, respectively. Grade 3,4 adverse events included neutropenia, appetite loss, hypokalemia and diarrhea in 31.4, 27.5, 11.8 and 11.8% of patients were reported. Grade 3,4 hand–foot syndrome was reported in 9.8% of patients [&lt;ulink linkID="2084466" linkType="Reference"&gt;2084466&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2010, data were presented at the 46th ASCO meeting in Chicago, IL, from a 185-patient study of  cetuximab plus XELIRI or XELOX chemotherapy, showing that both treatment regimens were effective with manageable tolerability profiles [&lt;ulink linkID="1105032" linkType="Reference"&gt;1105032&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2009, the company began an open-label, randomized, multicenter, phase I/II trial (&lt;ulink linkID="61664" linkType="Protocol"&gt;NCT01008475&lt;/ulink&gt;; EMR62242-004; POSEIDON) in patients with metastatic CRC in Europe and Israel. A total of 228 patients would receive abituzumab  in combination with &lt;ulink linkID="10388" linkType="Drug"&gt;cetuximab&lt;/ulink&gt; and &lt;ulink linkID="2871" linkType="Drug"&gt;irinotecan&lt;/ulink&gt; (standard of care; SOC). At that time, the trial was expected to complete in December 2014. In July 2013, the trial was ongoing  but not recruiting patients [&lt;ulink linkID="1056305" linkType="Reference"&gt;1056305&lt;/ulink&gt;]. In June 2014, data from the phase II section of the trial were presented at the 16th World Congress on Gastrointestinal Cancer in Barcelona, Spain. Patients (n = 216) received abituzumab (500 or 1000 mg iv, biw) plus SOC or SOC alone. Median PFS was 5.4, 5.6 and 5.6 months for the 500 and 1000 mg abituzumab + SOC and SOC alone groups, respectively. Overall survival (OS) was 15 and 14.4 months for the 500- and 1000-mg abituzumab groups, compared with 11.6 for the SOC only group. No difference in response rates was observed between the two groups. The primary endpoint of increase PFS was not met; however, the combination of abituzumab with SOC trended toward an increase in OS. The safety profile of the combination treatment was acceptable, with treatment-emergent adverse events were reported in all patients receiving the combination treatment and 98.6% of patients on SOC only. Adverse events deemed related to abituzumab treatment were reported in 48.6 and 56.5% of patients in the 500- and 1000-mg groups, respectively. No adverse event that led to death was deemed related to abituzumab treatment. The most common adverse events (in &amp;gt;/= 25%) included neutropenia, diarrhea, nausea and rash [&lt;ulink linkID="1576335" linkType="Reference"&gt;1576335&lt;/ulink&gt;]. In September 2014, further data were presented from POSEIDON trial at the 39th European Society for Medical Oncology congress in Madrid, Spain.  For patients with high alpha-v beta-6, alpha-v and alpha-v beta-5 expressions, the overall survival was 10.2 months in the SoC arm, and 15.3, 18.8 and 14.2 months, respectively, in abituzumab arm. The overall survival was 19.2 and 7.4 months for patients with high plasma CCL23 in abituzumab and placebo arms, respectively. Abituzumab exposure and its elimination half-life increased with dose (due to decrease clearance) whereas the mean volume of distribution remained constant. Dose-dependent accumulation of maximal serum concentrations was observed. Four patients in 500 mg abituzumab arm and three in 1000 mg arm had positive binding antibodies to abituzumab and none had positive neutralizing antibodies to abituzumab [&lt;ulink linkID="1596221" linkType="Reference"&gt;1596221&lt;/ulink&gt;]. The phase II trial was completed in April 2015 [&lt;ulink linkID="1056305" linkType="Reference"&gt;1056305&lt;/ulink&gt;], [&lt;ulink linkID="2029885" linkType="Reference"&gt;2029885&lt;/ulink&gt;]. In January 2015, results were published. Across the three arms, PFS (hazard ratio [HR]: 1.13 for arm A versus C and 1.11 for Arm B versus C) and response rates were found to be similar. However, there was a trend towards improved OS (HR: 0.83 for arm A versus C and 0.80 for Arm B versus C). Association of high tumor integrin alpha-v beta-6 expression was observed with longer OS in arms A (HR: 0.55) and B (HR: 0.41), than in arm C [&lt;ulink linkID="1635501" linkType="Reference"&gt;1635501&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2012, data from a phase II trial (&lt;ulink linkID="47386" linkType="Protocol"&gt;NCT00852228&lt;/ulink&gt;; OPTILIV) of cetuximab plus hepatic artery infusion (HAI) of irinotecan, 5-FU and oxaliplatin, administered to patients  with liver metastases from previously treated, wild-type KRAS CRC, were presented at the 48th ASCO meeting in Chicago, IL. Among 48 evaluable patients, the disease control rate was 85% [&lt;ulink linkID="1299199" linkType="Reference"&gt;1299199&lt;/ulink&gt;]. In October 2012, further data were presented at the 37th European Society for Medical Oncology Congress in Vienna, Austria. Patients (n = 64) received iv cetuximab (500 mg/m2) plus chronomodulated or conventional HAI of irinotecan, 5-FU, and oxaliplatin. The intent-to-treat objective tumor response rate was 45% (including two radiological complete responses), and disease control rate was 83%. Pathologic complete response was seen in one patient. The median PFS and the preliminary median survival was 9.1 and 28.6 months, respectively [&lt;ulink linkID="1325317" linkType="Reference"&gt;1325317&lt;/ulink&gt;]. In June 2013, further data from 18 patients were presented at the 49th ASCO Meeting in Chicago, IL.  The rate of objective responses was found to be 50% and rate of R0-R1  resection was 33.3%. The respective median PFS and OS duration was 11.6 and 28.6 months. Complete and partial responses were achieved by one and eight patients, respectively. A total of eight patients had stable disease and one patient had disease progression [&lt;ulink linkID="1427151" linkType="Reference"&gt;1427151&lt;/ulink&gt;]. In June 2014, further data were presented at the 50th ASCO meeting in Chicago, IL. In 19 patients who had resection, the median OS was 35 months and 4-year survival rate was 45%. Out of 45 patients who did not undergo resection, no patient survived for four years; median OS was 18.7 months [&lt;ulink linkID="1560033" linkType="Reference"&gt;1560033&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2010, data from a phase II trial evaluating cetuximab with &lt;ulink linkID="29831" linkType="Drug"&gt;sorafenib&lt;/ulink&gt; were presented at the 101st AACR meeting in Washington DC. Of 15 previously treated EGFR-positive, KRAS-mutant CRC patients enrolled, six had stable disease. Rash, electrolyte imbalances, hypertension and  diarrhea were the most common toxicities. Accrual was ongoing [&lt;ulink linkID="1088698" linkType="Reference"&gt;1088698&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2010, data from a Japanese phase II trial were presented at the Japanese Society of Medical Oncology annual meeting in Tokyo, Japan. The study evaluated the efficacy of cetuximab in combination with irinotecan for following chemotherapy in Japanese patients (n = 30) with advanced KRAS wild-type CRC. The primary endpoint was overall response  rate, which increased by 30%. The median PFS and OS also increased to 5.8 and 12.5 months, respectively [&lt;ulink linkID="1108507" linkType="Reference"&gt;1108507&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2009, phase II data from the BOND 2.5 trial were presented at the 45th ASCO meeting in Orlando, FL. Patients (n=33) previously treated with bevacizumab and chemotherapy received irinotecan at the same dose and schedule as last received prior to study, cetuximab 400 mg/m2 loading dose, then weekly at 250 mg/m2, plus bevacizumab 5 mg/kg q2w or 7.5 mg/kg q3w. Grade 3/4 toxicities included acneiform rash, hypomagnesemia, hypophosphatemia, neutropenia and diarrhea. At a median follow up of 32 months 3 partial responses and 11 patients with stable disease for over 4 months were seen. Median time to tumor progression was 3.9 months and median survival was 10.6 months [&lt;ulink linkID="1010068" linkType="Reference"&gt;1010068&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2003, a phase II study of cetuximab plus bevacizumab with or without irinotecan in bevacizumab-naiive patients with irinotecan-refractory mCRC began (&lt;ulink linkID="28495" linkType="Protocol"&gt;NCT00077298&lt;/ulink&gt;; CDR0000350086, MSKCC-03135, NCI-6444; BOND-2). The endpoints were time to tumor progression, response rates, OS and safety and tolerability. In Arm I patients (n=35) received cetuximab infusion weekly, iv bevacizumab infusion fortnightly or every 3 weeks; and irinotecan on day 1. In the second arm, patients (n=35) received cetuximab as in arm I and bevacizumab infusion fortnightly. By February 2009 the trial had been completed [&lt;ulink linkID="1017689" linkType="Reference"&gt;1017689&lt;/ulink&gt;]. Data were published in June 2009: 43 patients received cetuximab, bevacizumab and irinotecan  and 40 patients received cetuximab and bevacizumab. Toxicities were as was expected from the single agents. For cetuximab, bevacizumab and irinotecan , time to tumor progression was 7.3 months and the response rate was 37%; for the cetuximab and bevacizumab arm, time to progression was 4.9 months and the response rate was 20%. The OS for cetuximab, bevacizumab and irinotecan  was 14.5 months and the OS for cetuximab and bevacizumab was 11.4 months [&lt;ulink linkID="1270342" linkType="Reference"&gt;1270342&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2003, EMR 62202-501 (MABEL) began, to examine the combination of cetuximab and irinotecan in 1000 patients previously treated with irinotecan in several European countries [&lt;ulink linkID="499057" linkType="Reference"&gt;499057&lt;/ulink&gt;]. In June 2006, initial results from MABEL were reported at the 42nd ASCO meeting in Atlanta, GA. In 1123 patients, cetuximab plus irinotecan met the primary endpoint of a PFS rate at 12 weeks in patients with irinotecan-resistant mCRC [&lt;ulink linkID="670225" linkType="Reference"&gt;670225&lt;/ulink&gt;]. Final data were published in 2008. From 1147 patients enrolled, PFS rate at 12 weeks was 61%, and the median survival was 9.2 months [&lt;ulink linkID="970953" linkType="Reference"&gt;970953&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;In July 2001, Merck began enrolling patients in a phase II randomized, multicenter trial in irinotecan-refractory mCRC. Patients were randomized to receive single-agent cetuximab or cetuximab plus the same dose and schedule of irinotecan to which they were refractory; 225 patients were to be recruited [&lt;ulink linkID="437427" linkType="Reference"&gt;437427&lt;/ulink&gt;]. By February 2003, the trial (EMR 62202-007) had been completed, having enrolled 329 patients in over ten European countries [&lt;ulink linkID="479208" linkType="Reference"&gt;479208&lt;/ulink&gt;]. In June 2003, data from the phase II BOND (EMR 62202-007) study were presented at the 39th ASCO meeting in Chicago, IL, in which cetuximab was compared with cetuximab plus irinotecan in 329 patients with mCRC expressing EGFR, who had been previously treated with irinotecan. Patients in the combination arm received cetuximab (loading dose 400 mg/m2, then 250 mg/m2 weekly) plus irinotecan at the same dose and schedule on which their disease had progressed with previous irinotecan treatment. Cetuximab gave an overall response rate (ORR) of 11%, while the combination led to tumor shrinkage in 23% and tumor arrest in 33% of patients [&lt;ulink linkID="492151" linkType="Reference"&gt;492151&lt;/ulink&gt;], [&lt;ulink linkID="499057" linkType="Reference"&gt;499057&lt;/ulink&gt;]. Disease progression was slowed by &amp;gt; 4 months, and tumor shrinkage of &amp;gt;50% was observed in 22.9% of patients. Median survival for advanced patients was 8.6 months, with approximately a third of patients alive after 1 year [491581]. In the monotherapy arm of the study, a 10.8% response rate, 1.5-month median time to progression, 32.4% overall rate of disease control and 6.9 months of median survival time were seen. Severe toxicities in the monotherapy group were diarrhea (1.7%) and acne-like rash (5.2%), compared with 21.2% and 9.4% in the combination therapy arm [&lt;ulink linkID="491582" linkType="Reference"&gt;491582&lt;/ulink&gt;]. Similar data were presented in June 2003 at the fifth Perspectives in CRC International Congress in Barcelona, Spain [&lt;ulink linkID="498026" linkType="Reference"&gt;498026&lt;/ulink&gt;]. In September 2004, these data were presented at the Fourth International Monoclonal Antibodies in Cancer congress in Colorado Springs, CO [&lt;ulink linkID="560046" linkType="Reference"&gt;560046&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 1999, a phase II trial involving 98 patients with refractory CRC was initiated to evaluate cetuximab in combination with irinotecan [&lt;ulink linkID="342845" linkType="Reference"&gt;342845&lt;/ulink&gt;]. In November 2000, the company reported preliminary results from the trial, which demonstrated the activity of cetuximab and irinotecan, resulting in tumor shrinkage and slowed disease progression. The most common side effect of cetuximab observed was an acne-like rash. Anaphylaxis was infrequently observed during the first dose of cetuximab. In addition, cetuximab did not appear to cause or enhance side effects typically observed in treatment with chemotherapy [&lt;ulink linkID="388928" linkType="Reference"&gt;388928&lt;/ulink&gt;]. In May 2001, further data were presented at the 37th ASCO meeting in San Francisco, CA. Results from a phase II trial demonstrated, of the 120 patients with irinotecan-refractory disease, whose tumors expressed EGFR, when treated with 400 mg/m2 of cetuximab, 22.5% showed a partial response, while 7% had stable disease. Furthermore, cetuximab appeared to reduce toxicity of irinotecan [&lt;ulink linkID="408787" linkType="Reference"&gt;408787&lt;/ulink&gt;], [&lt;ulink linkID="408838" linkType="Reference"&gt;408838&lt;/ulink&gt;], [&lt;ulink linkID="409610" linkType="Reference"&gt;409610&lt;/ulink&gt;], [&lt;ulink linkID="411389" linkType="Reference"&gt;411389&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In November 2016, data from a study (&lt;ulink linkID="181632" linkType="Protocol"&gt;NCT02110082&lt;/ulink&gt;), which evaluated the safety and preliminary efficacy of &lt;ulink linkID="23886" linkType="Drug"&gt;urelumab&lt;/ulink&gt;, in combination with cetuximab , in patients with refractory mCRC  (n = 47) or SCCHN (n = 19), were presented at the 31st SITC Annual Meeting in National Harbor, MD. Patients received urelumab (0.1 mg/kg or 8 mg q3w) + cetuximab (400 mg/m2 on week 1 and 250 mg/m2 q1w thereafter). In patients receiving urelumab 0.1 mg/kg or 8 mg + cetuximab (n = 3 and 63, respectively), treatment-related AEs, treatment-related grade 3/4 ALT elevation, treatment-related serious AEs and treatment-related AEs leading to discontinuation was observed in 3 and 56; each 0; 0 and 2; and 0 and 2 patients, respectively. Best overall response like complete response, partial response, stable disease and partial disease was observed in each 0, each 0, 17 and 12, and 22 and 4 CRC and SCCHN patients, respectively. Confirmed overall response rate and disease control rate was each 0%, and 17 and 12%, respectively [&lt;ulink linkID="1883955" linkType="Reference"&gt;1883955&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;First-line combination therapy&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In June 2012, pooled analyses of data from phase II and III trials of cetuximab added to first-line chemotherapy, for patients with KRAS wild-type mCRC, were presented at the 48th ASCO meeting in Chicago, IL [&lt;ulink linkID="1299203" linkType="Reference"&gt;1299203&lt;/ulink&gt;], [&lt;ulink linkID="1299207" linkType="Reference"&gt;1299207&lt;/ulink&gt;], [&lt;ulink linkID="1299212" linkType="Reference"&gt;1299212&lt;/ulink&gt;]. In June 2012, pooled analyses were also presented at the 14th World Congress on Gastrointestinal Cancer in Barcelona, Spain [&lt;ulink linkID="1304595" linkType="Reference"&gt;1304595&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2010, a randomized, open-label, parallel-group-assignment, controlled, multicenter, phase III trial (&lt;ulink linkID="71683" linkType="Protocol"&gt;NCT01228734&lt;/ulink&gt;; EMR62202-057; TAILOR) was initiated in China to assess FOLFOX-4 with or without cetuximab in the 1st line treatment of in patients (n = 397) with KRAS wild-type mCRC. At that time, the trial was expected to complete in January 2017 [&lt;ulink linkID="1755166" linkType="Reference"&gt;1755166&lt;/ulink&gt;],  [&lt;ulink linkID="1755019" linkType="Reference"&gt;1755019&lt;/ulink&gt;]. In April 2016, topline data from the pivotal trial were reported, which showed that the study met its primary endpoint. Cetuximab plus FOLFOX significantly increased PFS compared with FOLFOX alone  [&lt;ulink linkID="1755019" linkType="Reference"&gt;1755019&lt;/ulink&gt;]. In July 2016, full data were reported (n = 393) showing that cetuximab plus FOLFOX and FOLFOX alone significant  improved median PFS  (9.2 versus 7.4 months, respectively) and  median  OS (20.7 versus 17.8 months,  respectively). The response rate for patients receiving  cetuximab plus FOLFOX was 61.1% compared with 39.5% for those patients receiving FOLFOX alone, and the combination decreased the risk of disease progression by 31% and the risk of death by 24% [&lt;ulink linkID="1777524" linkType="Reference"&gt;1777524&lt;/ulink&gt;]. In June 2016, similar clinical data were presented at the 18th World Congress on Gastrointestinal Cancer in Barcelona, Spain [&lt;ulink linkID="1781866" linkType="Reference"&gt;1781866&lt;/ulink&gt;]. In October 2016, clinical data were presented at the ESMO 2016 Congress in Copenhagen, Denmark. Efficacy in PFS and ORR were independent of tumor EGFR status as observed from 354 EGFR-evaluable patients from mITT population. In FOLFOX-4 + cetuximab treated group with EGFR status (positively staining EGFR cells) of 0, &amp;gt; 0 to 10%, &amp;gt; 10 to 20%, &amp;gt; 20 to 35% and &amp;gt;35 %, PFS was 9.2 and 7.9 months, 11.3 and 7.4 months, 9.3 and 8.1 months, 7.5 and 9.2 months, and 7.0 and 5.2 months, respectively; and ORR was 67.1 and 35.1%, 71.4 and 41.7%, 73.3 and 42.9%, 44.4 and 64.3% and 44.8 and 35.7%, respectively [&lt;ulink linkID="1805940" linkType="Reference"&gt;1805940&lt;/ulink&gt;] [&lt;ulink linkID="1801032" linkType="Reference"&gt;1801032&lt;/ulink&gt;]. In January 2017, further clinical data were presented at the 2017 ASCO Gastrointestinal Cancers Symposium in San Francisco, CA. Progression-free survival (PFS), overall survival (OS) and overall response rate (ORR) were found to be significantly greater in left (7.6 months, 18.7 months and 43.2%, respectively) compared with right sided (4.5 months, 9.3 months and 23.7%, respectively) tumors in the FOLFOX-4 + cetuximab arm. Furthermore, PFS and ORR were significantly greater in left (7.6 months and 43.2%, respectively) relative to right (4.5 months and 23.7%, respectively) sided tumors in the FOLFOX-4 arm, whereas OS was numerically greater (9.3 and 14.7 months at left and right sided, respectively) [&lt;ulink linkID="1896909" linkType="Reference"&gt;1896909&lt;/ulink&gt;]. In September 2017, further clinical data were presented at the ESMO 2017 Congress in Madrid, Spain. The difference observed in global health status/quality of life at baseline, week-8, week-24, week-40 and at final assessment was – 0.8, - 0.9, - 1.9, 4.9 and – 2.8, respectively, between cetuximab + FOLFOX-4 and FOLFOX-4 alone groups [&lt;ulink linkID="1960690" linkType="Reference"&gt;1960690&lt;/ulink&gt;]. In June 2018, further data were presented at the 54th ASCO Annual Meeting  in Chicago, IL. In the modified intent-to-treat population, final median OS by tumor location was 22 versus 18.3 months, respectively, (p = 0.007) in left sided tumors and 11.5 versus 9.4 months, respectively, in right-sided tumors with cetuximab +FOLFOX-4 versus FOLFOX-4 monotherapy treatment. No new or unexpected safety findings were reported [&lt;ulink linkID="2039491" linkType="Reference"&gt;2039491&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In January 2010,  pooled data from the CRYSTAL and OPUS  studies were presented at the ASCO GI meeting in Orlando, FL. In a subgroup analysis of pooled data from the CRYSTAL and OPUS studies (n = 845) of KRAS-wild-type mCRC patients treated with cetuximab and chemotherapy, the risk of death and PFS were reduced by 19% and 34% respectively for those on cetuximab plus chemotherapy compared to chemotherapy alone; the ORR in these patients was 57.3% compared to 38.5% [&lt;ulink linkID="1070930" linkType="Reference"&gt;1070930&lt;/ulink&gt;], [&lt;ulink linkID="1076236" linkType="Reference"&gt;1076236&lt;/ulink&gt;]. In November 2010, pooled analysis from the CRYSTAL and OPUS studies confirmed that BRAF mutation status was also a prognostic marker for cetuximab efficacy in mCRC [&lt;ulink linkID="1149683" linkType="Reference"&gt;1149683&lt;/ulink&gt;]. In June 2011, similar data were presented at the 47th ASCO meeting in Chicago, IL. In mCRC patients receiving first-line treatment that had KRAS Gly13Asp there was a poor prognosis, and this was more pronounced in patients treated with FOLFOX4 alone. First-line chemotherapy + cetuximab appeared to benefit KRAS Gly13Asp mutant mCRC patients in both the studies, and this effect was at a lower absolute effect level than for patients with wild-type KRAS mCRC [&lt;ulink linkID="1196421" linkType="Reference"&gt;1196421&lt;/ulink&gt;]. In June 2012, a pooled analysis of CRYSTAL and OPUS was presented at the 14th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The addition of cetuximab to chemotherapy treatment appeared to  benefit patients with intermediate- and high-prognostic risk  more than those with low-prognostic risk [&lt;ulink linkID="1304593" linkType="Reference"&gt;1304593&lt;/ulink&gt;]. In July 2012, a pooled analysis was presented at the Tenth Japanese Society of Medical Oncology Annual Meeting in Osaka, Japan. Patients with  no liver-limited disease had better treatment outcomes, compared with those with liver-limited disease  [&lt;ulink linkID="1314035" linkType="Reference"&gt;1314035&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2007, the phase III,  independent, randomized, controlled, head-to-head, FIRE-3 study (&lt;ulink linkID="45650" linkType="Protocol"&gt;NCT00433927&lt;/ulink&gt;) began to compare FOLFIRI plus cetuximab with FOLFORI plus bevacizumab in previously untreated patients with wild-type KRAS mCRC. The primary endpoint was PFS. The trial was to enroll 567 patients and complete in December 2016 [&lt;ulink linkID="1436107" linkType="Reference"&gt;1436107&lt;/ulink&gt;]. Data were presented at the 49th ASCO meeting in Chicago, IL in June 2013. A total of 592 patients were enrolled.  ORRs were comparable (62% vs 58%) and median PFS was  identical (10.3 and 10.4 months). However, OS was significantly better in the FOLFIRI plus cetuximab group (28.7 months versus 25 months in the bevacizumab group) [&lt;ulink linkID="1427134" linkType="Reference"&gt;1427134&lt;/ulink&gt;]. In September 2013, further data were presented at the 17th European Cancer Congress in Amsterdam, Netherlands; the trial included 752 mCRC patients; 592 had confirmed KRAS exon 2 wild-type tumors and were randomized to cetuximab plus FOLFIRI (n = 297) and bevacizumab plus FOLFIRI (n = 295). Data presented for 342 patients with RAS wild-type tumors demonstrated that OS was 33.1 months for cetuximab plus FOLFIRI and 25.6 months for bevacizumab plus FOLFIRI (objective response rates: 65.5 versus 59.6%), and in 178 patients with any RAS mutation, OS was 20.3 and 20.6 months, respectively (objective response rates: 38.0 versus 51.2%) and PFS was 7.5 and 10.1 months, respectively [&lt;ulink linkID="1482492" linkType="Reference"&gt;1482492&lt;/ulink&gt;].  In September 2013, further  data from were presented at the same meeting.  In wild-type intend-to-treat and Ras evaluable patients, the overall survival rates (ORRs) ranged from 61 to 62% with cetuximab versus 58 to 59.4% with bevacizumab, median PFS  ranged from 9.9 to 10 months with cetuximab versus 10.3 with bevacizumab and median OS was 28.7 months with cetuximab and 24.9 to 25 months with bevacizumab [&lt;ulink linkID="1480184" linkType="Reference"&gt;1480184&lt;/ulink&gt;]. In January 2014, data from an analysis of the effect of mutations in the EGFR-dependent signaling pathway on FOLFIRI plus cetuximab or bevacizumab treatment were presented at the 2014 Gastrointestinal Cancers Symposium in San Francisco, CA. Mutations in PIK3CA were found to have to effect on PFS or OS [&lt;ulink linkID="1517467" linkType="Reference"&gt;1517467&lt;/ulink&gt;]. In May 2014, data from a subgroup analysis in 395 patients who received second-line therapy were presented at the 50th ASCO meeting in Chicago, IL. A correlation between first-line PFS and choice of second-line mAb and second-line oxaliplatin use was observed. A trend towards favorable OS and second-line OS was observed in patients who received second-line therapy without mAbs. Also, a trend towards longer second-line therapy was observed in patients treated with first-line cetuximab [&lt;ulink linkID="1559969" linkType="Reference"&gt;1559969&lt;/ulink&gt;]. In May 2014, further data were presented at the same meeting. Carcinoembryonic antigen  shrinkage by &amp;gt;/= 75% significantly correlated with longer OS and PFS in the cetuximab group and with OS in the bevacizumab arm [&lt;ulink linkID="1560034" linkType="Reference"&gt;1560034&lt;/ulink&gt;]. In January 2015, further clinical data were presented from 124 patients at the 2015 ASCO Gastrointestinal Cancer Symposium in San Francisco, CA. In a subgroup of patients with RAS wild-type who received oxaliplatin pretreatment (n = 36), the respective ORR in the FOLFIRI + cetuximab and FOLFIRI + bevacizumab groups was 73.7 and 47.1% and the respective PFS and OS were  10.2 and 27.9 months  for FOLFIRI + cetuximab and were 9.9 and 44.3 months for FOLFIRI + bevacizumab [&lt;ulink linkID="1632903" linkType="Reference"&gt;1632903&lt;/ulink&gt;]. In January 2016, further clinical data from 992 patients were presented at the 2016 Gastrointestinal Cancers Symposium in San Francisco, CA. Pronounced differences in OS by time-interval analysis were observed between 24 and 30 months and between 30 and 36 months [&lt;ulink linkID="1730007" linkType="Reference"&gt;1730007&lt;/ulink&gt;]. No difference in OS was observed between groups. Hazard ratio between arms were not significantly different  [&lt;ulink linkID="1767290" linkType="Reference"&gt;1767290&lt;/ulink&gt;]. In July 2017, further data after central review  were presented at the 19th World Congress on Gastrointestinal Cancer in Barcelona, Spain. Clear superior survival outcome was observed in patients with conducted secondary resection compared to patients with resectable disease but without surgery, or to patients with unresectable disease (51.3 versus 30.8 and 18.6 months, respectively, p &amp;lt; 0.0001) [&lt;ulink linkID="1953446" linkType="Reference"&gt;1953446&lt;/ulink&gt;]. In June 2018, further data were presented at the 54th ASCO Annual Meeting in Chicago, IL. RAS wt population in FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab groups, median PFS was 10.3 versus 10.4 months (overall: n = 400; p = 0.71), 7.6 versus 9.0 months (right-sided primary tumors: n = 88; p = 0.13) and 10.7 versus 10.7 months (left-sided primary tumors: n = 307; p = 0.38), respectively; median OS was 31.1 versus 25.6 months (overall; p = 0.012), 18.3 versus 23 months (right-sided primary tumors; p = 0.29) and 36.4 versus 28 months (left-sided primary tumors; p = 0.004), respectively; ORR was 65.8 versus 58.7% (overall; p = 0.15), 52.6 versus 50% (right-sided primary tumors; p = 0.83) and 69 versus 61.7% (left-sided primary tumors; p = 0.19), respectively. Overall survival rates at three-year and five years showed a persistent OS benefit for patients with left-sided RAS wt tumors [&lt;ulink linkID="2039193" linkType="Reference"&gt;2039193&lt;/ulink&gt;]. In October 2018, further data were presented from ESMO Congress in Munich, Germany. Early tumor shrinkage (-20% tumor diameter following 6 weeks therapy; p = 0.034) and depth of response (p &amp;lt; 0.001) were associated with conversion to resectability. Post-nadir survival was improved by metastatic resection in cetuximab treated patients compared to bevacizumab treated patients [&lt;ulink linkID="2084572" linkType="Reference"&gt;2084572&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2005, the phase III trial CAIRO2 (&lt;ulink linkID="42639" linkType="Protocol"&gt;NCT00208546&lt;/ulink&gt;) began  to examine the combined regimen of cetuximab, &lt;ulink linkID="12205" linkType="Drug"&gt;capecitabine&lt;/ulink&gt;, oxaliplatin and bevacizumab in patients with previously untreated advanced CRC. In September 2007, initial data from the 700-patient study were presented at ECCO in Barcelona, Spain, which confirmed the safety of the addition of cetuximab to a combination of capecitabine, oxaliplatin and bevacizumab [&lt;ulink linkID="833328" linkType="Reference"&gt;833328&lt;/ulink&gt;]. Further data, presented at the 44th ASCO meeting in June 2008, showed that there was no clinical benefit of adding cetuximab to CapOx and bevacizumab. Median PFS was 10.7 months versus 9.8 months in the cetuximab arm, response rates were 40.6% vs 43.9% and median OS 20.4 months vs 20.3 months. There was no significant difference in PFS or OS between patients with a KRAS mutation and those without [&lt;ulink linkID="917035" linkType="Reference"&gt;917035&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2005, a randomized, open-label, active control, phase III study (&lt;ulink linkID="45108" linkType="Protocol"&gt;NCT00182715&lt;/ulink&gt;; EU-20516; COIN) was initiated in patients (estimated n = 2421) with mCRC. Previously untreated patients were to receive either continuous chemotherapy comprising oxaliplatin, leucovorin and fluorouracil (OxMdG) or oxaliplatin and capecitabine (XELOX) with or without cetuximab, or intermittent chemotherapy with OxMdG or XELOX [&lt;ulink linkID="1041140" linkType="Reference"&gt;1041140&lt;/ulink&gt;]. In September 2009, it was reported at the joint 15th ECCO and 34th ESMO Congress in Berlin, Germany, that the study did not meet its primary endpoint of OS; the median OS for wt-KRAS patients who received cetuximab plus chemotherapy was 17 months compared to 17.9 months for patients who received chemotherapy alone. In addition, wt-KRAS patients who received the cetuximab-based therapy also experienced increase in grade III or IV non-hematological events (77%), diarrhea (24%), hypomagnesemia (4%), hand foot syndrome (11%) and skin rash (20%); the respective incidences for the chemotherapy-alone group was 62, 14, 0, 4, and less than 1% [&lt;ulink linkID="1044331" linkType="Reference"&gt;1044331&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2003, EMR 62202-013 (phase III) was to enroll 900 previously untreated patients with non-resectable mCRC in Europe, Asia Pacific and Latin America, and evaluate cetuximab plus irinotecan, 5-FU and folinic acid (FOLFIRI), with survival as the endpoint [&lt;ulink linkID="499057" linkType="Reference"&gt;499057&lt;/ulink&gt;]. In May 2004, a randomized, open-label, active control, parallel assignment, safety and efficacy, phase III trial (&lt;ulink linkID="42408" linkType="Protocol"&gt;NCT00154102&lt;/ulink&gt;; EMR 62202-013; CRYSTAL) was initiated in patients (n = 1221) with previously untreated mCRC. Patients were to receive either: iv cetuximab (400 mg/m2) for the first infusion then weekly iv infusion (250 mg/m2), plus biweekly &lt;ulink linkID="2871" linkType="Drug"&gt;irinotecan&lt;/ulink&gt; (180 mg/m2), folinic acid (FA) infusion (400 mg/m2 (racemic) or 200 mg/m2 (L-form)), 5-FU bolus (400 mg/m2 followed by a 46-h continuous infusion of 2400 mg/m2); or 5-FU/FA plus irinotecan regimen without cetuximab. The primary endpoint measured PFS under 5-FU/FA plus irinotecan with or without cetuximab [&lt;ulink linkID="885966" linkType="Reference"&gt;885966&lt;/ulink&gt;]. In January 2007, initial results from CRYSTAL showed cetuximab plus FOLFIRI met the primary endpoint of increasing median duration of PFS over FOLFIRI alone [&lt;ulink linkID="756409" linkType="Reference"&gt;756409&lt;/ulink&gt;], [&lt;ulink linkID="756919" linkType="Reference"&gt;756919&lt;/ulink&gt;]. In June 2007, similar data were presented at the 43rd ASCO meeting in Chicago, IL [&lt;ulink linkID="804673" linkType="Reference"&gt;804673&lt;/ulink&gt;]. Further data, presented at ECCO in Barcelona, Spain in September 2007, demonstrated an overall 15% reduction in the risk of metastasis. Treatment also significantly increased response rate (47% in the cetuximab plus FOLFIRI group compared to 39% in the FOLFIRI alone group). In addition, the number of complete resections was three times higher in the cetuximab plus FOLFIRI arm compared with FOLFIRI alone [&lt;ulink linkID="833328" linkType="Reference"&gt;833328&lt;/ulink&gt;]. In May 2008, data from EMR 62202-013 were presented at the 44th annual ASCO meeting in Chicago, IL. The treatment effect of combination cetuximab/FOLFIRI in patients with KRAS wild-type was significantly enhanced compared with FOLFIRI alone. However, patients with KRAS mutation did not benefit from treatment [&lt;ulink linkID="911913" linkType="Reference"&gt;911913&lt;/ulink&gt;], [&lt;ulink linkID="912090" linkType="Reference"&gt;912090&lt;/ulink&gt;]. In September 2008, at the 33rd European Society for Medical Oncology (ESMO) Congress in Stockholm, Sweden, further data were presented showing a response rate of 77% for patients with KRAS wild-type tumors and metastases limited to the liver. OS in KRAS wild-type tumor patients receiving the drug was up to 25 months, compared to 21 months for FOLFIRI alone. However, this was not significant. OS in patients with KRAS mutant tumors did not differ between the treatment arms; ORR of those on cetuximab plus chemotherapy was 59% compared to 43% on chemotherapy alone [&lt;ulink linkID="943610" linkType="Reference"&gt;943610&lt;/ulink&gt;], [&lt;ulink linkID="943560" linkType="Reference"&gt;943560&lt;/ulink&gt;], [&lt;ulink linkID="943611" linkType="Reference"&gt;943611&lt;/ulink&gt;]. The company noted that the failure of the trial to meet its secondary endpoint of OS benefit, but its success in meeting its primary endpoint, may have been due to the randomization of a higher proportion of patients who began on the FOLFIRI-only arm to the cetuximab arm on progression [&lt;ulink linkID="943676" linkType="Reference"&gt;943676&lt;/ulink&gt;]. Data were published in April 2009. The hazard ratio for PFS in the cetuximab plus FOLFIRI group as compared with the FOLFIRI group was 0.85. No significant difference in the OS between the two groups was observed (HR: 0.93). In the KRAS wild-type patients, cetuximab + FOLFIRI resulted in a 32% decrease in the risk of progressive disease. Grade 3 or 4 adverse events that occurred more frequently in the combination group included skin reactions (19.7%), infusion-related reactions (2.5%) and diarrhea (15.7%). It was concluded that first-line treatment with cetuximab plus FOLFIRI reduced the risk of progression of mCRC compared with FOLFIRI alone; however, the benefit of cetuximab was limited to patients with KRAS wild-type tumors [&lt;ulink linkID="1018361" linkType="Reference"&gt;1018361&lt;/ulink&gt;], [&lt;ulink linkID="1018366" linkType="Reference"&gt;1018366&lt;/ulink&gt;]. In September 2009, results from a retrospective analysis of the CRYSTAL study were presented at the joint 15th Congress of the ECCO and 34th ESMO Congress in Berlin, Germany. Data showed that cetuximab plus FOLFIRI reduced the risk of disease progression by 30%, and increased the median OS to 19.9 months in the intent-to-treat population compared to 18.6 months for those who received FOLFIRI alone. In a subset of wild-type KRAS patients, the median OS was significantly increased to 23.5 months in patients who received cetuximab plus FOLFIRI compared to 20 months for FOLFIRI patients [&lt;ulink linkID="1044315" linkType="Reference"&gt;1044315&lt;/ulink&gt;], [&lt;ulink linkID="1044331" linkType="Reference"&gt;1044331&lt;/ulink&gt;].  In June 2010, data from CRYSTAL were presented at the ASCO meeting in Chicago, IL, which confirmed that KRAS was a strong predictive biomarker for cetuximab efficacy [&lt;ulink linkID="1104320" linkType="Reference"&gt;1104320&lt;/ulink&gt;]. In November 2010, results presented at ESMO in Milan, Italy, showed the median OS was 28.3 months in KRAS-wildtype patients with tumor shrinkage of 20% within the first 8 weeks of treatment [&lt;ulink linkID="1158241" linkType="Reference"&gt;1158241&lt;/ulink&gt;]. In April 2011, similar data were published [&lt;ulink linkID="1185329" linkType="Reference"&gt;1185329&lt;/ulink&gt;]. A new analysis from the CRYSTAL trial was presented at the 47th ASCO meeting in Chicago, IL in June 2011. Results showed that in patients with non-liver limited disease, ie metastatic disease which has progressed beyond the liver, cetuximab and FOLFIRI led to a significant increase in OS, compared to patients treated with chemotherapy alone (22.5 vs 17.4 months) [&lt;ulink linkID="1197637" linkType="Reference"&gt;1197637&lt;/ulink&gt;]. In September 2013, biomarker analysis was ongoing [&lt;ulink linkID="1482492" linkType="Reference"&gt;1482492&lt;/ulink&gt;]. In September 2013, further data from a post-hoc analysis performed in 476 patients were presented at the 2013 European Cancer Congress in Amsterdam, the Netherlands. In chemotherapy +  cetuximab arm, tumor response and early tumor shrinkage was  higher when compared with chemotherapy alone. In chemotherapy +  cetuximab arm, early tumor shrinkage was associated with global health status quality of life and social functioning at week-8  [&lt;ulink linkID="1481470" linkType="Reference"&gt;1481470&lt;/ulink&gt;]. In June 2014, further data were presented at the 50th ASCO meeting in Chicago, IL. In patients with wild-type RAS tumors, addition of cetuximab to FOLFOX4 was associated with significantly improved responses while no benefits were observed with a trend for worse outcome in patients harboring any RAS mutation [&lt;ulink linkID="1562309" linkType="Reference"&gt;1562309&lt;/ulink&gt;], [&lt;ulink linkID="1557268" linkType="Reference"&gt;1557268&lt;/ulink&gt;]. In January 2016, further clinical data were presented at the 2016 Gastrointestinal Cancers Symposium in San Francisco, CA. Compared with the respective treatment arms of the younger patient subgroup, there were more grade 3/4 adverse events in both treatment arms of older patient subgroup. In patients with RAS wild type tumors in younger and older patients in cetuximab + FOLFIRI for PFS  was 11.4 and 11.3 months, respectively; OS was 28.8 and 26.3 months, respectively; objective response rate were 65.9 and 67.2%, respectively  [&lt;ulink linkID="1729955" linkType="Reference"&gt;1729955&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In June 2018, data from a two arm phase II study (&lt;ulink linkID="72730" linkType="Protocol"&gt;NCT01251536&lt;/ulink&gt;; EudraCT 2009-009992-36; Everest 2) which evaluated the efficacy and safety of FOLFIRI in combination with standard or escalating dose of cetuximab as first line treatment in patients with mCRC were presented at the 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. Patients (n = 101 of 108 in five countries) received standard FOLFIRI (irinotecan 180 mg/m2, leucovorin 400 mg/m2, 5-FU 400 mg/m2 bolus, 5-FU 2400 mg/m2 infusion q2w) with cetuximab (250 mg/m2 weekly after loading with 400 mg/m2). Patients with no cetuximab-related skin toxicity by day 22 (n = 8) or 36 (n = 3), respectively, cetuximab was escalated to 350 mg/m2, then to 500 mg/m2. The ORR was 67% with 14 patients in CR. During study treatment, six deaths unrelated to treatment occurred [&lt;ulink linkID="2054700" linkType="Reference"&gt;2054700&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In  June 2018, clinical data from the run-in phase of the single arm multicentric phase II study (AVETUX; AIO-KRK-0216; &lt;ulink linkID="300844" linkType="Protocol"&gt;NCT03174405&lt;/ulink&gt;) which assessed the safety and efficacy of avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer conducted at ten German sites were presented at the 54th ASCO Annual Meeting in Chicago, IL. The AVETUX regimen was shown to be feasible with an acceptable safety profile. The noted response rate of 75% and disease control rate of 95% in the first 20 patients demonstrate the high efficacy of the AVETUX regimen [&lt;ulink linkID="2039598" linkType="Reference"&gt;2039598&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2017, clinical data from a randomized, multicenter, phase II trial  (&lt;ulink linkID="90613" linkType="Protocol"&gt;NCT01675999&lt;/ulink&gt;; PRODIGE 22) evaluating neoadjuvant FOLFOX4 + cetuximab in patients with locally advanced colorectal cancer were presented at the ESMO 2017 Congress in Madrid, Spain. Patients (n = 120, from 37 French centers) were randomized to receive adjuvant FOLFOX after colectomy (arm A control) or neoadjuvant FOLFOX for 4 cycles before surgery and 8 cycles after (arm B). RAS wild-type patients received peri-operative FOLFOX + cetuximab prior to colectomy (arm C). Major pathological responses (Tumor Regression Grade 1 to 2; primary endpoint) were observed in 7.7, 44.2 and 6.3% of patients in arms A, B and C respectively (p &amp;lt; 0.001) [&lt;ulink linkID="1960696" linkType="Reference"&gt;1960696&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In   October 2016, results from a post hoc analysis of a phase II study (EudraCT 2009-014041-81; CAPRI-GOIM) of cetuximab + FOLFIRI in patients with mCRC (n = 340) were presented at the ESMO 2016 Congress in Copenhagen, Denmark. Out of 182 patients who underwent next generation sequencing (NGS), 104 were wild type (WT) for KRAS, NRAS, BRAF and PIK3CA genes. In the intention to treat population, NGS cohort and quadruple WT patients, median progression-free survival and overall response rate were comparable between age subgroups [&lt;ulink linkID="1806043" linkType="Reference"&gt;1806043&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2016, results from the subgroup and primary endpoint analysis of a multicenter, single-arm, phase II study (NCT01051167, CEBIFOX) that evaluated cetuximab as first-line therapy in patients with KRAS wild-type mCRC were presented at the ESMO 2016 Congress in Copenhagen, Denmark. Patients were treated with cetuximab (500 mg/m2, q2w) + mFOLFOX6. Median progression-free survival and overall survival (OS) was 9.6 and 29.4 months, respectively. Overall, 17.8 and 10.6% of patients had additional RAS or BRAF mutations, respectively, which had negative effect on outcomes. However, 62.5% of patients had TP53 mutations that did not impact outcomes [&lt;ulink linkID="1805751" linkType="Reference"&gt;1805751&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2014, data from a phase II trial (&lt;ulink linkID="45966" linkType="Protocol"&gt;NCT00527111&lt;/ulink&gt;) of chemoradiotherapy with or without cetuximab in patients with locally advanced rectal adenocarcinoma were presented at the 2014 Gastrointestinal Cancers Symposium in San Francisco, CA. The pathological complete response, OS and local recurrence rates were similar across both treatment cohorts [&lt;ulink linkID="1517436" linkType="Reference"&gt;1517436&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2011, data from a phase II open-label trial (&lt;ulink linkID="45558" linkType="Protocol"&gt;NCT00479752&lt;/ulink&gt;; CECOG/CORE1.2.002), evaluating the efficacy and safety of FOLFOX-4  plus weekly cetuximab versus FOLFOX-4 plus cetuximab every 2 weeks as first-line therapy in patients (n = 152) with mCRC with wild-type KRAS, were presented at the Gastrointestinal Cancers Symposium of ASCO in San Francisco, CA. Both treatment regimens demonstrated similar efficacy; response rates were 51% and 63% for the weekly and every second week treatment regimens, respectively [&lt;ulink linkID="1162040" linkType="Reference"&gt;1162040&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2008, an open-label, phase I/II study (&lt;ulink linkID="31738" linkType="Protocol"&gt;NCT00778830&lt;/ulink&gt;; APEC; EMR 62202-505; CTR20131098) of cetuximab, in combination with FOLFIRI or FOLFOX, was initiated in patients (n = 288) with KRAS wild-type mCRC in the Asia Pacific region. The study was expected to be completed in June 2013 [&lt;ulink linkID="1455592" linkType="Reference"&gt;1455592&lt;/ulink&gt;]. In February 2009, the trial was initiated in China [&lt;ulink linkID="1572656" linkType="Reference"&gt;1572656&lt;/ulink&gt;]. In July 2013, clinical data were presented at the 15th World Congress on Gastrointestinal Cancer in Barcelona, Spain. Administering cetuximab q2w resulted in similar efficacy and safety profiles to those reported in pivotal studies with the same dosing regimen. Early tumor shrinkage of &amp;gt;/= 20% at week 8 seemed to be an on-treatment marker showing association with long-term benefit [&lt;ulink linkID="1450128" linkType="Reference"&gt;1450128&lt;/ulink&gt;]. ​In January 2015, further clinical data were presented from 289 patients at the 2015 ASCO Gastrointestinal Cancer Symposium in San Francisco, CA.​ The median survival  was 26.8 months in the KRAS wild-type population. Death occurred in 64% of patients. Cetuximab + FOLFOX or FOLFIRI was active and tolerable as first-line therapy [&lt;ulink linkID="1632911" linkType="Reference"&gt;1632911&lt;/ulink&gt;]. In June 2016, further clinical data were presented at the 18th World Congress on Gastrointestinal Cancer in Barcelona, Spain. Median PFS and OS of 13.0 and 28.4 months was observed; while 64.7 and 10.8% of patients who underwent curative R0 resections achieved best confirmed objective response rate in the RAS-wt population (n = 167), respectively. Median depth of response (DpR) of 62.2%; interquartile range (IQR) of 39.1 to 80.0%; median time to tumor size nadir of 5.9 months was observed in the overall DpR-evaluable population; while median DpR of 62.2 and 62.5%; IQR of 40.0 to 80.7% and 38.1 to 79.0%; median time to nadir was 5.9 months and 7.4 months was observed in FOLFOX plus cetuximab (n = 103) and FOLFIRI plus cetuximab (n = 56) treatment subgroups, respectively [&lt;ulink linkID="1781825" linkType="Reference"&gt;1781825&lt;/ulink&gt;]. In January 2018, further clinical data were presented at the ASCO Gastrointestinal Cancers Symposium in San Francisco, CA. In L-sided, R-sided subgroups and RAS wt population, the best confirmed overall response rate (primary endpoint) observed was 65.5 versus 74.4, 52.6 versus 50 and 62.7 versus 68.4%, respectively, in cetuximab + FOLFOX versus cetuximab + FOLFIRI groups [&lt;ulink linkID="2000640" linkType="Reference"&gt;2000640&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2006, a randomized, open-label, active control, parallel assignment, safety and efficacy, phase II trial (&lt;ulink linkID="43950" linkType="Protocol"&gt;NCT00439517&lt;/ulink&gt;; EMR200025-001; FUTURE) was initiated in previously untreated patients (expected n = 400) with mCRC, worldwide. Patients were to receive UFOX plus cetuximab (400 mg/m2 on day 1 of cycle 1 and 250 mg/m2 at each subsequent day 1, as well as on days 8, 15 and 22) or FOLFOX4 plus cetuximab. The primary endpoint measure was PFS. The study was expected to complete enrollment in July 2009, and complete in March 2012 [&lt;ulink linkID="886254" linkType="Reference"&gt;886254&lt;/ulink&gt;].  In June 2012, clinical data were presented at the 14th World Congress on Gastrointestinal Cancer in Barcelona, Spain. There was no clear difference between UFOX plus cetuximab and FOLFOX4 plus cetuximab with regard to OS but PFS and response rates favored the FOLFOX4  over UFOX regimen [&lt;ulink linkID="1304598" linkType="Reference"&gt;1304598&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2005, a randomized, open-label, active-control, parallel-group, phase II trial (&lt;ulink linkID="45946" linkType="Protocol"&gt;NCT00286130&lt;/ulink&gt;; CECOG/CORE1.2.001) was initiated in 117 patients with mCRC at sites in Europe. Patients were to receive first-line cetuximab in combination with FOLFOX-6 (leucovorin + 5-FU + oxaliplatin) or FOLFIRI (leucovorin + 5-FU + irinotecan). The primary endpoint was PFS at 9 months. The trial completed in October 2007 [&lt;ulink linkID="976546" linkType="Reference"&gt;976546&lt;/ulink&gt;], [&lt;ulink linkID="976405" linkType="Reference"&gt;976405&lt;/ulink&gt;]. In January 2009, data were presented at the 2009 Gastrointestinal Cancers Symposium of ASCO in San Francisco, CA. The data showed that treatment with cetuximab in combination with either regimen resulted in response rates of 53 and 36% in patients with KRAS wild-type tumors and mutant tumors, respectively. A non-significant trend towards improved OS was also observed in patients with KRAS wild-type tumor compared with those with mutant tumors (24 versus 16.7 months) [&lt;ulink linkID="976405" linkType="Reference"&gt;976405&lt;/ulink&gt;]. In May 2009, similar data were presented at the 45th ASCO meeting in Orlando, FL [&lt;ulink linkID="1010016" linkType="Reference"&gt;1010016&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2005, a randomized, open-label, active control, parallel group, efficacy, phase II trial (&lt;ulink linkID="42755" linkType="Protocol"&gt;NCT00125034&lt;/ulink&gt;; EMR 62202-047; OPUS) was initiated in previously untreated patients (expected n = 345) with mCRC in Europe, Russia, Israel and Ukraine. Patients were to receive FOLFOX-4 plus cetuximab or FOLFOX-4 alone. The primary endpoint was best ORR. The study had completed enrollment by March 2008 [&lt;ulink linkID="886368" linkType="Reference"&gt;886368&lt;/ulink&gt;]. Initial data from OPUS were presented at the 43rd ASCO meeting in Chicago, IL in June 2007. A total of 337 patients had been enrolled. The best overall confirmed response rate was 45.6% in the cetuximab plus FOLFOX group and 35.7% in FOLFOX-only patients. PFS and OS were not available at that time [&lt;ulink linkID="797664" linkType="Reference"&gt;797664&lt;/ulink&gt;]. In May 2008, further data were presented at the 44th annual ASCO meeting in Chicago, IL. The response rate was 61% in the cetuximab plus FOLFOX4 arm, compared with 37% in the FOLFOX4-only arm. This equated to a 43% reduction in the risk of progression in wild-type KRAS patients [&lt;ulink linkID="911913" linkType="Reference"&gt;911913&lt;/ulink&gt;], [&lt;ulink linkID="910657" linkType="Reference"&gt;910657&lt;/ulink&gt;]. In December 2008, the results of the trial were published [&lt;ulink linkID="976553" linkType="Reference"&gt;976553&lt;/ulink&gt;]. In September 2009, further data were presented at the joint 15th ECCO and 34th ESMO Congress in Berlin, Germany. Cetuximab plus FOLFOX-4 increased the median OS in wt-KRAS patients to 22.8 months compared with 18.5 months for FOLFOX-4 alone [&lt;ulink linkID="1044315" linkType="Reference"&gt;1044315&lt;/ulink&gt;]. In January 2010, similar results were presented at the ASCO GI meeting in Orlando, FL [&lt;ulink linkID="1070930" linkType="Reference"&gt;1070930&lt;/ulink&gt;]. In January 2011, further data were presented at the Gastrointestinal Cancers Symposium of ASCO in San Francisco, CA. A total or 69% of patients with wild-type KRAS experienced tumor shrinkage of &amp;gt;20% within the first 8 weeks of cetuximab plus FOLFOX4 treatment; a long-term medium OS of 26.2 months was observed in these patients. A total of 46% of patients in the FOLFOX chemotherapy treatment group experienced tumor shrinkage of 20% or greater; within this treatment group, medium OS was 21.8 months [&lt;ulink linkID="1162040" linkType="Reference"&gt;1162040&lt;/ulink&gt;]. In June 2013, subgroup data from 97 patients evaluable for ERCC-1expression were presented at the 49 th ASCO Meeting in Chicago, IL. In the FOLFOX-4 alone arm, the median PFS and OS durations were shorter in patients with high ERCC-1 levels (5.8 and 11.5 months, respectively) than in patients with low ERCC 1 levels (9.2 and 18.5 months, respectively) [&lt;ulink linkID="1427100" linkType="Reference"&gt;1427100&lt;/ulink&gt;]. In December 2013, biomarker data on RAS tumor status analysis was expected in January 2014 [&lt;ulink linkID="1510961" linkType="Reference"&gt;1510961&lt;/ulink&gt;]. In January 2014, data on an analysis to investigate the effect of RAS mutations on the benefit of cetuximab and FOLFOX4 treatment were presented at the 2014 Gastrointestinal Cancers Symposium in San Francisco, CA. Patients originally deemed wildtype (n = 179) were screened for additional mutations; of the 118 evaluable patients, 36 were found to have further mutations. In patients treated with or without cetuximab (n = 17 and 19, respectively), the response rate was 36.2 and 48.7%, respectively, for patients with further mutations compared with 61.1 and 30.4%, respectively, for wildtype patients [&lt;ulink linkID="1517464" linkType="Reference"&gt;1517464&lt;/ulink&gt;]. In June 2014, further data were presented at the 50th ASCO meeting in Chicago, IL. In patients with wild-type RAS tumors, addition of cetuximab to FOLFOX4 was associated with significantly improved responses while no benefits were observed with a trend for worse outcome in patients harboring any RAS mutation [&lt;ulink linkID="1562307" linkType="Reference"&gt;1562307&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2003, phase II data on cetuximab in combination with FOLFIRI were presented at the 39th ASCO meeting in Chicago, IL. A total of 23 patients with previously untreated mCRC expressing EGFR received a starting dose of cetuximab 400 mg/m2, followed by weekly doses of 250 mg/m2. FOLFIRI was administered every 2 weeks as irinotecan (180 mg/m2), folinic acid (400 mg/m2), prior to 5-FU infusion) and either low-dose 5-FU (300 mg/m2 bolus and a 46 h continuous infusion 2000 mg/m2) or high dose (400 mg/m2 bolus and 46 h continuous infusion 2400 mg/m2). There were no dose limiting toxicities in the low-dose 5-FU group; however, there were three dose-limiting toxicities in the high-dose group, including grade 3 diarrhea, grade 3 neutropenia and grade 4 anaphylactoid reaction [&lt;ulink linkID="491987" linkType="Reference"&gt;491987&lt;/ulink&gt;], [&lt;ulink linkID="493139" linkType="Reference"&gt;493139&lt;/ulink&gt;]. Of 21 evaluable patients, 52% showed partial response and 43% achieved stable disease, for an overall tumor growth control rate of 95% [&lt;ulink linkID="491593" linkType="Reference"&gt;491593&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I/II&lt;/subtitle&gt;In April 2016, clinical data were presented from 33 patients at the 107th AACR Annual Meeting in New Orleans, LA, USA. In colorectal cancer, EREG methylation was associated with lack of response to cetuximab treatment [&lt;ulink linkID="1749390" linkType="Reference"&gt;1749390&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2004, data from a phase I/II study of cetuximab plus FOLFOX-4 regimen as a first-line treatment in 42 EGFR-expressing mCRC patients showed 81% responded to treatment and the disease was controlled in 98% of patients. The addition of cetuximab did not increase the adverse events associated with FOLFOX4 [&lt;ulink linkID="568059" linkType="Reference"&gt;568059&lt;/ulink&gt;]. There was a 2.6% complete response rate, 52.6% partial response rate and 23.7% disease stability. The most common side effects were diarrhea, skin reactions and neutropenia [&lt;ulink linkID="568059" linkType="Reference"&gt;568059&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;As of February 2003, EMR 62202-009, a phase I/II trial examining previously untreated mCRC treated with cetuximab, irinotecan, 5-FU and folinic acid, had begun in Germany. The trial had enrolled all 60 patients by February 2004 [&lt;ulink linkID="479208" linkType="Reference"&gt;479208&lt;/ulink&gt;], [&lt;ulink linkID="523312" linkType="Reference"&gt;523312&lt;/ulink&gt;]. Data were published in 2006. Patients received either cetuximab plus low-dose 5-FU plus irinotecan and folinic acid, or cetuximab plus high-dose 5-FU plus irinotecan and folinic acid. There were no dose limiting toxicities in the low 5-FU group and three DLTs (20%) in the high 5-FU group (two patients with diarrhea grade 3 and one patient with diarrhea grade 4). Chemotherapy did not affect the pharmacokinetics of cetuximab. A total of 14 patients (67%) had a confirmed response, and six (29%) had stable disease. Median time to progression was 9.9 months. Median survival time was 33 months [&lt;ulink linkID="1270387" linkType="Reference"&gt;1270387&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By February 2003, EMR 62202-010, a phase I/II trial examining cetuximab plus fortnightly FOLFIRI in previously untreated CRC patients had begun in France [&lt;ulink linkID="479208" linkType="Reference"&gt;479208&lt;/ulink&gt;], [&lt;ulink linkID="523312" linkType="Reference"&gt;523312&lt;/ulink&gt;]. By July 2003, enrollment for EMR 62202-010 was complete [&lt;ulink linkID="499057" linkType="Reference"&gt;499057&lt;/ulink&gt;]. The safety profile of this regimen was found to be acceptable [&lt;ulink linkID="1270108" linkType="Reference"&gt;1270108&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;By February 2003, a phase I/II trial (EMR 62202-021) was planned to examine cetuximab plus FUFOX, (5-FU, folinic acid and oxaliplatin) in 50 previously untreated mCRC patients in Austria and Germany [&lt;ulink linkID="479208" linkType="Reference"&gt;479208&lt;/ulink&gt;]. The trial was completed by July 2007; 49 patients were enrolled. The chemotherapy did not affect the pharmacokinetics of cetuximab [&lt;ulink linkID="1270108" linkType="Reference"&gt;1270108&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;By February 2003, the phase I/II EMR 62202-018 trial was planned to examine cetuximab plus FOLFOX (5-FU, folinic acid and oxaliplatin) in 50 previously untreated mCRC patients in France, Spain and Belgium [&lt;ulink linkID="479208" linkType="Reference"&gt;479208&lt;/ulink&gt;]. By February 2004, enrollment was complete at 42 patients [&lt;ulink linkID="523312" linkType="Reference"&gt;523312&lt;/ulink&gt;]. The trial was completed by July 2007; 49 patients were enrolled. The chemotherapy did not affect the pharmacokinetics of cetuximab [&lt;ulink linkID="1270108" linkType="Reference"&gt;1270108&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase 	I&lt;/subtitle&gt;In January 2018, clinical data from a phase I dose finding study (UMIN000018217)  which evaluated the safety, efficacy, MTD and recommended dose of cetuximab plus FOLFOXIRI in Japanese patients with RAS wild-type metastatic colorectal cancer were presented at the ASCO Gastrointestinal Cancers Symposium in San Francisco, CA. Patients (n = 9) received an escalating dose of iv irinotecan (100, 120, and 150 mg/m2 in the dose levels 0, 1, and 2, respectively) and a fixed dose of iv oxaliplatin (85 mg/m2), continuous infusion 5-fluorouracil (2400 mg/m2) plus l-leucovorin (200 mg/m2), and cetuximab (an initial dose of 400 mg/m2 followed by 250 mg/m2/week). No patients experienced a DLT (the MTD was not reached), and the dose level 2 (irinotecan 150 mg/m2) was established as the recommended dose. Of nine patients, one patient had complete response, seven patients had partial response, and one patient had progressive disease, with an overall response rate of 89%. The median progression free survival was 14.0 months [&lt;ulink linkID="2000653" linkType="Reference"&gt;2000653&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Adjuvant combination therapy&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In June 2013, data from a phase III, randomized study (New EPOC) that compared cetuximab as an add-on to chemotherapy with chemotherapy alone in KRAS wild-type operable CRC patients were presented at the 49th ASCO Meeting in Chicago, IL. Median PFS  was 14.1 months in the cetuximab combination group and 20.5 months in chemotherapy group [&lt;ulink linkID="1456063" linkType="Reference"&gt;1456063&lt;/ulink&gt;]. In November 2017, further mature analysis data were presented at the 2017 NCRI Cancer Conference in Liverpool, UK. The mature analysis of PFS was not significantly different (p = 0.291), in contrast to the primary analysis. In chemotherapy and cetuximab treatment groups, the median PFS was 23.9 and 15.5 months, respectively (hazard ratio [HR] = 1.17); median PPS was 35.4 and 23.5 months, respectively, (HR = 1.60); median OS was 81.0 and 55.4 months, respectively (HR = 1.45); median survival in patients with preoperative response was 81.1 and 60.7 months, respectively (HR = 1.40), and without preoperative response was 79.9 and 34.5 months, respectively (HR = 2.19); in patients with &amp;gt;/= 4 metastases/poor differentiation of primary/p-stage IIIA disease was 59.2 and 58.3 months, respectively (HR = 0.95), and in patients without &amp;gt;/= 4 metastases/poor differentiation of primary/N2 disease was not reached and 45.8 months, respectively (HR = 2.37) [&lt;ulink linkID="1998897" linkType="Reference"&gt;1998897&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In November 2005, a randomized, open-label, active control, phase III study (&lt;ulink linkID="44015" linkType="Protocol"&gt;NCT00265811&lt;/ulink&gt;; EU-20547; PETACC-8) was initiated in patients with stage III colon cancer in the adjuvant setting. Patients were to receive adjuvant oxaliplatin, leucovorin and fluorouracil, with or without cetuximab. Completion was expected by December 2014 [&lt;ulink linkID="1042763" linkType="Reference"&gt;1042763&lt;/ulink&gt;]. Enrollment of the 2566 patients was completed in 2009 [&lt;ulink linkID="1079607" linkType="Reference"&gt;1079607&lt;/ulink&gt;]. In May 2012, data from an interim analysis of the trial were reported, showing that the drug did not improve disease-free survival and that its use in that setting was not supported [&lt;ulink linkID="1288990" linkType="Reference"&gt;1288990&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In February 2004, a multicenter, randomized, active-controlled, phase III trial (&lt;ulink linkID="57708" linkType="Protocol"&gt;NCT00079274&lt;/ulink&gt;; CDR0000355132; NCCTG-N0147; ECOG-N0147) began in the US to compare the efficacy of cetuximab in combination with different chemotherapy regimens in patients with stage III colon cancer (n = 3768) following surgery. The primary endpoint was disease-free survival at 3 years, with a secondary outcome of OS [&lt;ulink linkID="1106380" linkType="Reference"&gt;1106380&lt;/ulink&gt;]. In June 2010, data were presented at the 46th ASCO annual meeting in Chicago, IL. The trial failed to meet the primary endpoint; in patients with KRAS wild-type tumors, the addition of cetuximab to chemotherapy did not improve disease-free survival or OS compared to chemotherapy alone. In addition, there was increased toxicity and a greater difference in treatment outcomes in patients aged &amp;gt;/= 70 years [&lt;ulink linkID="1106343" linkType="Reference"&gt;1106343&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;BRAF-mutant CRC&lt;/subtitle&gt;In June 2016, an Array-sponsored, global, randomized, open-label, global, phase III trial (&lt;ulink linkID="274873" linkType="Protocol"&gt;NCT02928224&lt;/ulink&gt;; ARRAY-818-302; 2015-005805-35; BEACON CRC) began in patients (expected n = 615 ) with BRAF-mutant mCRC in the second- or third-line following previous systemic therapy  to assess binimetinib, encorafenib and cetixumab versus cetixumab and irinotecan-based therapy. The primary endpoints were OS and  ORR of the triplet therapy versus the control arm. At that time, patient enrollment was expected to complete in 2018 [&lt;ulink linkID="1769245" linkType="Reference"&gt;1769245&lt;/ulink&gt;], [&lt;ulink linkID="1769248" linkType="Reference"&gt;1769248&lt;/ulink&gt;]. In September 2016,  Array reached a SPA agreement with the FDA for the trial, that the design and planned analysis of the study was adequate to support regulatory submission  [&lt;ulink linkID="1795998" linkType="Reference"&gt;1795998&lt;/ulink&gt;]. In February 2017, Array expected to complete patient enrollment in the safety lead-in  in March 2017  [&lt;ulink linkID="1899165" linkType="Reference"&gt;1899165&lt;/ulink&gt;], [&lt;ulink linkID="1899417" linkType="Reference"&gt;1899417&lt;/ulink&gt;].  In May 2017, enrollment in the randomized portion of the trial was ongoing and recruitment was expected to be completed by 2018, with topline data anticipated in 2019 [&lt;ulink linkID="1928620" linkType="Reference"&gt;1928620&lt;/ulink&gt;]. In September 2017, safety lead-in data of 30 patients were presented at the ESMO 2017 Congress in Madrid, Spain. In patients with BRAF(V600E) mCRC, confirmed ORR (CR + PR) was 41% (3 + 38%), SD was observed in 52% of patients, and PD was not observed. The majority of responses were seen at 6 weeks (first tumor assessment). Grade 3/4 adverse events (AEs) reported in &amp;gt;/= 10% of patients were nausea, vomiting, urinary tract infection, and increased blood creatine kinase (all grade 3) [&lt;ulink linkID="1960662" linkType="Reference"&gt;1960662&lt;/ulink&gt;], [&lt;ulink linkID="1957575" linkType="Reference"&gt;1957575&lt;/ulink&gt;], [&lt;ulink linkID="1960055" linkType="Reference"&gt;1960055&lt;/ulink&gt;]. In January 2018, updated results from the 30 patient safety lead-in data were presented at the ASCO 2018 Gastrointestinal Cancers Symposium in San Francisco, CA. At that time, the median PFS was 8 months, and the ORR was 48%, with 3 patients achieving complete responses. The ORR was 62% in the 16 patients who received only one prior line of thearpy [&lt;ulink linkID="1998532" linkType="Reference"&gt;1998532&lt;/ulink&gt;]. Further safety lead-in data were presented at the same conference.  ORR was  31% (3 PR and 1 CR) in patients with  two previous lines of therapy. Of 28 patients with BRAF (V600E) mutation and post-baseline tumor assessment, tumor regressions were observed in all but 1 patient. Among 14 responding patients, responses were ongoing in 6 patients. Of the remaining 15 patients who all achieved SD as their best response, 9 had prolonged SD of &amp;gt;/= 6 months. The elevated CEA and CA19-9 values  were decreased [&lt;ulink linkID="2000619" linkType="Reference"&gt;2000619&lt;/ulink&gt;]. In June 2018, further safety lead-in data were presented at the 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. In patients who had one versus two previous regimens, the median PFS was similar (7.6 versus 8.1 months, respectively). A single patient reported grade 3/4 skin-related adverse event (grade 3 rash) [&lt;ulink linkID="2054699" linkType="Reference"&gt;2054699&lt;/ulink&gt;]. In January 2019, safety and efficacy results were presented  at ASCO GI in San Francisco, CA, for the BEACON CRC trial, showing mature median OS was 15.3 months for patients treated with the triplet therapy. The updated median PFS and ORR were the same as previously reported   at 8 months and 48%, respectively. At that time, topline results were expected in  1H19  [&lt;ulink linkID="2110623" linkType="Reference"&gt;2110623&lt;/ulink&gt;], [&lt;ulink linkID="2110754" linkType="Reference"&gt;2110754&lt;/ulink&gt;].  Further results were presented at the same conference. Triple therapy with encorafenib + binimetinib + cetuximab continued to be well-tolerated with no unexpected toxicities. Grade 3/4 skin toxicities rate continued to be lower than generally observed with cetuximab in mCRC [&lt;ulink linkID="2113104" linkType="Reference"&gt;2113104&lt;/ulink&gt;]. In May 2019, data from an interim analysis were reported which showed that the trial met both of its primary endpoints. Results from the trial showed that BRAF-mutant mCRC patients who received the triple treatment demonstrated a significant improvement in ORR (26.1% versus 1.9%, p&amp;lt;0.0001) and OS (median 9.0 months versus 5.4 months, p&amp;lt;0.0001) compared to cetuximab plus irinotecan-containing regimens. The analysis of ORR was based on the first 331 randomized patients, while the interim analysis of OS included all 665 randomized patients and was based on a data cutoff date in February of 2019, approximately two weeks after the last patient was enrolled [&lt;ulink linkID="2153883" linkType="Reference"&gt;2153883&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2019, an interventional, single group assignment, open-label, single-arm, multicener phase II study (&lt;ulink linkID="355139" linkType="Protocol"&gt;NCT03693170&lt;/ulink&gt;; W00090 GE 2 01; ANCHOR CRC) of &lt;ulink linkID="73843" linkType="Drug"&gt;encorafenib&lt;/ulink&gt;, &lt;ulink linkID="55305" linkType="Drug"&gt;binimetinib&lt;/ulink&gt; in combination with  cetuximab was initiated in the US and Spain in patients (expected n = 90)  with previously untreated BRAF V600E-mutant mCRC. The primary endpoint was to determine the confirmed overall response rate (OR) based on local tumor assessments. At that time, the trial was expected to complete in October 2020 [&lt;ulink linkID="2119113" linkType="Reference"&gt;2119113&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Head and neck cancer&lt;/subtitle&gt;&lt;subtitle&gt;First-line monotherapy&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In June 2013, a randomized, parallel-assignment, open-label, multicenter, phase III trial (&lt;ulink linkID="142709" linkType="Protocol"&gt;NCT01884623&lt;/ulink&gt;; 2012-004967-38, 2012/1937) was initiated in France, in patients (expected n = 164) with recurrent and/or metastatic SCCHN, to assess the efficacy of first-line monotherapy cetuximab when compared with methotrexate. The trial was expected to be completed by June 2019 [&lt;ulink linkID="1456595" linkType="Reference"&gt;1456595&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Combination with radiation: second-line therapy&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In May 2000, a randomized, active control, phase III trial (&lt;ulink linkID="33037" linkType="Protocol"&gt;NCT00004227&lt;/ulink&gt;; IMCL-CP02-9815; EMR 62202-006; BONNER) was initiated in patients who were previously treated with chemotherapy over 3 years before, with stage III or IV cancer of the oropharynx, hypopharynx or larynx (locally advanced SCCHN). Patients were to receive radiotherapy alone or with cetuximab [&lt;ulink linkID="945353" linkType="Reference"&gt;945353&lt;/ulink&gt;]. The trial was expected to enroll 424 patients in Europe, the US, Israel, Australia, New Zealand and South Africa [&lt;ulink linkID="499057" linkType="Reference"&gt;499057&lt;/ulink&gt;]. Data were published in February 2006. The median duration of locoregional control was significantly greater at 24.4 months in patients treated with cetuximab plus radiotherapy and 14.9 months for radiotherapy alone. With a median follow-up of 54 months, the median duration of OS was 49.0 months in patients treated with combined therapy and 29.3 months for radiotherapy alone. Radiotherapy plus cetuximab significantly prolonged PFS. With the exception of acneiform rash and infusion reactions, the incidence of grade 3 or greater toxic effects, including mucositis, did not differ significantly between the groups [&lt;ulink linkID="1270452" linkType="Reference"&gt;1270452&lt;/ulink&gt;]. In September 2008, 5-year OS data from IMCL-CP02-9815 were presented at the American Society for Therapeutic Radiology and Oncology annual meeting in Boston, MA. The cetuximab OS rate was 45% compared to 36% with radiotherapy alone; the survival rate at 3 years was 55% and 45% for the cetuximab and radiotherapy alone arms, respectively [&lt;ulink linkID="945316" linkType="Reference"&gt;945316&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Combination with radiation: first-line therapy&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In June 2017, data from a phase III, randomized trial (GORTEC 2007-02; &lt;ulink linkID="71915" linkType="Protocol"&gt;NCT01233843&lt;/ulink&gt;) which evaluated the impact of p16 expression on induction Taxotere-Cisplatin-5 FU (TPF) followed by cetuximab radiotherapy in 360 patients with N2b-N3 SCCHN were presented at the 53rd ASCO meeting in Chicago, IL. Patients were randomized to receive concurrent chemoradiotherapy (CRT; arm A) or induction TPF followed by cetuximab radiotherapy (arm B). A significant improvement in PFS (primary endpoint) was observed in p16+ patients relative to p16- oropharyngeal cancer (OPC) patients (p &amp;lt; 0.0001). In favor of arm B, a significant benefit regarding distant metastasis was observed, and this effect was not different between the p16+ and p16- OPC; however, there was no benefit of TPF + cetuximab radiotherapy compared with CRT for loco-regional control, regardless of p16 status [&lt;ulink linkID="1932242" linkType="Reference"&gt;1932242&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 1999, a phase III trial (IMC-9815)  was being initiated in the US and Europe in patients (expected n = 416) with locally advanced head and neck cancer who would be treated with radiation therapy alone or radiation therapy plus weekly infusions of cetuximab. The primary endpoint was control of locoregional disease [&lt;ulink linkID="317654" linkType="Reference"&gt;317654&lt;/ulink&gt;], [&lt;ulink linkID="349325" linkType="Reference"&gt;349325&lt;/ulink&gt;], [&lt;ulink linkID="367670" linkType="Reference"&gt;367670&lt;/ulink&gt;], [&lt;ulink linkID="594829" linkType="Reference"&gt;594829&lt;/ulink&gt;]. Data were presented in August 2004. Addition of cetuximab to high-dose radiation in 424 patients with locoregional advanced head and neck cancer resulted in a significant improvement in locoregional control and OS. One-year locoregional control was 59% for radiotherapy versus 69% for cetuximab plus radiation. Two-year locoregional control was 48% for radiotherapy compared with 56% for cetuximab plus radiation. One-year and two-year survival was 55% and 44%, respectively, for radiotherapy, versus 62% and 57%, respectively, for cetuximab in addition to radiation. Median survival was 28 months for radiotherapy versus 54 months for cetuximab and radiation [&lt;ulink linkID="556848" linkType="Reference"&gt;556848&lt;/ulink&gt;]. Similar data were presented in October 2004 at the 23rd European Society for Therapeutic Radiology and Oncology Annual Meeting in Amsterdam, the Netherlands [&lt;ulink linkID="573100" linkType="Reference"&gt;573100&lt;/ulink&gt;]. In January 2007, data presented at the Multidisciplinary Head and Neck Cancer Symposium demonstrated that cetuximab, in addition to radiation therapy, does not increase the rate or duration some side effects. The median follow-up period was 54 months; the median duration of mucositis or dysphagia was 3 months [&lt;ulink linkID="758745" linkType="Reference"&gt;758745&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Combination with radiotherapy: earlier-stage data&lt;/subtitle&gt;In September 2009, data were presented at the Joint ECCO15/34th ESMO conference in Berlin, Germany from a study 20 of patients with locally advanced laryngeal cancer treated with iv cetuximab (400 mg/m2 1 week before hyperfractionated radiotherapy and then 250 mg/m2/week during radiotherapy). Of the 18 patients who completed radiotherapy, the complete response rate was 80%, while three patients underwent a laryngectomy for persistent disease. After a median follow-up of 15 months, 18 patients (90%) were disease-free and the larynx preservation rate was 66%. Grade 3/4 toxicities were stomatitis (n=6), acne-like rash (n=4), radiation dermatitis (n=5) and dysphagia, diarrhea, vomiting, fatigue, skin infection and pneumonia (n = 1 each) [&lt;ulink linkID="1047486" linkType="Reference"&gt;1047486&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2009, the company began a phase II trial in Japan (&lt;ulink linkID="49400" linkType="Protocol"&gt;NCT00865098&lt;/ulink&gt;; EMR 62241 - 053). The multicenter, open-label study would enroll 20 patients with newly diagnosed, locally advanced, non-metastatic SCCHN to receive  an initial dose of 400 mg/m2 of cetuximab, infused 6 or 7 days before starting radiotherapy, followed by weekly infusions of 250 mg/m2 of cetuximab and radiotherapy for 6 weeks. The primary endpoint would be the completion rate of patients that complete more than 70% of planned dose administrations. Secondary endpoints would include safety and adverse events [&lt;ulink linkID="1012629" linkType="Reference"&gt;1012629&lt;/ulink&gt;]. Enrollment was completed in June 2010 [&lt;ulink linkID="1125158" linkType="Reference"&gt;1125158&lt;/ulink&gt;]. In September 2011, intent-to-treat data were presented at the European Multidisciplinary Cancer Congress in Stockholm, Sweden. At week 8, complete response, partial response and stable disease were achieved in 9, 9 and 3 patients, respectively. In addition, the response rate at 8-week post radiotherapy was 86.4% in an investigator assessment (sensitivity analysis) [&lt;ulink linkID="1222594" linkType="Reference"&gt;1222594&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2017, clinical data from phase Ib study (&lt;ulink linkID="214991" linkType="Protocol"&gt;NCT02282371&lt;/ulink&gt;) were presented from 11 stage III-IVB SCCHN patients at the 53rd ASCO meeting in Chicago, IL. Patients (n = 11) received cetuximab 400 mg/m2 iv loading dose prior to IMRT, followed by 250 mg/m2 iv ×7 weeks infusions during intensity modulated radiotherapy. BYL7-19 was given po during IMRT in three dose levels 200, 250 and 300 mg/day in a standard 3 + 3 dose escalation design. Patients who had withdrawn from the treatment were three due to nausea (grade 1) occurred within 2 days of BYL-719 and anaphylaxis with cetuximab infusion. Oral mucositis, oral pain, lymphocyte count decreased, nausea, weight loss, dysphagia, hyperglycemia, diarrhea, dysgeusia, fatigue, vomiting, ALT elevation and radiations dermatitis were drug-related toxicities reported. Patients who had achieved complete response and remained free of disease was nine [&lt;ulink linkID="1932407" linkType="Reference"&gt;1932407&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2008, clinical data reported at ASCO 2008 demonstrated the safety profile of cetuximab maintenance therapy when administered after concomitant cetuximab plus accelerated boost radiotherapy (RT), in patients with locally advanced oropharyngeal carcinoma [&lt;ulink linkID="910506" linkType="Reference"&gt;910506&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Results of a phase I trial of cetuximab in combination with radiation in patients with unresectable head and neck cancer were reported to the seventh International Conference on Human Antibodies and Hybridomas in September 1999. A standard dose-escalation procedure was employed in 16 patients (70 to 76.8 Gy). Cetuximab was delivered as a loading dose of 100 to 500 mg/m2 iv, followed by seven weekly infusions of 100 to 250 mg/m2. There was no increase in severity or frequency of irradiation-related toxicities upon the addition of cetuximab to radiation therapy and the combination therapy was shown to be safe and well tolerated. Of the 15 evaluable patients, 14 achieved complete responses based on physical and endoscopic examination [&lt;ulink linkID="373131" linkType="Reference"&gt;373131&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Combination with chemotherapy: second-line therapy&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In May 1999, a pivotal phase III trial was initiated in a planned 114 patients with refractory advanced SCCHN, to evaluate the effect of cetuximab in combination with &lt;ulink linkID="51933" linkType="Drug"&gt;cisplatin&lt;/ulink&gt;. Under the trial protocol, patients with advanced SCCHN and metastatic disease were to be treated with cisplatin alone or cisplatin plus weekly infusions of cetuximab. The primary endpoint of the trial was response and time to disease progression [&lt;ulink linkID="324314" linkType="Reference"&gt;324314&lt;/ulink&gt;], [&lt;ulink linkID="367670" linkType="Reference"&gt;367670&lt;/ulink&gt;]. In May 2001, preliminary data were presented at the 37th ASCO meeting in San Francisco, CA. In the study, 96 patients received between 250 and 400 mg/m2 cetuximab in combination with 75 to 100 mg/m2 cisplatin in four courses. Of these, 85 were evaluable; of 41 with stable disease as a result of platinum therapy prior to joining the trial, one experienced a complete response, while nine had partial responses (ORR of 24%). Toxicity was described as manageable [&lt;ulink linkID="408759" linkType="Reference"&gt;408759&lt;/ulink&gt;], [&lt;ulink linkID="408842" linkType="Reference"&gt;408842&lt;/ulink&gt;], [&lt;ulink linkID="409886" linkType="Reference"&gt;409886&lt;/ulink&gt;]. The median time to progression was 6.2 months while median survival was 7.9 months [&lt;ulink linkID="428752" linkType="Reference"&gt;428752&lt;/ulink&gt;]. In May 2002, further data were presented at the 38th ASCO meeting in Orlando, FL. By that time the trial had enrolled 123 patients; the median survival for cetuximab was 9.19 months, compared with 7.96 months for placebo [&lt;ulink linkID="451631" linkType="Reference"&gt;451631&lt;/ulink&gt;]. In September 2004, these data was presented at the Fourth International Monoclonal Antibodies in Cancer congress in Colorado Springs, CO [&lt;ulink linkID="560046" linkType="Reference"&gt;560046&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In  August 2016, a randomized, parallel-group, open-label, phase Ib/II study (&lt;ulink linkID="172603" linkType="Protocol"&gt;NCT02054442&lt;/ulink&gt;; MOHN01; EudraCT 2013-002886-20; DHNS 2013-01; COMMENCE) began in the Netherlands in patients (expected n = 51) with recurrent or metastatic SCCHN. At that time, the trial was estimated to complete in February 2018 [&lt;ulink linkID="2092837" linkType="Reference"&gt;2092837&lt;/ulink&gt;]. In October 2018, results were presented at the 2018 ESMO Congress in Munich, Germany. In the phase Ib study, patients with previously untreated R/M SCCHN were treated with weekly methotrexate 40 mg/m2 and cetuximab 250 mg/m2, following a loading dose of cetuximab 400 mg/m2. In the phase II study, patients were randomized (1:2) to methotrexate or the combination. In the phase Ib study (n = 6), DLTs were not observed and median PFS was 24.4 weeks. In the phase II study (n = 45), median PFS (primary endpoint) was significantly different between the methotrexate and combination groups (8 and 17 weeks, respectively; p = 0.009) [&lt;ulink linkID="2084549" linkType="Reference"&gt;2084549&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2017, an open-label, non-randomized, multicenter, multi-arm, phase II trial (&lt;ulink linkID="292328" linkType="Protocol"&gt;NCT03082534&lt;/ulink&gt;; 160621, MISP 52211) began to evaluate the efficacy of combination therapy of &lt;ulink linkID="CP312688" linkType="Compound"&gt;pembrolizumab&lt;/ulink&gt; with cetuximab in patients (expected n = 83) with recurrent/metastatic SCCHN in the US. In April 2017, the trial was to complete in May 2020 [&lt;ulink linkID="1915298" linkType="Reference"&gt;1915298&lt;/ulink&gt;]. In June 2018, clinical data from 17 patients were presented at the 54th ASCO Annual Meeting in Chicago, IL. Of 15 evaluable patients, partial response, stable disease, progressive disease were observed in seven, three and five patients, respectively; complete response was not achieved. A total of two patients discontinued treatment early to pursue hospice; per protocol, listed as progressive disease. There were no DLTs. A total of 142 adverse events (AEs) were reported. Of the 29 grade 3+ AEs, treatment-related were only five. No treatment-related deaths were reported [&lt;ulink linkID="2039270" linkType="Reference"&gt;2039270&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2014,  data from  the phase II AIO trial:1108 (&lt;ulink linkID="105447" linkType="Protocol"&gt;CeFCiD&lt;/ulink&gt;) to evaluate the safety and efficacy of cetuximab in combination with fluorouracil and cisplatin alone or in combination with docetaxel were presented at the 39th European Society for Medical Oncology congress in Madrid, Spain. Recurrent/metastatic head and neck cancer patients (n = 180) were randomized to received cetuximab (400/250 mg/sqm) on days 1, 8, 15 q3w in combination with cisplatin (40 mg/m2), docetaxel (40 mg/m2), or fluorouracil (2000 mg/m2 ) (arm-A) or standard cisplatin (100 mg/m2) + fluorouracil (1000 mg/m2) + cetuximab (400/250 mg/m2) on days 1, 8, 15 q3w (arm-B). Toxicity was similar in both treatment arms  [&lt;ulink linkID="1596184" linkType="Reference"&gt;1596184&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2009, phase II data from a study of cetuximab in combination with docetaxel in platinum-pretreated patients (n=84) with recurrent SCCHN were presented at the 45th ASCO meeting in Orlando, FL. Cetuximab (initial dose of 400 mg/m2, followed by subsequent weekly doses of 250 mg/m2) and docetaxel (35 mg/m2 on days 1, 8, 15 of a 4-week cycle) was administered for a maximum of 6 cycles. A disease control rate of 39% was seen. Response was unrelated to previous platinum sensitivity. Median PFS was 4 months and median OS was 7 months. Grade III/IV toxicities included gastric perforation (n = 1), pneumonia (n = 7), mucositis and skin toxicities [&lt;ulink linkID="1012986" linkType="Reference"&gt;1012986&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A phase II trial, investigating cetuximab in combination with weekly &lt;ulink linkID="3803" linkType="Drug"&gt;paclitaxel&lt;/ulink&gt; (80 mg/m2) in patients with recurrent SCCHN, was presented at the 43rd ASCO meeting in Chicago, IL, in June 2007. Complete responses had been observed in 7 patients, partial responses in 18, and stable disease in 6 patients for an ORR of 71% and disease control rate of 88%. The main grade 3/4 toxicities were as follows: 8 patients had acne-like rash; 7 had neutropenia with 1 febrile neutropenia; 6 asthenia; 3 mucositis; 2 infusion-related reactions to paclitaxel and 1 to cetuximab; 2 peripheral neuropathies; 1 diarrhea; 1 vomiting; and 1 conjunctivitis [&lt;ulink linkID="797547" linkType="Reference"&gt;797547&lt;/ulink&gt;]. In September 2009, further data were presented at the Joint ECCO15/34th ESMO Conference in Berlin, Germany.The ORR was 45%, with one complete response and 35% stable disease. After a median follow up of 10 months, the PFS and OS were 6.5 and 7 months, respectively. Grade 2/3 toxicities were acne-like rash (30%), asthenia (15%), anemia (10%) and mucositis (10%) [&lt;ulink linkID="1047486" linkType="Reference"&gt;1047486&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2003, a phase II trial (EMR 62202-016) of cetuximab plus platinum in platinum-refractory metastatic or recurrent SCCHN, had completed enrollment, with 106 patients in Europe recruited [&lt;ulink linkID="499057" linkType="Reference"&gt;499057&lt;/ulink&gt;]. By February 2004, EMR 62202-016 had been completed [&lt;ulink linkID="523312" linkType="Reference"&gt;523312&lt;/ulink&gt;]. Data were published in June 2007. During the combination therapy phase, the objective response rate was zero, disease control rate was 26%, and TTP was 50 days. Median OS was 178 days [&lt;ulink linkID="1270666" linkType="Reference"&gt;1270666&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2003, data from a phase II study (622002-003) were presented at the 39th ASCO meeting in Chicago, IL. In the multicenter phase II trial, 56 patients with recurrent or metastatic nasopharyngeal carcinoma were given cetuximab (400 mg/m2 loading dose followed by 250 mg/m2/week) plus carboplatin (AUC = 5 every 3 weeks). Of 53 evaluable patients, 9 had partial responses, 1 had an unconfirmed partial response and 25 had stable disease. ORR was 17% and the median number of cycles received was 2.55. Common adverse events included rash, nausea, vomiting and asthenia [&lt;ulink linkID="491635" linkType="Reference"&gt;491635&lt;/ulink&gt;], [&lt;ulink linkID="492104" linkType="Reference"&gt;492104&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Data from a phase II combination trial of cetuximab plus cisplatin/&lt;ulink linkID="44383" linkType="Drug"&gt;carboplatin&lt;/ulink&gt; were presented at the 38th ASCO meeting in Orlando, FL in May 2002. Patients with recurrent SCCHN were treated with cetuximab 400 mg/m2 followed by 250 mg/m2 weekly, with the same dose and schedule of platinum that the patients had previously progressed on. Of 96 patients enrolled, safety data was available for 80. Adverse events included rash, acne, dry skin, asthenia, fever and vomiting. All 96 patients were evaluated for response; two exhibited a complete response, 12 had a partial response and 38 had stable disease [&lt;ulink linkID="451799" linkType="Reference"&gt;451799&lt;/ulink&gt;], [&lt;ulink linkID="451986" linkType="Reference"&gt;451986&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Combination with chemotherapy: first-line therapy&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In July 2015, a randomized, open-label, parallel-assignment, phase III trial (&lt;ulink linkID="223956" linkType="Protocol"&gt;NCT02383966&lt;/ulink&gt;; EMR062202-060; CHANGE2) was initiated in China to evaluate cetuximab + cisplatin + 5-FU versus cisplatin + 5-FU in first-line patients (estimated n = 240) with recurrent or metastatic SCCHN. The primary endpoint was PFS [&lt;ulink linkID="1806941" linkType="Reference"&gt;1806941&lt;/ulink&gt;]. In November 2018, data were presented at the at the ESMO Asia Congress in Singapore which showed that the trial met its primary endpoint. Data from 243 Chinese patients showed that the addition of cetuximab to platinum-based chemo therapy improved PFS (median 5.5 versus 4.2 months), overall survival (median 10.2 versus 8.4 months) and overall response rate (50 versus 27%). At that time, Merck was planning to discuss the results with the Chinese NMPA and planned to file for approval for the additional indication in China [&lt;ulink linkID="2097906" linkType="Reference"&gt;2097906&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2003, EMR 62202-002, a phase III study of platinum/5-FU alone or plus cetuximab as first-line therapy in metastatic or recurrent SCCHN was planned [&lt;ulink linkID="499057" linkType="Reference"&gt;499057&lt;/ulink&gt;]. In December 2004, a randomized, open-label, active control, parallel assignment, efficacy phase III trial in the first-line setting (&lt;ulink linkID="41162" linkType="Protocol"&gt;NCT00122460&lt;/ulink&gt;; EMR 62202-002; EXTREME) was initiated in patients (n = 442) with recurrent and/or metastatic SCCHN in Europe, Russia and Ukraine. Patients were to receive either: initial cetuximab dose (400 mg/m2, over 2 h) followed by weekly doses (250 mg/m2, over 1 h) plus cisplatin (100 mg/m2 on day 1) and 5-FU (100 mg/m2 continuous iv from day 1 to day 4) every 3 weeks or carboplatin (AUC 5 IV on day 1) and 5-FU (100 mg/m2 continuous iv from day 1 to day 4) every 3 weeks; or platinum-based therapy alone. The primary endpoint was OS. The study was completed in July 2007 [&lt;ulink linkID="885969" linkType="Reference"&gt;885969&lt;/ulink&gt;]. In April 2007, results from the EXTREME trial demonstrated that it had met its primary endpoint of OS. Patients receiving cetuximab had a significantly higher response rate, an almost doubling of the time to tumor progression and a significantly longer survival [&lt;ulink linkID="780576" linkType="Reference"&gt;780576&lt;/ulink&gt;], [&lt;ulink linkID="833328" linkType="Reference"&gt;833328&lt;/ulink&gt;]. Further data were published in September 2008. OS in the cetuximab-treated group was 10.1 months versus 7.4 months for chemotherapy alone. PFS was also significantly increased (5.6 versus 3.3 months) and tumor response rates were also higher (36 versus 20%) [&lt;ulink linkID="942406" linkType="Reference"&gt;942406&lt;/ulink&gt;], [&lt;ulink linkID="942453" linkType="Reference"&gt;942453&lt;/ulink&gt;]. In May 2009, further data were presented at the 45th ASCO meeting in Orlando, FL. There was no difference in terms of OS, PFS and response rates between FISH-positive and FISH-negative tumors [&lt;ulink linkID="1015780" linkType="Reference"&gt;1015780&lt;/ulink&gt;]. In November 2009, similar data were published [&lt;ulink linkID="1057324" linkType="Reference"&gt;1057324&lt;/ulink&gt;]. In October 2012, further data were presented at the 2012 Congress of the European Society for Medical Oncology in Vienna, Austria. Treatment outcomes (OS, PFS and ORR) with cetuximab were independent of  human papillomavirus status [&lt;ulink linkID="1332471" linkType="Reference"&gt;1332471&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In September 2017, data from a randomized phase IIb B490 study which evaluated the efficacy and safety of first line cetuximab and cisplatin with or without paclitaxel in patients with recurrent/metastatic head and neck cancer were presented at the ESMO 2017 Congress in Madrid, Spain. Of 201 patients, 100 and 91 were randomized to receive cetuximab + cisplatin (arm A) or cetuximab + cisplatin + paclitaxel combination (arm B), respectively, with maintenance cetuximab after 6 cycles. In arm A and B, CR was achieved by 5 and 6 patients, respectively; PR was achieved by 36 and 40 patients, respectively; SD was observed in 35 and 22 patients, respectively; ORR was 41.8 and 51.7%, respectively; DCR was 77.6 and 76.4%, respectively; median OS was 13 and 11 months, respectively (p = 0.117); and median PFS (primary endpoint) was 6 and 7 months, respectively (p = 0.906) [&lt;ulink linkID="1960612" linkType="Reference"&gt;1960612&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2010, a randomized, double-blind, parallel-assignment, phase II trial (&lt;ulink linkID="64716" linkType="Protocol"&gt;NCT01081041&lt;/ulink&gt;; 13611; I4E-MC-JXBD) evaluating first-line cetuximab, using ImClone versus &lt;ulink linkID="14881" linkType="Company"&gt;Boehringer Ingelheim&lt;/ulink&gt; manufacturing processes, in combination with cisplatin or carboplatin and 5-fluorouracil began in patients (expected n = 230) in the US, Canada and Mexico with locoregionally recurrent and/or metastatic SCCHN. The primary endpoint was incidence of treatment-related adverse events from randomization to 30 days after treatment discontinuation. At that time, the trial was estimated to complete in December 2013 [&lt;ulink linkID="1330233" linkType="Reference"&gt;1330233&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2009, an open-label, single-arm, multicenter, phase II trial (&lt;ulink linkID="60123" linkType="Protocol"&gt;NCT00971932&lt;/ulink&gt;; EMR 62241-056) to assess the safety and efficacy of cetuximab in combination with chemotherapy as first-line treatment of recurrent and/or  metastatic SCCHN was initiated in Japanese patients  (n =33). In July 2012, the trial was still underway [&lt;ulink linkID="1466397" linkType="Reference"&gt;1466397&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2003, a phase II trial (EMR 62202-008) of cetuximab plus platinum/5-FU as first-line therapy in metastatic or recurrent SCCHN, had completed enrollment of 53 patients in France, Belgium and Spain [&lt;ulink linkID="499057" linkType="Reference"&gt;499057&lt;/ulink&gt;]. By February 2004, EMR 62202-008 had been completed [&lt;ulink linkID="523312" linkType="Reference"&gt;523312&lt;/ulink&gt;]. In June 2003, initial data from study 622002-008 were presented at the 39th ASCO meeting in Chicago, IL. Twelve patients had been treated at the first dose level (5-FU 600 mg/m2). Grade 3 or 4 toxicity included diarrhea, vomiting, conjunctivitis and febrile neutropenia. The cisplatin group had two dose-limiting toxicities, dehydration and elevated transaminase levels. Ten cisplatin and six carboplatin patients had been treated at the second dose (5-FU 800 mg/m2). Grade 3 and 4 toxicities included diarrhea and fever. Ten patients had a partial response, eight had stable disease and six had progressive disease [&lt;ulink linkID="491637" linkType="Reference"&gt;491637&lt;/ulink&gt;], [&lt;ulink linkID="492104" linkType="Reference"&gt;492104&lt;/ulink&gt;]. Data were published in May 2006. The most common grade 3/4 adverse events in both groups were leucopenia (38%), asthenia (25%), vomiting (14%), and thrombocytopenia (15%). The ORR was 36%, with no clear trend toward an increased efficacy at the highest dose of FU, and no impact of the concomitant chemotherapy regimens on cetuximab pharmacokinetics [&lt;ulink linkID="1270665" linkType="Reference"&gt;1270665&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Combination with chemotherapy: earlier-stage data&lt;/subtitle&gt;In May 1999, results of a phase Ib/IIa study of nine patients with advanced SCCHN treated with cetuximab in combination with &lt;ulink linkID="51933" linkType="Drug"&gt;cisplatin&lt;/ulink&gt; were presented at the 35th ASCO meeting in Atlanta, GA. The results demonstrated a response rate of 66%, including one complete and five partial responses. All of the responders had failed previous therapy. In addition, results from a phase Ib/IIa dose-escalation study of cetuximab in combination with radiotherapy involving 15 patients with advanced head and neck cancer were presented. All 15 patients achieved a response; 13 experienced a complete response (100% tumor regression) and 2 experienced partial responses (greater than 50% regression) [&lt;ulink linkID="326444" linkType="Reference"&gt;326444&lt;/ulink&gt;], [&lt;ulink linkID="325927" linkType="Reference"&gt;325927&lt;/ulink&gt;]. The median follow-up time, at this time, was 6 months for all patients and the duration of response had been up to and in excess of 39 months. The 2-year disease-free survival rate was 65%; higher than that seen with radiotherapy alone. At this time a phase III trial was being conducted comparing radiotherapy to radiotherapy plus cetuximab treatment [&lt;ulink linkID="391713" linkType="Reference"&gt;391713&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Data from a phase Ib/IIa dose-escalation trial of cetuximab in combination with cisplatin in head and neck cancer and NSCLC were presented at the 33rd ASCO meeting in May 1997. The trial involved 22 patients and no dose-limiting toxicities were found in the doses studied. There was evidence of antitumor activity [&lt;ulink linkID="246979" linkType="Reference"&gt;246979&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Combination with sequential chemoradiotherapy&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In June 2017, data from a multicenter phase II ECRIPS study (UMIN000009928), which evaluated the toxicity and efficacy of docetaxel, cisplatin and cetuximab followed by cetuximab concurrent with radiotherapy in patients with local advanced SCCHN (n = 54), were presented at the 53rd ASCO meeting in Chicago, IL. Patients received induction chemotherapy of cisplatin 75 mg/m2 and docetaxel 75 mg/m2 on day1 and repeated q3w up to a total of three courses. Patients received cetuximab at an initial dose of 400 mg/m2 followed by 250 mg/m2 weekly until the end of radiotherapy (70Gy/35fr) which was started after last administration of docetaxel. Treatment compliance (primary endpoint) was 75.9%. Two-year progression-free survival rate was 84.3%, and two-year overall survival was 90.6% [&lt;ulink linkID="1932501" linkType="Reference"&gt;1932501&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2014, first results from a phase II randomized, German multicenter study (&lt;ulink linkID="52036" linkType="Protocol"&gt;DeLOS-II&lt;/ulink&gt;; NCT00508664) of induction therapy with docetaxel, cisplatin and 5-fluorouracil or docetaxel, cisplatin and cetuximab followed by radiotherapy with or without cetuximab in patients with resectable laryngeal and hypopharyngeal locally advanced, non-metastatic cancer were presented at the 50th ASCO meeting in Chicago, IL. A total of 174 patients were included in this study. Adequate early response, defined as &amp;gt;/= 30% surface shrinkage in endoscopy after first cycle, was observed in 72.4% of patients; 58 and 68 patients in groups without and with cetuximab had early responses, respectively. Induction therapy with docetaxel, cisplatin and cetuximab was less toxic and superior to docetaxel, cisplatin and 5-fluorouracil in terms of larynx preservation [&lt;ulink linkID="1562673" linkType="Reference"&gt;1562673&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In  May 2014, data from  two clinical trials (RTOG 0522 and RTOG 0234) were presented at the 50th ASCO meeting in Chicago, IL. Overall, 386 patients with head and neck carcinoma reported grade 2 to 4 cetuximab rash. Patients with grade 2 to 4 cetuximab rash were associated with increased OS, while no effect was observed for PFS [&lt;ulink linkID="1562679" linkType="Reference"&gt;1562679&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2009, data were reported at the 45th ASCO meeting in Orlando, FL, from a French, randomized, phase II trial (&lt;ulink linkID="45962" linkType="Protocol"&gt;NCT00169247&lt;/ulink&gt;; TREMPLIN) of sequential chemoradiotherapy (CRT) for larynx preservation. Previously untreated larynx or hypopharynx squamous cell carcinoma patients with locally advanced, non-metastatic disease who were eligible for total laryngectomy (n = 153) received three cycles of induction chemotherapy (docetaxel (75 mg/m2 day 1), cisplatin (75 mg/m2 day 1), 5-FU (750 mg/m2 days 1 to 5)). Patients with responses of &amp;gt; 50% were randomized to concurrent CRT (70 Gy and cisplatin 100 mg/m2 days 1, 22 and 43) or concurrent radiotherapy (70 Gy; 7 weeks) and cetuximab (initial dose of 400 mg/m2, followed by 250 mg/m2 (qw)). The full protocol of induction chemotherapy was administered to 74% of patients; two toxic deaths occurred and febrile neutropenia was 11%. Following induction chemotherapy, 85% of patients had a response of &amp;gt; 50%; 60 patients were randomized to the cisplatin arm and 56 to the cetuximab arm. 43% of patients could receive the full protocol in the cisplatin arm, compared with 71% in the cetuximab arm. The primary endpoint was larynx preservation at 3 months: 92 and 98% of respective patients in the cisplatin and cetuximab arms had their larynx in place without evidence of disease [&lt;ulink linkID="1015780" linkType="Reference"&gt;1015780&lt;/ulink&gt;]. In September 2009, these data were presented at the joint ECCO15/34th ESMO Conference in Berlin, Germany. 26% of patients had cetuximab-related toxicity compared to 50% on cisplatin [&lt;ulink linkID="1047486" linkType="Reference"&gt;1047486&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Data from a phase II trial were reported at the 43rd ASCO meeting in Chicago, IL, in June 2007. Cetuximab was administered in combination with chemotherapy and radiotherapy to 40 patients. Data from 20 evaluable patients demonstrated an unexpected skin toxicity in 18 subjects. Objective responses were seen in 16 individuals and two patients who achieved partial disease were then rendered disease free following surgery [&lt;ulink linkID="796233" linkType="Reference"&gt;796233&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2007, preliminary data were presented at the Multidisciplinary Head and Neck Cancer Symposium; the trial enrolled 21 patients treated with cetuximab plus radiotherapy and chemotherapy, with 18 available for analysis of toxicity and response. A complete response was observed in 72% of patients after 2 months and 95% were disease free [&lt;ulink linkID="758742" linkType="Reference"&gt;758742&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Data were presented at the 39th ASCO meeting in Chicago, IL in May 2003. From February to November 2000, 22 patients with locoregionally advanced SCCHN who had not received prior radiation therapy received a single daily dose of radiation (1.8 Gy/day) for 4 weeks, then two doses of radiation in a day (1.8 Gy and 1.6 Gy) for 2 weeks. Cisplatin (100 mg/m2) was added during weeks 1 to 4 and cetuximab at 400 mg/m2 with the first dose of cisplatin, followed by another dose of cetuximab at 250 mg/m2 on weeks 2 to 10. The toxicity profile prompted early closure of the trial, but preliminary efficacy data warranted investigation with less toxic schedules of this combination [&lt;ulink linkID="492164" linkType="Reference"&gt;492164&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Combination with other therapies&lt;/subtitle&gt;In February 2017, a single-group, open-label, phase II trial (&lt;ulink linkID="281093" linkType="Protocol"&gt;NCT02979977&lt;/ulink&gt;; 1608018260) of &lt;ulink linkID="54449" linkType="Drug"&gt;afatinib&lt;/ulink&gt; combination with cetuximab began in patients (expected n = 50) in the US for the second-line treatment of recurrent or metastatic SCCHN. The primary endpoint was tumor shrinkage and ORR. The study was to complete in January 2019 [&lt;ulink linkID="1906729" linkType="Reference"&gt;1906729&lt;/ulink&gt;], [&lt;ulink linkID="1905909" linkType="Reference"&gt;1905909&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2016, an open-label, randomized, phase III study (&lt;ulink linkID="282943" linkType="Protocol"&gt;NCT02999087&lt;/ulink&gt;; GORTEC 2017-01; REACH) of &lt;ulink linkID="83065" linkType="Drug"&gt;avelumab&lt;/ulink&gt; in combination with RT-cetuximab  compared   to standard of care, was to begin in patients (expected n = 688) with  locally advanced, non-metastatic SCCHN, in April 2017. The study was to complete in January 2021 [&lt;ulink linkID="1888081" linkType="Reference"&gt;1888081&lt;/ulink&gt;]. In June 2018, clinical data were presented at the 54th ASCO Annual Meeting in Chicago, IL. First step (stopping rule in case of &amp;gt;/= 7 patients with grade &amp;gt;/= 4 adverse events) safety analysis (n = 14) revealed that three patients developed grade 4 adverse events according to NCI CTCAE v4.03 (dermatitis, lymphopenia and po mucositis). At that time, 27 additional patients were enrolled in 2nd step (stopping rule in case of &amp;gt;/= 8 patients with grade &amp;gt;/= 4 adverse event) [&lt;ulink linkID="2039234" linkType="Reference"&gt;2039234&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2016, a phase I study (&lt;ulink linkID="276200" linkType="Protocol"&gt;NCT02938273&lt;/ulink&gt;; N16BIR) was to begin in October 2016 to assess the safety and efficacy of concurrent &lt;ulink linkID="83065" linkType="Drug"&gt;avelumab&lt;/ulink&gt;, cetuximab and radiotherapy as first line treatment in patients (expected n = 10) with locally advanced SCCHN. At that time, the study was expected to complete in October 2018. In December 2016, the study was initiated in the Netherlands [&lt;ulink linkID="1865780" linkType="Reference"&gt;1865780&lt;/ulink&gt;]. In June 2018, clinical data of six patients were presented at the 54th ASCO meeting in Chicago, IL. Grade 3 cetuximab-related infusion reaction was experienced by one patient and later withdrew from study before avelumab was administered. A single 81 year old patient who experienced no toxicity except grade 2 dysphagia discontinued treatment after two avelumab cycles and 12 x 2 Gy radiotherapy. Of the four remaining patients who completed the treatment, two were still treated with maintenance therapy. A total of 2 weeks after completion of radiotherapy and 2 weeks after the completion of maintenance therapy (Ojiri 0), all patients were in complete remission. A single patient had an Ojiri 1 response 2 weeks after maintenance therapy [&lt;ulink linkID="2044309" linkType="Reference"&gt;2044309&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Neoadjuvant therapy&lt;/subtitle&gt;In June 2016, clinical data from a prospective phase II WINDOW trial (&lt;ulink linkID="71134" linkType="Protocol"&gt;NCT01218048&lt;/ulink&gt;) of neoadjuvant immune biomarker modulation with cetuximab followed by adjuvant therapy with concurrent chemoradiotherapy or radiotherapy with or without cetuximab were presented at the 52nd ASCO meeting in Chicago, IL. Patients (n = 40) with SCCHN received cetuximab (400 mg/m2 then 250 mg/m2/week) for 3 to 4 weeks preoperatively, followed by adjuvant chemo-radiation with or without cetuximab.  Median follow up for PFS was found to be 24. During window exposure rash found was not associated with response but was associated with Fcgamma R genotype [&lt;ulink linkID="1765616" linkType="Reference"&gt;1765616&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;n July 2008, Merck began a phase I/II trial (&lt;ulink linkID="48187" linkType="Protocol"&gt;NCT00714649&lt;/ulink&gt;; CHIRON 2008-01) of neoadjuvant cetuximab in patients with SCCHN in Belgium. The open-label, active-controlled, parallel-assigned study was to evaluate the safety and efficacy of cetuximab followed by surgery. In the phase I portion, patients were to receive three pre-operative doses of cetuximab with a 24-h delay between the last dose and surgery. The phase II portion would be carried out if the fifth schedule was safe. At that time, a total of 40 patients were to be enrolled; the study completed in May 2011 [&lt;ulink linkID="951500" linkType="Reference"&gt;951500&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Phase II data (&lt;ulink linkID="38931" linkType="Protocol"&gt;NCT00089297&lt;/ulink&gt;) were presented at the 43rd ASCO meeting in Chicago, IL, in June 2007. These preliminary data demonstrated in 74 patients with stage III or stage IV head and neck cancer that neoadjuvant induction cetuximab plus chemotherapy, followed by cetuximab plus chemoradiation elicited a complete pathological response at the primary site [&lt;ulink linkID="797546" linkType="Reference"&gt;797546&lt;/ulink&gt;]. Data indicated that event-free survival was 79% at 1 year, and 63% of patients had an objective response [&lt;ulink linkID="1649415" linkType="Reference"&gt;1649415&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other studies&lt;/subtitle&gt;In June 2018, clinical data from Veterans health registry data which examined patients with stage III-IV head and neck squamous cell carcinoma treated with definitive intent concurrent radiotherapy using either cisplatin (n = 970) or cetuximab (n = 3016) were presented at the 54th ASCO Annual Meeting in Chicago, IL. In cetuximab and cisplation groups, median OS was 1.5 and 3.8 years (unadjusted; HR: 1.75; p &amp;lt; 0.001), 1.8 and 4.2 years (PS matched; HR: 1.66; p &amp;lt; 0.001), 0.8 and 1.0 years (oral cavity; HR: 1.62; p = 0.02), 1.0 and 4.6 years (oropharynx; HR: 1.63; p &amp;lt; 0.001), 1.4 and 3.2 years (larynx/hypopharynx; HR: 1.87; p &amp;lt; 0.001) and 1.6 and 3.9 years (low-dose cisplatin, PS matched groups; HR: 1.53; p &amp;lt; 0.001), respectively [&lt;ulink linkID="2039869" linkType="Reference"&gt;2039869&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Non-small-cell lung cancer&lt;/subtitle&gt;&lt;subtitle&gt;Combination with chemotherapy: first-line therapy&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In  September 2015, clinical data were presented  from SWOG-0819 phase III trial, at the IASLC 16th World Conference on Lung Cancer in Denver, CO. Patients (n = 1333) with advanced NSCLC were randomized to receive paclitaxel, carboplatin and bevacizumab or paclitaxel, carboplatin, bevacizumab and cetuximab. OS and PFS in cetuximab arm was 10.9 and 4.6 months, respectively when compared with control (9.4 and 4.5 months, respectively) for entire population, 13.4 and 5.4 months, respectively when compared with control (9.8 and 4.8 months, respectively) for EGFR fluorescent in situ hybridization+ (FISH+) patients [&lt;ulink linkID="1693850" linkType="Reference"&gt;1693850&lt;/ulink&gt;]. In June 2016, further clinical data were presented at the 52nd ASCO meeting in Chicago, IL. The response rates and disease control rate was achieved in 34 and 31%, 79 and 84% in bevacizumab excluded inappropriate and bevacizumab excluded choice patients, respectively [&lt;ulink linkID="1765646" linkType="Reference"&gt;1765646&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The open-label, phase III trial &lt;ulink linkID="42037" linkType="Protocol"&gt;NCT00112294&lt;/ulink&gt; began in December 2004 in the US, to examine taxane plus carboplatin treatment in combination with cetuximab in previously untreated advanced/metastatic NSCLC patients. Primary endpoint was PFS. Data from &lt;ulink linkID="42037" linkType="Protocol"&gt;NCT00112294&lt;/ulink&gt; (BMS CA225-099) were published in July 2007. The study did not meet its primary endpoint of PFS. However, secondary endpoints, including response rate, were significant and favored the cetuximab arm. The study included more than 600 patients from the US and Canada [&lt;ulink linkID="812538" linkType="Reference"&gt;812538&lt;/ulink&gt;], [&lt;ulink linkID="1230193" linkType="Reference"&gt;1230193&lt;/ulink&gt;]. In August 2008, OS data were reported; median OS in patients receiving cetuximab in combination with a taxane and carboplatin was 9.7 months, compared to 8.4 months for chemotherapy alone, which was not significantly different [&lt;ulink linkID="939402" linkType="Reference"&gt;939402&lt;/ulink&gt;]. In September 2009, similar data were presented at the Third Asian-Pacific Perspectives in Lung Cancer Conference in Singapore [&lt;ulink linkID="1044390" linkType="Reference"&gt;1044390&lt;/ulink&gt;]. In September 2011, data from a retrospective subgroup analysis to determine the correlation between EGFR immunohistochemistry expression and outcomes were presented at the European Multidisciplinary Cancer Congress in Stockholm, Sweden. In the cetuximab group, higher ORR was seen in patients with high EGFR expression compared with low EGFR expression; however, this effect was not observed in the chemotherapy-alone arm. High or low EGFR expression had no effect on PFS or OS [&lt;ulink linkID="1224124" linkType="Reference"&gt;1224124&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2004, an international randomized, parallel assignment, efficacy, phase III trial (&lt;ulink linkID="43703" linkType="Protocol"&gt;NCT00148798&lt;/ulink&gt;; FLEX) was initiated in chemotherapy-naive advanced NSCLC patients (n = 1125). Patients were to receive cetuximab plus &lt;ulink linkID="51933" linkType="Drug"&gt;cisplatin&lt;/ulink&gt; and &lt;ulink linkID="6408" linkType="Drug"&gt;vinorelbine&lt;/ulink&gt;, or cisplatin and vinorelbine alone. The primary endpoint was OS. By February 2006, patient enrollment was complete [&lt;ulink linkID="651509" linkType="Reference"&gt;651509&lt;/ulink&gt;], and the study was completed in May 2007 [&lt;ulink linkID="829538" linkType="Reference"&gt;829538&lt;/ulink&gt;]. In September 2007, initial data showed that cetuximab had achieved the primary endpoint of increasing OS compared with chemotherapy alone [&lt;ulink linkID="829236" linkType="Reference"&gt;829236&lt;/ulink&gt;]. In May 2008, further data were presented at the 44th annual ASCO meeting in Chicago, IL. OS and response rates were improved in the combination arm, and the overall safety profile was tolerable [&lt;ulink linkID="911913" linkType="Reference"&gt;911913&lt;/ulink&gt;], [&lt;ulink linkID="912093" linkType="Reference"&gt;912093&lt;/ulink&gt;] [&lt;ulink linkID="913889" linkType="Reference"&gt;913889&lt;/ulink&gt;]. In November 2008, data were presented at the  Multidisciplinary Symposium in Thoracic Oncology in Chicago, IL; median OS in patients who developed skin rash within 3 weeks of treatment was 15 months, compared to 8.8 months in those who did not [&lt;ulink linkID="962937" linkType="Reference"&gt;962937&lt;/ulink&gt;]. In September 2009, final data were presented at the Third Asian-Pacific Perspectives in Lung Cancer Conference in Singapore. Median OS was 11.3 vs 10.1 months with or without cetuximab, respectively [&lt;ulink linkID="1044390" linkType="Reference"&gt;1044390&lt;/ulink&gt;]. In December 2010, further data were presented at the Multidisciplinary Symposium in Thoracic Oncology in Chicago, IL. The data showed that the addition of cetuximab significantly increased the response rate from 28.1% to 44.4% in patients with high EGFR expression [&lt;ulink linkID="1180162" linkType="Reference"&gt;1180162&lt;/ulink&gt;]. In September 2011, safety data from a subgroup analysis were presented at the European Multidisciplinary Cancer Congress in Stockholm, Sweden. No excess in thromboembolic, cardiac or septic events were observed in the high EGFR compared with the low EGFR expression group. In the cetuximab plus chemotherapy group, the incidence of septic events was higher than the chemotherapy arm of both the high and low EGFR expression groups. Significantly improved survival benefit was observed in the high EGFR expression group without disproportionately increasing toxicity compared with low EGFR expression patients with the addition of cetuximab to chemotherapy [&lt;ulink linkID="1223978" linkType="Reference"&gt;1223978&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In June 2009, data from a phase II study (S0536; &lt;ulink linkID="28599" linkType="Protocol"&gt;NCT00368992&lt;/ulink&gt;) investigating carboplatin, paclitaxel and cetuximab plus bevacizumab in treatment-naive advanced non-squamous cell NSCLC patients were presented at the 45th ASCO meeting in Orlando, FL. Patients received carboplatin AUC 6, paclitaxel 200 mg/m2, bevacizumab 15 mg/kg iv on day 1 q3w, cetuximab 400 mg/m2 on day 1 then 250 mg/m2 weekly for up to 6 cycles, followed by bevacizumab 15 mg/kg q3w and cetuximab 250 mg/m2 weekly until progression. Overall toxicities were acceptable. Median partial response was seen in 54% of patients with stable disease of 23%: disease control rate was77%. With median follow up of 15 months, PFS was 7 months, OS was 14 months and 1-year survival was 57% [&lt;ulink linkID="1012999" linkType="Reference"&gt;1012999&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2009, data from a phase II trial of cetuximab combined with either &lt;ulink linkID="3199" linkType="Drug"&gt;gemcitabine&lt;/ulink&gt; followed by &lt;ulink linkID="2953" linkType="Drug"&gt;docetaxel&lt;/ulink&gt; or carboplatin/gemcitabine in chemotherapy-naive patients with advanced NSCLC were presented at the 45th ASCO meeting in Orlando, FL. Patients received cetuximab 400 mg/m2 loading dose followed by 250 mg/m2 weekly either combined with gemcitabine 1000 mg/m2 on days 1 and 8 for 2 cycles q3w followed by docetaxel 75 mg/m2 on day 1 for 2 cycles q3w (arm A) or carboplatin AUC5 day 1 and gemcitabine 1200 mg/m2 days 1 and 8 for 4 cyclesq3w (arm B). Maintenance cetuximab was administered until disease progression or unacceptable toxicity. Grade 1 or 2 skin reactions related to treatment occurred in 84 and 77% of patients in arm A and B, respectively. Toxicity was more common in those receiving carboplatin. Cetuximab did not significantly increase chemotherapy toxicity in the induction phase and is well tolerated in the maintenance phase [&lt;ulink linkID="1012871" linkType="Reference"&gt;1012871&lt;/ulink&gt;]. In September 2011, further phase II data were presented at the European Multidisciplinary Cancer Congress in Stockholm, Sweden. During the first cycle of treatment, the incidence of cetuximab-related grade 1/2 skin reactions was 69 and 65% for arms A and B, respectively; in the subsequent cycles, the incidence decreased from 22 to 11% for arm A compared with 24 to 15% for arm B. The primary endpoint of grade 3/4 hematological toxicities without therapeutic interaction were higher in arm B compared with arm A. The ORRs were 19 and 31% for arms A and B, respectively. No significant differences were observed in OS. At that time, the phase III study part involving 608 patients was ongoing [&lt;ulink linkID="1223569" linkType="Reference"&gt;1223569&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2009, an open-label, non-randomized, phase II study (&lt;ulink linkID="49692" linkType="Protocol"&gt;NCT00867009&lt;/ulink&gt; ; 10726, H3E-MC-S104) was initiated in Europe, to assess the safety, efficacy and response rate in patients (n = 113) with advanced or metastatic non-squamous NSCLC who showed no progress  on induction treatment with pemetrexed, cisplatin and cetuximab. The patients received maintenance treatment with pemetrexed and cetuximab. In September 2014, the trial was completed [&lt;ulink linkID="1612253" linkType="Reference"&gt;1612253&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2007, data from a phase II trial of cetuximab in combination with &lt;ulink linkID="2953" linkType="Drug"&gt;docetaxel&lt;/ulink&gt; and carboplatin were presented at the 43rd ASCO meeting in Chicago, IL. In the study, chemotherapy-naive patients were treated with 400 mg/m2 of cetuximab on day 1 and 250 mg/m2 on days 8 and 15, plus 75 mg/m2 of docetaxel on day 1 and carboplatin on day 1 of a 21-day cycle for up to 6 cycles. Of 76 evaluable patients, the response rate was 14.5% and the median PFS was 4.7 months, with a median OS of 11 months. The combination was well tolerated with neutropenia being the most common adverse event [&lt;ulink linkID="802194" linkType="Reference"&gt;802194&lt;/ulink&gt;], [&lt;ulink linkID="797426" linkType="Reference"&gt;797426&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2003, results from a randomized, phase II trial (study EMR 62202-011; LUCAS) were reported; the trial evaluated cetuximab in combination with cisplatin and vinorelbine compared to cisplatin and vinorelbine alone. Cetuximab plus cisplatin and vinorelbine increased tumor response rates (53% vs 32.3%) in 61 patients with chemotherapy-naive advanced NSCLC [&lt;ulink linkID="491474" linkType="Reference"&gt;491474&lt;/ulink&gt;], [&lt;ulink linkID="492104" linkType="Reference"&gt;492104&lt;/ulink&gt;]. In June 2003, further data were presented at the 39th ASCO meeting in Chicago, IL. Adverse events noted were leukopenia (16.7%), nausea/vomiting (13.9%), asthenia (11.1%) and infection (11.1%), two of which were attributable to cetuximab [&lt;ulink linkID="491433" linkType="Reference"&gt;491433&lt;/ulink&gt;], [&lt;ulink linkID="491596" linkType="Reference"&gt;491596&lt;/ulink&gt;], [&lt;ulink linkID="499057" linkType="Reference"&gt;499057&lt;/ulink&gt;]. By February 2004, enrollment in EMR 62202-011 had been completed, at 86 patients [&lt;ulink linkID="523312" linkType="Reference"&gt;523312&lt;/ulink&gt;]. In September 2004, further data were presented at the fourth International Monoclonal Antibodies in Cancer congress in Colorado Springs, CO. The objective response rates were 35% confirmed (54% unconfirmed) and 28% confirmed (33% unconfirmed), with overall disease control of 84% and 68%, in the combination group and chemotherapy group, respectively [&lt;ulink linkID="560046" linkType="Reference"&gt;560046&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Combination with chemotherapy: second-line therapy&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;By October 2004, ImClone and BMS were planning a phase III trial (IMCL-0452; SELECT; &lt;ulink linkID="42292" linkType="Protocol"&gt;NCT00095199&lt;/ulink&gt;) to evaluate chemotherapy with &lt;ulink linkID="2953" linkType="Drug"&gt;docetaxel&lt;/ulink&gt; or &lt;ulink linkID="3536" linkType="Drug"&gt;pemetrexed&lt;/ulink&gt;, or the same chemotherapy in combination with cetuximab in 800 patients with previously treated metastatic, unresectable, or locally-advanced NSCLC. The primary endpoint was tumor response rate [&lt;ulink linkID="563334" linkType="Reference"&gt;563334&lt;/ulink&gt;]. The trial began  in January 2005 [&lt;ulink linkID="1284128" linkType="Reference"&gt;1284128&lt;/ulink&gt;]. In 2006/07 was amended to alter the randomization between docetaxel and pemetrexed to physicians choice, to account for changes in standard therapy [&lt;ulink linkID="1270771" linkType="Reference"&gt;1270771&lt;/ulink&gt;].By September 2011, the trial had completed [&lt;ulink linkID="1284128" linkType="Reference"&gt;1284128&lt;/ulink&gt;]. In June 2012,  data were presented at the 48th ASCO meeting in Chicago, IL. Patients received docetaxel (75 mg/m2) or pemetrexed (500 mg/m2) on day 1, and then patients (n = 938; intent-to-treat population) were randomized within the groups to receive docetaxel or pemetrexed alone or with cetuximab (400/250 mg/m2 initial/weekly) for up to six 3-week cycles. The median PFS and OS was 2.89 and 6.93 months, respectively, for the pemetrexed + cetuximab group (n = 301), and 2.76 and 7.79 months, respectively, for the pemetrexed alone (n = 304) group. In the pemetrexed + cetuximab versus pemetrexed group, the ORR was 6.6 versus 4.3%, and disease control rate was 52.2 versus 48%. In the combined chemotherapy + cetuximab versus chemotherapy group, the investigator median PFS was 2.79 versus 2.27 months, and the median OS was 5.74 versus 7.85 months [&lt;ulink linkID="1299410" linkType="Reference"&gt;1299410&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In May 2002, data were presented at the 38th ASCO meeting in Orlando, FL from a phase II study in chemotherapy refractory/resistant patients with advanced NSCLC using cetuximab in combination with &lt;ulink linkID="2953" linkType="Drug"&gt;docetaxel&lt;/ulink&gt;. Cetuximab was administered as 400 mg/m2 iv during the first week, followed by 250 mg/m2 iv weekly doses and docetaxel was administered at 75 mg/m2 every 3 weeks. From 20 evaluable patients, four achieved a partial response and six had stable disease. Minimal toxicities were observed including acneiform rash in five patients (grade 1 to 3) and febrile neutropenia in two patients (grade 2 to 3) [&lt;ulink linkID="452447" linkType="Reference"&gt;452447&lt;/ulink&gt;]. Further data presented at the 14th EORTC-NCI-AACR meeting in Frankfurt, Germany, showed that of 30 evaluable patients, 8 had achieved a partial response and 8 had stable disease [&lt;ulink linkID="471470" linkType="Reference"&gt;471470&lt;/ulink&gt;]. In May 2003, additional data were presented at the 39th ASCO meeting in Chicago, IL. Thirteen patients treated with the combination achieved a partial response, and eight had stable disease. Time-to-progression was 86 days, and the median number of cycles was four. Adverse reactions included grade 3 infection, rash and fatigue [&lt;ulink linkID="491399" linkType="Reference"&gt;491399&lt;/ulink&gt;], [&lt;ulink linkID="491431" linkType="Reference"&gt;491431&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Combination with chemotherapy: earlier-stage data&lt;/subtitle&gt;In a phase Ib/IIa study investigating the efficacy of cetuximab with gemcitabine and carboplatin, 20 patients with advanced NSCLC had a partial response and 21 had stable disease following treatment. Cetuximab (400 mg/m2 iv over 2 h) was given for the first week, followed by weekly doses of 250 mg/m2 over 1 h. Carboplatin (AUC = 5; day 1) and gemcitabine (1000 mg/m2 on days 1 and 8) were also administered. Disease control was achieved in 88.6% of patients. Severe hematological toxicities included thrombocytopenia, leukopenia and anemia [&lt;ulink linkID="491343" linkType="Reference"&gt;491343&lt;/ulink&gt;], [&lt;ulink linkID="491474" linkType="Reference"&gt;491474&lt;/ulink&gt;]. A phase I/II study of cetuximab, at the same dose as above, combined with paclitaxel (225 mg/m2 on day 1) and carboplatin (AUC = 6 on day 1 every 3 weeks) in 31 previously untreated patients demonstrated a partial response in 29% (9 patients) and stable disease in 35.5% (11 patients). Disease control was achieved in 64.5% (20 patients). Median OS was 472 days. Adverse events included an acne-like rash and fatigue [&lt;ulink linkID="491436" linkType="Reference"&gt;491436&lt;/ulink&gt;], [&lt;ulink linkID="491474" linkType="Reference"&gt;491474&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Combination with chemoradiotherapy&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In June 2007, data from a phase II trial of cetuximab in combination with chemoradiation were presented at the 43rd ASCO meeting. In the study, patients were initially treated with 400 mg/m2 cetuximab on day 1 of week 1, increased to 250 mg/m2 with concurrent radiation, carboplatin and paclitaxel at week 2. From 87 evaluable subjects, the response rate was 62% and 12-month OS was 68% [&lt;ulink linkID="797715" linkType="Reference"&gt;797715&lt;/ulink&gt;]. In May 2008, further data were presented at the 44th annual ASCO meeting in Chicago, IL; 20% of patients experienced grade 4 hematologic toxicities, 8% grade 3 esophagitis, and 7% grade 3 to 4 pneumonitis. Five grade 5 events were also noted [&lt;ulink linkID="911589" linkType="Reference"&gt;911589&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Gastric cancer&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;By September 2011, phase III trials for gastric cancer were ongoing in Japan [&lt;ulink linkID="1234184" linkType="Reference"&gt;1234184&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2008, Merck Serono initiated a phase III, multicenter, open-label, randomized, controlled study (&lt;ulink linkID="42756" linkType="Protocol"&gt;NCT00678535&lt;/ulink&gt;; EXPAND), to evaluate the clinical benefit of cetuximab in combination with &lt;ulink linkID="51933" linkType="Drug"&gt;cisplatin&lt;/ulink&gt; and &lt;ulink linkID="12205" linkType="Drug"&gt;capecitabine&lt;/ulink&gt; as a first-line treatment for patients (estimated n = 870) with advanced/metastatic gastric adenocarcinoma, including gastroesophageal junction adenocarcinoma. The primary endpoint was PFS. By January 2011, patient recruitment had been completed, and the study was completed in March 2012 [&lt;ulink linkID="923604" linkType="Reference"&gt;923604&lt;/ulink&gt;], [&lt;ulink linkID="1158844" linkType="Reference"&gt;1158844&lt;/ulink&gt;], [&lt;ulink linkID="1306332" linkType="Reference"&gt;1306332&lt;/ulink&gt;]. In July 2012, it was reported that the 904-patient trial did not achieve the primary endpoint, as the combination treatment did not significantly increase PFS [&lt;ulink linkID="1306313" linkType="Reference"&gt;1306313&lt;/ulink&gt;]. In September 2012,  further data were presented at the 37th European Society for Medical Oncology Congress in Vienna, Austria. Patients (n = 870) received cetuximab (400 mg/m2 initially and then 250 mg/m2/week) + cisplatin  + capecitabine  in group 1 or cisplatin + capecitabine in group 2. In group 1 and 2, the PFS (primary endpoint) was 4.4 and 5.6 months, and OS  was 9.4 and 10.7 months, respectively. In groups 1 and 2, the best ORRs were 30 and 29%, and the disease control rates were 73 and 71%, respectively, two patients in each group showed complete response; in the respective groups, 134 and 129 patients showed partial response, 196 and 186 had stable disease, and 65 and 61 had progressive disease. At that time, biomarker analysis was ongoing [&lt;ulink linkID="1325910" linkType="Reference"&gt;1325910&lt;/ulink&gt;], [&lt;ulink linkID="1332473" linkType="Reference"&gt;1332473&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In June 2010, data were presented at the 46th ASCO meeting in Chicago, IL, from a phase II trial evaluating cetuximab in combination with modified CPT-11, leucovorin and  5-FU in previously treated gastric cancer patients. Results showed the median time-to-treatment progression and OS rates were 4.9 and 8.1 months, respectively. Of 49 evaluable patients, complete and partial responses were seen in 1 and 16 patients, respectively, while stable and progressive disease was seen in 25 and 7 patients [&lt;ulink linkID="1105219" linkType="Reference"&gt;1105219&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2009, data were presented at the 45th ASCO meeting in Orlando, FL. A phase II study assessed the use of cetuximab when administered in combination with weekly cisplatin, and a 24-h infusion of high-dose 5-FU and leucovorin for the first-line treatment of advanced gastric cancer. The combination produced favorable overall response and survival rates and had low toxicity [&lt;ulink linkID="1010084" linkType="Reference"&gt;1010084&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2009, data were presented at the 45th ASCO meeting in Orlando, FL. A phase II study, AGMT GASTRIC-2 assessed the efficacy of administering oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. Response rates were 63% and the disease control rate was 86%. Overall, the drug combination was safe and active in gastric cancer [&lt;ulink linkID="1012931" linkType="Reference"&gt;1012931&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2009, data were presented at the 45th ASCO meeting in Orlando, FL. In a phase Ib/II trial (&lt;ulink linkID="47683" linkType="Protocol"&gt;NCT00445861&lt;/ulink&gt;, SWS-SAKK-75/06) the efficacy of cetuximab in combination with cisplatin and docetaxel was assessed in patients with resectable, locally advanced esophageal carcinoma. The drug combination showed antineoplastic activity [&lt;ulink linkID="1010086" linkType="Reference"&gt;1010086&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2009, data were presented at the 45th ASCO meeting in Orlando, FL, from a phase II trial in patients with esophago-gastric cancer. The trial evaluated the safety and tolerability of cetuximab in combination with irinotecan. The combination was well tolerated. Of 48 patients, a complete response, partial response, overall response, stable disease and tumor control was achieved by 4, 38, 42, 35 and 73% [&lt;ulink linkID="1010046" linkType="Reference"&gt;1010046&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2009, an  open label, single group assignment, phase II trial (&lt;ulink linkID="48227" linkType="Protocol"&gt;NCT00857246&lt;/ulink&gt;; 04-72 (H12637), BMS #CA225112) was initiated in  the US, in patients (n = 30) with gastric cancer, to assess the safety and efficacy of cetuximab in combination with irinotecan and cisplatin as neoadjuvant therapy. At that time, the trial was expected to complete in June 2015. In October 2015, the trial was completed [&lt;ulink linkID="1642851" linkType="Reference"&gt;1642851&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2007, a non-randomized, open label, uncontrolled, interventional phase II trial (&lt;ulink linkID="45738" linkType="Protocol"&gt;NCT00477711&lt;/ulink&gt;) was initiated in 41 advanced gastric cancer patients in China.  The study was to investigate the efficacy of cetuximab with cisplatin and capecitabine as first-line treatment. The primary endpoint was tumor response rate within a year. Secondary outcomes included 5-year time to progression, disease control rate, OS, K-ras, b-raf, p53 gene mutation and EGFR gene copy number versus tumor response [&lt;ulink linkID="843718" linkType="Reference"&gt;843718&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2005, BMS initiated a non-randomized, open-label, active control, interventional phase II safety and efficacy trial in 36 patients with advanced esophageal or gastric cancer. The primary endpoint was response rate of cetuximab, and the secondary endpoint was safety and response duration. By January 2007, recruitment was ongoing [&lt;ulink linkID="843731" linkType="Reference"&gt;843731&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2005, data on a trial combining cetuximab with irinotecan and bevacizumab in metastatic gastric and esophageal cancer were presented at the Gastrointestinal Cancers Symposium in Hollywood, FL. In a 2-arm randomized trial, 34 patients received irinotecan, at the same dose and schedule as they had received prior to the study, with the addition of cetuximab 400 mg/m2 loading dose followed by weekly cetuximab at 250 mg/m2 and bevacizumab 5 mg/kg administered every other week. In the comparator arm of the study, 31 patients received the same therapy but without irinotecan. In the first arm, 29% of patients experienced grade 3 to 4 diarrhea, compared with 1% in second arm. About 9% of patients in the irinotecan arm experienced grade 3 or 4 neutropenia, not experienced in the second arm. Patients in arms 1 and 2 experienced 47and 45% acneiform rash, respectively [&lt;ulink linkID="584450" linkType="Reference"&gt;584450&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Breast cancer&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In June 2014, data were presented from a randomized, parallel-arm, phase II trial of &lt;ulink linkID="15541" linkType="Drug"&gt;ixabepilone&lt;/ulink&gt; alone or in combination with  cetuximab in  40 patients with triple-negative breast cancer at the 50th ASCO meeting in Chicago, IL. In the ixabepilone and ixabepilone + cetuximab groups, the respective pathological complete response rates (primary endpoint) were 14.3 and 28%, in patients with breast cancer and were 14.3 and 24% in patients with breast and axillary lymph nodes; the respective response rates were 93 and 72% [&lt;ulink linkID="1562604" linkType="Reference"&gt;1562604&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2007, a randomized, open-label, active control, parallel assignment efficacy phase II trial (&lt;ulink linkID="44309" linkType="Protocol"&gt;NCT00463788&lt;/ulink&gt;; EMR 200027-051; BALI-1) was planned in patients (expected n = 180) with ER-negative, PgR-negative, HER2-negative (triple negative) metastatic breast cancer in Europe and Israel. Patients were to receive either an initial dose of iv cetuximab (400 mg/m2) followed by weekly doses (250 mg/m2), plus iv cisplatin (75 mg/m2 on day 1) every 3 weeks, with a maximum of 6 cycles, or cisplatin alone. The primary endpoint was overall response [&lt;ulink linkID="886347" linkType="Reference"&gt;886347&lt;/ulink&gt;]. Initial results were presented at the 35th Congress of the European Society for Medical Oncology (ESMO) in November 2010, in Milan, Italy. The primary endpoint of response rate was not met, despite a strong trend toward improved tumor response. However, an improved tumor response rate (20.0% vs 10.3%) was seen in women treated with cetuximab plus chemotherapy, and cetuximab-treated patients demonstrated a significant reduction in risk of progression compared with chemotherapy alone. The chance of complete response or partial response was also twice as high for patients receiving cetuximab in combination with chemotherapy (OR = 2.126), compared to chemotherapy alone [&lt;ulink linkID="1138405" linkType="Reference"&gt;1138405&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2005, BMS initiated a US randomized, open-label, uncontrolled, parallel assignment, efficacy phase II trial (&lt;ulink linkID="42507" linkType="Protocol"&gt;NCT00248287&lt;/ulink&gt;) in 154 patients with metastatic breast cancer. The trial was to determine the objective response rates produced by irinotecan and carboplatin therapy with or without cetuximab. The trial was expected to complete in June 2013 [&lt;ulink linkID="843752" linkType="Reference"&gt;843752&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Phase Ib/IIa trials, carried out in 1996, studied the effects of cetuximab in combination with paclitaxel in the treatment of breast cancer. Previously treated patients were given an injection of cetuximab as a weekly, dose-escalating, 4-week protocol, with doses up to 200 mg/m3. If the disease stabilized, a further 8-week course began [&lt;ulink linkID="199214" linkType="Reference"&gt;199214&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Prostate cancer&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;A phase II trial (&lt;ulink linkID="48185" linkType="Protocol"&gt;NCT00661492&lt;/ulink&gt;) was initiated in May 2008; the trial was designed to compare the time to progression with the combination of mitoxantrone and cetuximab versus &lt;ulink linkID="11519" linkType="Drug"&gt;mitoxantrone&lt;/ulink&gt; alone in patients with metastatic androgen-independent prostate cancer patients previously treated with docetaxel-based chemotherapy. The trial was expected to enroll 130 patients and complete in May 2010. The trial was ongoing but not recruiting as of April 2010 [&lt;ulink linkID="1025499" linkType="Reference"&gt;1025499&lt;/ulink&gt;]. In  December 2016, the trial was completed  [&lt;ulink linkID="1025499" linkType="Reference"&gt;1025499&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 1997, preliminary results from a phase Ib/IIa trial evaluating cetuximab and doxorubicin for late-stage prostate cancer were presented at the 33rd ASCO meeting in Denver, CO. Of 30 patients evaluated, there was a strong suggestion of biological activity and stabilization of disease [&lt;ulink linkID="246979" linkType="Reference"&gt;246979&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Mesothelioma&lt;/subtitle&gt;An open-label phase II trial (&lt;ulink linkID="61143" linkType="Protocol"&gt;NCT00996567&lt;/ulink&gt;) began in October 2009 for the first-line treatment of pleural mesothelioma in combination with cisplatin or carboplatin/pemetrexed. The first phase of the trial was to enroll 18 patients, and if a positive interim analysis was seen, a further 43 patients would be enrolled. The primary endpoint was PFS rate at 18 weeks. The  trial was expected to complete in  September 2015. In December 2014, the trial was recruiting participants [&lt;ulink linkID="1657523" linkType="Reference"&gt;1657523&lt;/ulink&gt;]. In June 2017, clinical data from 18 patients were presented at the 53rd ASCO meeting in Chicago, IL. At 18 weeks, 13 patients were alive and without progression. At week 18, median progression free survival (primary endpoint) was 24 weeks, median overall survival (secondary endpoint) was 49 weeks. Partial response was observed in 44% of patients. The treatment was well tolerated. Skin rash (89%, mainly grade 1 to 2) was the most common adverse event reported [&lt;ulink linkID="1940377" linkType="Reference"&gt;1940377&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pancreatic cancer&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;Results from a phase III study (&lt;ulink linkID="41005" linkType="Protocol"&gt;NCT00075686&lt;/ulink&gt;; SWOG S0205) were published in April 2007 from a trial examining cetuximab plus gemcitabine in patients with locally advanced unresectable or metastatic pancreatic cancer. The trial did not meet its primary endpoint of OS. The open-label study compared cetuximab plus gemcitabine to gemcitabine alone in more than 700 patients with pancreatic cancer in the first-line setting [&lt;ulink linkID="782188" linkType="Reference"&gt;782188&lt;/ulink&gt;]. Final efficacy data from the trial were presented in June 2007 at the 43rd ASCO meeting in Chicago, IL; a total of 766 patients were randomized to receive the combination (1000 mg/m2 gemcitabine weekly for 7 weeks out of 8, plus cetuximab 400 mg/week or placebo). OS for the combination was 6.4 months, versus 5.9 months for placebo. PFS was 3.5 and 3 months, respectively, and the time-to-treatment failure differed by 0.7 months between the groups. Partial responses were seen in 12% of combination patients and 13% of placebo patients. The only grade 3 or 4 toxicities noted in the combination patients were skin toxicities and allergic reactions. Although the combination did not improve outcome, analysis was ongoing to determine the contribution of EGFR expression and skin rash on outcome [&lt;ulink linkID="802194" linkType="Reference"&gt;802194&lt;/ulink&gt;], [&lt;ulink linkID="801374" linkType="Reference"&gt;801374&lt;/ulink&gt;], [&lt;ulink linkID="801410" linkType="Reference"&gt;801410&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;By December 1999, a phase II trial of cetuximab in combination with gemcitabine in patients with pancreatic carcinoma had been initiated [&lt;ulink linkID="349626" linkType="Reference"&gt;349626&lt;/ulink&gt;]. In May 2001, data the trial were presented at the 37th ASCO meeting in San Francisco, CA. Of 41 patients enrolled who received 400 mg/m2 cetuximab followed by 250 mg/m2/week, with 1000 mg/m2/week gemcitabine, 5 (12%) experienced partial responses, while 16 (39%) achieved stable disease or minor responses. The median time to progression of 16 weeks, compared favorably with published results for gemcitabine alone (9 weeks). The combination was well tolerated, with 41% experiencing fatigue, 38% skin toxicity, and 38% grade 1/2 fever [&lt;ulink linkID="410153" linkType="Reference"&gt;410153&lt;/ulink&gt;], [&lt;ulink linkID="408860" linkType="Reference"&gt;408860&lt;/ulink&gt;]. Patients treated with the combination had a 1-year survival rate of 33%, compared with 18% for gemcitabine alone [&lt;ulink linkID="423268" linkType="Reference"&gt;423268&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Bladder cancer&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In May 2008, a phase II study (&lt;ulink linkID="45704" linkType="Protocol"&gt;NCT00645593&lt;/ulink&gt;) was initiated to compare first-line treatment of chemotherapy (gemcitabine + cisplatin) with or without cetuximab in patients with urothelial  cancer. The trial was designed to enroll 81 patients and complete in 2013 [&lt;ulink linkID="1025510" linkType="Reference"&gt;1025510&lt;/ulink&gt;]. In June 2012, data were reported at the  48th ASCO meeting in Chicago, IL. A total of  84 patients were response evaluable, in arm A (gemcitabine + cisplatin) and B (gemcitabine + cisplatin + cetuximab) the response rate was 57 and 62.5%, respectively. Median PFS and median survival in arms A and B were 8.5 and 7.6 months, and 14 and 14 months, respectively. E-cadherin did not correlate with outcome [&lt;ulink linkID="1607314" linkType="Reference"&gt;1607314&lt;/ulink&gt;]. In May 2014, further results from 85 evaluable patients were published demonstrating  that ORRs were 57.1 and 61.4% for arm A and arm B, respectively. The median OS times were 17.4 and 14.3 months, respectively [&lt;ulink linkID="1629623" linkType="Reference"&gt;1629623&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2006, an open-label, randomized, single-group assigned, interventional, phase II study (&lt;ulink linkID="42312" linkType="Protocol"&gt;NCT00350025&lt;/ulink&gt;; FER-GU-004) which evaluated the efficacy of cetuximab in combination with or without paclitaxel was initiated in patients (n = 26) with previously treated urothelial cancer [&lt;ulink linkID="1449346" linkType="Reference"&gt;1449346&lt;/ulink&gt;]. In February 2011, results were presented. The cetuximab arm was closed because of progression in 9 of the 11 patients. The cetuximab +  paclitaxel arm accrued 28 patients. Median PFS was 16 weeks and the ORR was 25% [&lt;ulink linkID="1172008" linkType="Reference"&gt;1172008&lt;/ulink&gt;]. In October 2012,  results were published. A total of 39 patients were enrolled for the study. PFS &amp;gt; 16 weeks was reported in 12 of 28 patients and the median PFS was 16.4 weeks (12 to 25.1 weeks). It was also observed that ORR was 25% (11 to 45%; three complete responses and four partial responses) and the median OS was 42 weeks (95% CI, 30.4 to 78 weeks) [&lt;ulink linkID="1352867" linkType="Reference"&gt;1352867&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Cervical cancer&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In June 2009, data from a phase II trial of cisplatin and cetuximab in patients with advanced or recurrent carcinoma of the cervix were presented at the 45th ASCO meeting in Orlando, FL. Cisplatin was administered at 30 mg/m2 on days 1 and 8. cetuximab was given at 400 mg/m2 on day 1, with all subsequent doses at 250 mg/m2 (days 8, and 15) on a 21 day cycle. Of 69 were evaluable patients there were 8 (12%) responses: 8% among patients with prior chemotherapy and 17% among chemotherapy-naive patients. One patient had grade 4 anemia. This combination was adequately tolerated but did not indicate additional benefit beyond cisplatin therapy [&lt;ulink linkID="1012930" linkType="Reference"&gt;1012930&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2006, a phase II trial (&lt;ulink linkID="31411" linkType="Protocol"&gt;NCT00292955&lt;/ulink&gt;) was initiated to evaluate the antitumor activity of cetuximab prior to cisplatin and radiotherapy and with concurrent cisplatin and radiotherapy in women with locally advanced or metastatic cervical carcinoma. The trial was designed to enroll 30 patients and complete in February 2012. However, no further development has been reported since May 2011 [&lt;ulink linkID="1025513" linkType="Reference"&gt;1025513&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Sarcoma&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In March 2005, a non-randomized, open-label, active-control, parallel-assignment, phase II trial (&lt;ulink linkID="24626" linkType="Protocol"&gt;NCT00148109&lt;/ulink&gt;, UMCC 2004-078) began in the US to examine the efficacy of cetuximab in patients (n = 45) with metastatic and/or locally advanced soft tissue and bony sarcoma. The trial completed in December 2009 [&lt;ulink linkID="1025518" linkType="Reference"&gt;1025518&lt;/ulink&gt;]. Data were published in January 2012. The trial enrolled 21 and 15 evaluable patients in the EGFR+ and EGFR- subgroup, respectively. One of the EGFR+ patients (4.8%) achieved 4-month PFS. Median PFS and OS were 1.7 months and 7.7 months, respectively. Three of 15 EGFR- patients (20%) achieved 4-month PFS. Median PFS and OS were 1.8 months and 15.7 months, respectively. No responses were seen in either group. There was no correlation between clinical outcomes and expression of MAP-K, PTEN or phospho-EGFR [&lt;ulink linkID="1270842" linkType="Reference"&gt;1270842&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Endometrial cancer&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In October 2006, a phase II study (&lt;ulink linkID="34024" linkType="Protocol"&gt;NCT00392769&lt;/ulink&gt;) was initiated in the US to evaluate the overall disease control rate of cetuximab in patients with progressive or recurrent endometrial cancer. The trial was designed to enroll 40 patients and completed in December 2010 [&lt;ulink linkID="1025523" linkType="Reference"&gt;1025523&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Liver cancer&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;At ASCO 2007, final phase II results from an open-label trial in unresectable hepatocellular carcinoma were presented. From 32 enrolled patients, there were no complete remissions and no partial remissions; 44.4% of patients experienced stable disease for &amp;gt; 8 weeks. PFS at 6 months was 22.2% [&lt;ulink linkID="796228" linkType="Reference"&gt;796228&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Biliary cancer&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In September 2008, an investigator-led, company-sponsored, open-label phase II trial (&lt;ulink linkID="45696" linkType="Protocol"&gt;NCT00747097&lt;/ulink&gt;; ECHO) to assess cetuximab plus gemcitabine in advanced cholangiosarcoma, excluding gallbladder cancer. The primary endpoint was PFS; the trial was expected to enroll 43 patients, and completed in September 2010 [&lt;ulink linkID="1271067" linkType="Reference"&gt;1271067&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2007, a investigator-led, company-sponsored, phase II trial (&lt;ulink linkID="48200" linkType="Protocol"&gt;NCT00552149&lt;/ulink&gt;; BINGO; CSET 1287) for advanced biliary cancer began in France. In the randomized, open label study, 100 patients were to receive iv infusions of 1000 mg/m2 of gemcitabine plus 100 mg/m2  oxaliplatin with or without cetuximab every 2 weeks. The primary endpoint was efficacy according to crude PFS. At that time, the trial was expected to complete in October 2010 [&lt;ulink linkID="981857" linkType="Reference"&gt;981857&lt;/ulink&gt;]. In June 2013, further   data from 150 patients were presented at the 49th ASCO meeting in Chicago, IL.  Tumor KRAS, BRAF and KRAS plus BRAF mutations were observed in 18, 4 and 22 % of patients respectively. Out of 77 patients, 18 patients had high EGFR score (&amp;gt;/= 200). In both the treatment arms, significant differences in PFS or OS were not observed in the presence or absence of either KRAS or BRAF mutations. The overexpression of EGFR and tumor KRAS/BRAF mutations were seen in 24 and 23% of patients, respectively [&lt;ulink linkID="1427067" linkType="Reference"&gt;1427067&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Ovarian cancer&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;An open-label phase II trial (&lt;ulink linkID="34587" linkType="Protocol"&gt;NCT00082212&lt;/ulink&gt;) was initiated in November 2004 to evaluate cetuximab in persistent or recurrent ovarian cancer or primary peritoneal carcinoma. The primary endpoint was primary response rate. The trial was expected to enroll 25 patients, but was terminated due to lack of efficacy [&lt;ulink linkID="1271110" linkType="Reference"&gt;1271110&lt;/ulink&gt;]. In June 2007, data were presented at the 43rd ASCO meeting in Chicago, IL. The trial was halted as there were not enough responders in the first 25 patients treated. One patient achieved a partial response and 9 had stable disease. Median PFS was 2.1 months [&lt;ulink linkID="798104" linkType="Reference"&gt;798104&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2003, an open-label phase II trial (&lt;ulink linkID="35168" linkType="Protocol"&gt;NCT00063401&lt;/ulink&gt;) began to evaluate cetuximab plus paclitaxel and carboplatin in patients with advanced ovarian, primary peritoneal or fallopian tube cancer. The primary endpoint was PFS, and the trial was expected to enroll 39 patients, and completed in June 2006 [&lt;ulink linkID="1271105" linkType="Reference"&gt;1271105&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Thymoma&lt;/subtitle&gt;In December 2009, an investigator-led, company-sponsored, open-label, single group assignment, phase II study (&lt;ulink linkID="62374" linkType="Protocol"&gt;NCT01025089&lt;/ulink&gt; ; 09-038) was initiated in the US, to assess the safety and efficacy of the drug  plus   chemotherapy (&lt;ulink linkID="51933" linkType="Drug"&gt;cisplatin&lt;/ulink&gt;, &lt;ulink linkID="28573" linkType="Drug"&gt;doxorubicin&lt;/ulink&gt;, &lt;ulink linkID="52332" linkType="Drug"&gt;cyclophosphamide&lt;/ulink&gt;) in patients (n = 28) with  locally advanced or recurrent  thymoma or thymic carcinoma. At that time, the study was expected to complete in December 2017 [&lt;ulink linkID="1636894" linkType="Reference"&gt;1636894&lt;/ulink&gt;].  In October 2017, clinical data were presented at the IASLC 18th World Conference on Lung Cancer in Yokohama, Japan. Mean percentage of treatment effect (pathological response; primary endpoint) was 20.88. Mean RECIST response to cetuximab alone was -0.54, and to C-CAP was -16.02. Objective response rate was 50%. Grade 4 AEs reported were febrile neutropenia and leukocytes (n = 1 each). Serious AEs (grade 3 to 4) occurred in nine patients [&lt;ulink linkID="1971964" linkType="Reference"&gt;1971964&lt;/ulink&gt;]. In April 2018, the trial was ongoing and expected to complete in December 2019 [&lt;ulink linkID="1636894" linkType="Reference"&gt;1636894&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Anal cancer&lt;/subtitle&gt;In June 2012, an open-label, investigator-led, company-sponsored phase I study (&lt;ulink linkID="88460" linkType="Protocol"&gt;NCT01621217&lt;/ulink&gt;; NOAC8.Version1) began in patients (expected n = 21) in Norway and Sweden with locally advanced anal cancer to assess the efficacy of cetuximab given in combination with 5-fluorouracil, &lt;ulink linkID="69850" linkType="Drug"&gt;mitomycin C&lt;/ulink&gt; and radiotherapy  [&lt;ulink linkID="1446832" linkType="Reference"&gt;1446832&lt;/ulink&gt;]. In December 2015, data were published. A total of 91% of patients reported a local CR 3 months following the completion of treatment. However, two of the patients developed liver metastases, yielding a total CR rate of 73% [&lt;ulink linkID="1721323" linkType="Reference"&gt;1721323&lt;/ulink&gt;]. In March 2018, the trial was ongoing  and expected to complete in January 2019 [&lt;ulink linkID="1446832" linkType="Reference"&gt;1446832&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Glioma&lt;/subtitle&gt;Phase II data from a 55-patient trial in recurrent high-grade glioma were presented at the 44th ASCO meeting in June 2008. Median time to progression was 1.9 months, and median OS was 5.1 months. The 6-month PFS and ORR were 7.3 and 8.4%, respectively. The disease control rate was 36.4%; three patients had a partial response and 17 had stable disease [&lt;ulink linkID="911055" linkType="Reference"&gt;911055&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Neuropathic pain&lt;/subtitle&gt;In June 2015, a randomized, cross-over, placebo-controlled, double-blind, single-center phase II trial (&lt;ulink linkID="234100" linkType="Protocol"&gt;NCT02490436&lt;/ulink&gt;; SFK3 / 062202_281, 2015-001195-21, 2015/618/REK sør-øst D) was planned to be initiated in Norway in patients (n = 14)  with neuropathic pain, in September 2015. The trial was expected to complete in December 2016 [&lt;ulink linkID="1676056" linkType="Reference"&gt;1676056&lt;/ulink&gt;]. In October 2015, the trial was initiated. In October 2016, the trial was completed [&lt;ulink linkID="1676056" linkType="Reference"&gt;1676056&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Renal cancer&lt;/subtitle&gt;In December 1997, a phase II open-label study was also initiated in 53 patients with metastatic renal cell carcinoma, in order to assess time to disease progression, tumor-response rate and survival [&lt;ulink linkID="271226" linkType="Reference"&gt;271226&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Solid tumors&lt;/subtitle&gt;In June 2010, a phase II, non-randomized study (&lt;ulink linkID="63940" linkType="Protocol"&gt;NCT01063075&lt;/ulink&gt;; 13420  I4E-MC-JXBB) was initiated to evaluate the pharmacokinetics of cetuximab and carboplatin, in the US and Canada, in patients (n = 34) with advanced solid tumors. The study was completed in May 2015  [&lt;ulink linkID="1737688" linkType="Reference"&gt;1737688&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2007, phase I data on cetuximab in combination with erlotinib were presented at the 19th AACR-NCI-EORTC International Conference in San Francisco, CA. From August 2005 to December 2006, 25 patients with advanced solid tumors were enrolled and treated with erlotinib daily (150 mg) and cetuximab (iv weekly without a loading dose), which was escalated in three sequential cohorts: 100 mg/m2, 200 mg/m2 and 250 mg/m2. 22 patients were treated: one patient each at dose levels 1 and 2 and 20 patients at dose level 3. The majority of patients had advanced NSCLC (n = 14). Two patients had colorectal cancer. Other cancers included adenocarcinoma of unknown origin, epithelial mesothelioma, carcinoid, bladder, esophageal and cervical cancer. At dose level 3 (250 mg/m2 cetuximab) patients received a median of 5.5 weeks of study therapy while the two subjects treated at two lower dose levels had a median duration of study therapy of 7 to 8 weeks. The main reason for dose omission for both drugs across all dose levels was skin rash. One DLT (skin toxicity) was observed at the highest dose level. Main toxicities (any grade/grade 3 to 4) observed across all dose cohorts were: rash (22/2), diarrhea (17/1), nausea (7/1), fatigue/asthenia (9/2) and hypomagnesemia (10/2). Best responses were disease stabilization (4 NSCLC, 1 CRC, 1 cervical cancer, 1 carcinoid) in 7 patients with a median duration of 16 weeks, and progressive disease in 11 patients. Four patients were not evaluable for tumor response. Dose level 3 (250mg/m2 cetuximab weekly IV plus 150mg PO daily of erlotinib) was identified as the recommended dose for phase II for the combination [&lt;ulink linkID="843078" linkType="Reference"&gt;843078&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2003, data on cetuximab in combination with irinotecan were presented at the 94th AACR meeting, Washington DC. The impact of cetuximab on PK parameters of irinotecan, and that of irinotecan on PK values of cetuximab in 15 patients (14 with gastrointestinal cancer, 1 with prostate cancer) were investigated. Cetuximab did not impact on the single-dose PK of irinotecan, and irinotecan did not impact on the PK of cetuximab [&lt;ulink linkID="496933" linkType="Reference"&gt;496933&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2003, data were presented at the 39th ASCO meeting in Chicago, IL. Thirty patients with advanced solid tumors of epithelial origin were randomized to a single iv infusion of cetuximab (50 to 500 mg/m2). Over the dose range tested, AUC (0 to t) and AUC (0 to infinity) increased in a dose-related manner following infusions of cetuximab up to 400 mg/m2 and then plateaued at the 500 mg/m2 dose. The mean Cmax increased in a dose proportional manner up to the 400 mg/m2 dose and then remained at the same level for the 500 mg/m2 dose. The elimination half life of 3 to 4 days supported a once weekly dosing schedule at 250 mg/m2. Skin biopsies revealed a decrease in EGFR protein levels across the 250 to 500 mg/m2 dose range, with a maximal effect occurring at 400 mg/m2 and a decrease in EGFR levels across the 50 and 100 mg/m2 doses. From 38 evaluable patients there were 3 partial responses and 13 cases of stable disease [&lt;ulink linkID="492040" linkType="Reference"&gt;492040&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Neuropathic pain&lt;/subtitle&gt;By September 2012, data had demonstrated that EGFR inhibitors showed dramatic clinical efficacy in patients with persistent severe, therapy resistant neuropathic pain, including cancer pain, phantom limb pain, failed back surgery, and complex regional pain syndrome [&lt;ulink linkID="1327009" linkType="Reference"&gt;1327009&lt;/ulink&gt;]. In January 2012, similar data were published. In the study, four of the five patients responded  within 24 h of iv administration, with a mean decrease in worst pain from 9 to 1 on a 10-point scale. All the four EGFR inhibitors (cetuximab, &lt;ulink linkID="12646" linkType="Drug"&gt;panitumumab&lt;/ulink&gt;, &lt;ulink linkID="11603" linkType="Drug"&gt;gefitinib&lt;/ulink&gt;, &lt;ulink linkID="11961" linkType="Drug"&gt;erlotinib&lt;/ulink&gt;) were found to be  effective [&lt;ulink linkID="1684233" linkType="Reference"&gt;1684233&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;&lt;subtitle&gt;Colorectal cancer&lt;/subtitle&gt;In April 2015, preclinical data were presented at the 106th AACR meeting in Philadelphia, PA. In various patient-derived xenograft (PDX) CRC mouse models with B-raf muation, cetuximab + &lt;ulink linkID="58618" linkType="Drug"&gt;LSN-3074753&lt;/ulink&gt; combination synergistically showed a disease control rate (DCR) of 50%, while cetuximab or LSN-3074753 alone has a DCR of 8.3 and 17%, respectively. In PDX CRC models with KRas mutation, DCR was greater in cetuximab + LSN-3074753 combination group (42%), when compared with cetuximab (16.3%) and LSN-3074753 (21%) drugs alone [&lt;ulink linkID="1648659" linkType="Reference"&gt;1648659&lt;/ulink&gt;], [&lt;ulink linkID="1653340" linkType="Reference"&gt;1653340&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2011, preclinical data were presented at the 102nd AACR meeting in Orlando, FL. Preclinical studies were performed to screen for add-on therapies to increase the efficacy of the cetuximab and &lt;ulink linkID="2871" linkType="Drug"&gt;irinotecan&lt;/ulink&gt; combination for mCRC s with KRAS or BRAF gene mutations. Of the 14 compounds tested, only 17-AAG at 80 mg/kg, everolimus at 25 mg/kg and DC-101at 40 mg/kg significantly split the tumor stasis ceiling established with cetuximab plus irinotecan therapy in HT-29 and HCT-116 cell lines [&lt;ulink linkID="1176763" linkType="Reference"&gt;1176763&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2007, preclinical data were presented at the 43rd ASCO meeting in Chicago, IL. In vitro using cells lines expressing various levels of human epidermal growth factor receptor (EGFR), cetuximab was found to elicit antibody-dependent cellular cytotoxicity against EGFR-expressing tumors. Cetuximab was also shown to bind to human FcRIIIa [&lt;ulink linkID="797183" linkType="Reference"&gt;797183&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2004,  data were presented at the Strategies for Monoclonal Antibody Therapy meeting in London, UK. Cetuximab bound to EGFr with an affinity of 0.2 nM  [&lt;ulink linkID="550695" linkType="Reference"&gt;550695&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2004, preclinical data were presented at the 95th AACR meeting in Orlando, FL. The inhibition of EGFr with cetuximab in relation to AKT inhibition in A431 squamous cell carcinoma cells was examined. Time course studies of this process revealed that receptor inhibition resulted in decreased AKT activation for exposure to cetuximab (5 mg/ml) for less than 12 h. This effect was not found for 24 h exposures to cetuximab. Furthermore, greater inhibition of AKT activation occurred as time of exposure to cetuximab was reduced from 12 h to 1.5 h [&lt;ulink linkID="531517" linkType="Reference"&gt;531517&lt;/ulink&gt;]. Another study presented at the same meeting described the conjugation of boron-containing dendrimers to cetuximab [&lt;ulink linkID="532508" linkType="Reference"&gt;532508&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2003,  data were presented at the 15th AACR-NCI-EORTC meeting in Boston, MA. Studies in colorectal tumor models using a variety of cell lines indicated  cetuximab can interact effectively with multiple chemotherapeutic agents, including 5-FU, SN-38, &lt;ulink linkID="4577" linkType="Drug"&gt;topotecan&lt;/ulink&gt; and &lt;ulink linkID="51570" linkType="Drug"&gt;vinblastine&lt;/ulink&gt; to produce broad antitumor responses. Further studies on cetuximab plus cisplatin showed the combination to be therapeutically synergistic in a cisplatin-refractory human colon carcinoma xenograft. Data also demonstrated  cetuximab monotherapy was at least as effective as &lt;ulink linkID="11603" linkType="Drug"&gt;gefitinib&lt;/ulink&gt; monotherapy in a model of colon carcinoma [&lt;ulink linkID="513769" linkType="Reference"&gt;513769&lt;/ulink&gt;], [&lt;ulink linkID="513774" linkType="Reference"&gt;513774&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2003,  data were presented at the 94th AACR Meeting, Washington, DC. NCI-N87 human gastric carcinoma cells were stimulated with EGF in the presence or absence of cetuximab and immunoprecipitated with EGFR or HER2 specific antibodies. Treatment of NCI-N87 cells with cetuximab completely inhibited phosphorylation of EGFR-EGFR homodimers and EGFR-HER2 heterodimers. In vivo, athymic mice bearing established NCI-N87 xenografts were treated with cetuximab (1mg ip every 3 days). The growth of NCI-N87 tumors was significantly inhibited with cetuximab therapy, compared with control groups. Immunohistological analysis of cetuximab-treated tumors showed a decrease in EGFR-HER2 signaling and reduced tumor cell proliferation [&lt;ulink linkID="496906" linkType="Reference"&gt;496906&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2002, preclinical data were presented at the 27th European Society for Medical Oncology in Nice, France, which showed  cetuximab was able to restore irinotecan-induced cytotoxicity in previously irinotecan-resistant refractory colon carcinoma cells [&lt;ulink linkID="471955" linkType="Reference"&gt;471955&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2002,  data  were presented at the 93rd AACR meeting in San Francisco, CA. The activity of cetuximab as a single-agent therapy and in combination with a three-drug chemotherapy regimen of irinotecan, 5-FU and leucovorin, was assessed in two colorectal carcinoma xenograft models. Treatment with cetuximab plus the three-drug chemotherapy regimen significantly inhibited the growth of the xenografts, when compared with controls. The combination regimen demonstrated enhanced antitumor activity, when compared with either the three-drug chemotherapy regimen or cetuximab alone. Additionally, tumors treated with cetuximab plus the three-drug chemotherapy regimen showed extensive tumor necrosis, decreased tumor cell proliferation and increased tumor cell apoptosis [&lt;ulink linkID="446472" linkType="Reference"&gt;446472&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2000, ImClone presented preclinical data at the 91st AACR meeting demonstrating  cetuximab may interfere with DNA-damage repair [&lt;ulink linkID="379143" linkType="Reference"&gt;379143&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Cetuximab has been used in combination with antisense therapy and has demonstrated greater cytotoxicity in cell culture assays, especially with low doses of antisense compound, cytotoxic drug and antibody [&lt;ulink linkID="302859" linkType="Reference"&gt;302859&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Animal studies demonstrated  cetuximab enhances the effect of cancer chemotherapy. In April 1997, results of a preclinical study were presented at the 88th AACR meeting in San Diego, CA. Treatment of human bladder carcinoma cells, growing orthotopically in mice, with cetuximab resulted in a significant inhibition of tumor growth, compared with controls [&lt;ulink linkID="242505" linkType="Reference"&gt;242505&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Head and neck cancer&lt;/subtitle&gt;In April 2013, preclinical data were  presented at the   104th AACR Meeting in Washington DC. Cetuximab downregulated lactate dehydrogenase A and inhibited glycolysis in cetuximab-sensitive cells in a HIF-1 alpha downregulation-dependent manner. Response of cetuximab-resistant cells to cetuximab was markedly increased with the addition of a small molecule lactate dehydrogenase A inhibitor. Cetuximab showed no noticeable inhibitory effect on glycolysis in nontransformed cells [&lt;ulink linkID="1402433" linkType="Reference"&gt;1402433&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2008, preclinical data were presented at the 99th AACR meeting in San Diego, CA, showing that a combination of &lt;ulink linkID="12973" linkType="Drug"&gt;sunitinib&lt;/ulink&gt;, cetuximab and radiation therapy led to supra-additive effects on tumor regression in an orthotopic CAL33 head and neck cancer xenograft model [&lt;ulink linkID="894593" linkType="Reference"&gt;894593&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2000, preclinical results were presented at the 91st AACR meeting in San Francisco, CA, which demonstrated cetuximab's mechanism in association with radiation, as well as highly selective antitumor activity in mouse models of SCCHN and breast cancer [&lt;ulink linkID="361568" linkType="Reference"&gt;361568&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Non-small-cell lung cancer&lt;/subtitle&gt;In November 2003, preclinical data were presented at the 15th AACR-NCI-EORTC meeting in Boston, MA, which showed cetuximab monotherapy to be at least as effective as &lt;ulink linkID="11603" linkType="Drug"&gt;gefitinib&lt;/ulink&gt; monotherapy in a model of lung carcinoma [&lt;ulink linkID="513769" linkType="Reference"&gt;513769&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2000, a presentation at the 11th NCI-EORTC-AACR meeting in Amsterdam, the Netherlands, examined the effects of EGFR blockade by cetuximab on the in vitro and in vivo growth of human NSCLC xenografts. Cetuximab treatment dose-dependently suppressed growth of established tumors, compared with control animals in EGFR-positive tumors of squamous, neuroendocrine and adenocarcinoma origin. The drug achieved this effect through the inhibition of VEGF, FGF and IL-8. Combination therapy of taxane or platin-based drugs with cetuximab in NSCLC showed an enhanced antitumor effect [&lt;ulink linkID="391217" linkType="Reference"&gt;391217&lt;/ulink&gt;]. Cetuximab has a Kd value of 0.1 nM  for the EGF receptor  [&lt;ulink linkID="391739" linkType="Reference"&gt;391739&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;br&gt;&lt;/br&gt;&lt;subtitle&gt;Pancreatic cancer&lt;/subtitle&gt;In April 1999, results from a murine model of human pancreatic tumor showed  that cetuximab with &lt;ulink linkID="3199" linkType="Drug"&gt;gemcitabine&lt;/ulink&gt; caused a 90% reduction in pancreatic tumors, compared with a 27% response rate using gemcitabine alone. Also, cetuximab alone caused significant tumor regression and destruction of liver metastases, compared with gemcitabine [&lt;ulink linkID="321259" linkType="Reference"&gt;321259&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Prostate cancer&lt;/subtitle&gt;In March 2001, in vitro and in vivo results were presented at the 92nd AACR meeting in New Orleans, LA. In vitro cetuximab did not significantly inhibit proliferation of PV-3M-LN4 cells. In vivo, cetuximab significantly inhibited the tumorigenicity and metastasis of PC-3M-C225 xenografts [&lt;ulink linkID="405184" linkType="Reference"&gt;405184&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In January 2016, Merck entered into a collaboration with &lt;ulink linkID="1038368" linkType="Company"&gt;Biocartis&lt;/ulink&gt; for the development and marketing in countries outside the US, China and Japan of  new liquid biopsy RAS biomarker test for mCRC patients using Biocartis' Idylla automated molecular diagnostic system to detect an extended panel of RAS mutations [&lt;ulink linkID="1908821" linkType="Reference"&gt;1908821&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2014, Merck entered into a collaboration agreement with Sysmex Inostics (a subsidiary of &lt;ulink linkID="DOL1000670" linkType="Company"&gt;Sysmex&lt;/ulink&gt;) to develop and commercialize a blood-based RAS biomarker test for the diagnosis of patients with mCRC [&lt;ulink linkID="1564444" linkType="Reference"&gt;1564444&lt;/ulink&gt;]; in April 2016, the new liquid biopsy RAS biomarker test was granted CE Mark approval and it was to be made accessible for mCRC patients in Europe, Asia, Latin America and Australia. The OncoBEAM RAS CRC assay was described as a comprehensive 34-mutation panel based on the BEAMing technology [&lt;ulink linkID="1908821" linkType="Reference"&gt;1908821&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2013, Merck entered into an agreement with &lt;ulink linkID="1062214" linkType="Company"&gt;Inven2&lt;/ulink&gt; under which Merck was granted exclusive license to INven2's EGFR inhibitors patent portfolio [&lt;ulink linkID="1541914" linkType="Reference"&gt;1541914&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2012, a KRAS genetic test, the therascreen KRAS RGQ PCR Kit  developed by QIAGEN, was approved by the FDA [&lt;ulink linkID="1306857" linkType="Reference"&gt;1306857&lt;/ulink&gt;], [&lt;ulink linkID="1306866" linkType="Reference"&gt;1306866&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2004, &lt;ulink linkID="19220" linkType="Company"&gt;Repligen&lt;/ulink&gt; and the &lt;ulink linkID="18225" linkType="Company"&gt;Massachusetts Institute of Technology&lt;/ulink&gt; (MIT) initiated patent infringement proceedings against ImClone for infringement of  &lt;ulink linkID="IN1048455" linkType="Patent"&gt;US-04663281&lt;/ulink&gt;. The patent, which is assigned to MIT and exclusively licensed to Repligen, covers use of certain genetic elements that increase protein production in a mammalian cell. Repligen and MIT alleged that the cell line used by ImClone to produce cetuximab employed  technology claimed in the patent-in-suit. In July 2006, a summary judgment ruled in favor of Repligen and MIT and rejected ImClone's defense of patent exhaustion; the court found that neither the transfer of the cell line to the NCI by Repligen's predecessor nor the subsequent transfer to ImClone by the NCI exhausted the proprietary rights of Repligen and MIT, thereby eliminating these arguments from being a potential defense for ImClone. In June 2007, the Court ruled that ImClone's lawyers had attempted to influence a key witness in the case and had prejudiced Repligen and MIT from fully prosecuting their case. Subsequently, the court barred one member of ImClone's counsel  [&lt;ulink linkID="803885" linkType="Reference"&gt;803885&lt;/ulink&gt;]. In September 2007, a settlement was reached whereby ImClone made a payment of $65 million to Repligen and MIT, with Repligen granting ImClone a nonexclusive sublicense to certain patent rights [&lt;ulink linkID="829011" linkType="Reference"&gt;829011&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2000, &lt;ulink linkID="25560" linkType="Company"&gt;Lonza Biologics&lt;/ulink&gt; agreed to be a second source manufacturer of cetuximab [&lt;ulink linkID="381527" linkType="Reference"&gt;381527&lt;/ulink&gt;].  In February 2004,  Lonza's' manufacturing facility for the production of cetuximab was  granted FDA approval [&lt;ulink linkID="523128" linkType="Reference"&gt;523128&lt;/ulink&gt;]. In April 2004, the FDA accepted ImClone's chemistry, manufacturing and controls sBLA for the licensure of the BB36 manufacturing facility [&lt;ulink linkID="533352" linkType="Reference"&gt;533352&lt;/ulink&gt;]. In June 2004, the FDA approved the manufacturing plant [&lt;ulink linkID="545306" linkType="Reference"&gt;545306&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;&lt;subtitle&gt;There are two evaluations of this drug.&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;Merrill S Kies, University of Texas &lt;ulink linkType="Company" linkID="23382"&gt;MD Anderson Cancer Center&lt;/ulink&gt;, 1515 Holcombe Blvd, Houston, USA; and, Paul M Harari, Department of Human Oncology, Clinical Science Center, &lt;ulink linkType="Company" linkID="DOL1000742"&gt;University of Wisconsin&lt;/ulink&gt; Medical School, 600 Highland Avenue, Madison, USA.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Submission date: 8 May 2002&lt;/subtitle&gt;&lt;subtitle&gt;Publication date: 10 July 2002&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;Squamous cell carcinoma of the head and neck (SCCHN) is a major international health problem, which affected more than 500,000 people in 2001. In the US, SCCHN is the sixth leading cause of cancer-related death, and in 2001, accounted for 45,000 cases and 13,000 deaths [&lt;ulink linkType="reference" linkID="455294"&gt;455294&lt;/ulink&gt;]. Chronic tobacco and/or alcohol abuse are responsible for 80 to 90% of cases. For patients with advanced disease at diagnosis, current clinical trials focus on improving the integration of chemotherapy and radiation with objectives of organ preservation and increasing locoregional tumor control.&lt;/para&gt;&lt;para&gt;Recent randomized trials with platinum-based concomitant chemoradiation have resulted in improved locoregional tumor control and overall survival for combined therapy compared with radiotherapy alone [&lt;ulink linkType="reference" linkID="454729"&gt;454729&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="454736"&gt;454736&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="454754"&gt;454754&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="455307"&gt;455307&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;At many major medical centers, surgical resection as a component of primary management is commonly limited to oral cavity and advanced laryngeal primary cancers. Despite improvements in the treatment of patients with stage III/IV disease, however, the risk of locoregional or distant disease recurrence remains substantial, affecting 30 to 50% and 10 to 30% of patients, respectively [&lt;ulink linkType="reference" linkID="454770"&gt;454770&lt;/ulink&gt;]. Moreover, both acute (especially mucocutaneous effects) and long term (cervical fibrosis and swallowing dysfunction) toxicity remain prevalent with intensified chemoradiation regimens. Thus, there is a pressing need for the development of new treatment strategies with enhanced treatment efficacy and reduced normal-tissue toxicity. Active investigations are underway for the identification and development of compounds with novel and more directed or 'targeted' mechanisms of action. This evaluation will consider promising preliminary work with &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt;, a chimeric monoclonal antibody directed against the epidermal growth factor receptor (EGFR).&lt;/para&gt;&lt;para&gt;The EGFR, also known as HER1 or ErbB1, represents a promising molecular target for cancer therapy. EGFR is expressed in high concentration by many human cancers, including brain, breast, ovarian, lung, pancreas and genitourinary cancers [&lt;ulink linkType="reference" linkID="455063"&gt;455063&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="455633"&gt;455633&lt;/ulink&gt;]. In SCCHN, EGFR expression is reported in over 90% of specimens [&lt;ulink linkType="reference" linkID="455015"&gt;455015&lt;/ulink&gt;] and has been associated with advanced stage and poor prognosis [&lt;ulink linkType="reference" linkID="455015"&gt;455015&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="455032"&gt;455032&lt;/ulink&gt;]. EGFR mRNA and protein expression are also increased in dysplastic lesions and histologically normal mucosa from SCCHN patients [&lt;ulink linkType="reference" linkID="455035"&gt;455035&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="455043"&gt;455043&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="455044"&gt;455044&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;These findings implicate EGFR upregulation as a critical event in the development of cancer. Therefore, therapeutic strategies to block or downregulate EGFR have been developed with the intent of inhibiting tumor cell proliferation and inducing disease regression [&lt;ulink linkType="reference" linkID="455045"&gt;455045&lt;/ulink&gt;]. EGFR targeting strategies include antisense gene therapy, EGFR-specific tyrosine kinase inhibitors, and anti-EGFR antibodies, such as &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt;. After ligand binding, a sequence of biochemical processes and signal transduction pathways are activated. Specific ligands (EGF, transforming growth factor-a, &lt;ulink linkType="Drug" linkID="5932"&gt;amphiregulin&lt;/ulink&gt;, epiregulin, heparin-binding factor or betacellulin) associate with the extracellular domain prompting EGFR dimerization, high-affinity binding, activation of the intrinsic intracellular domain and autophosphorylation on tyrosine residues. This initiates a cascade of intracellular signaling events [&lt;ulink linkType="reference" linkID="454904"&gt;454904&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="454905"&gt;454905&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Activated EGFR, with either homo- or heterodimer formation, initiates multiple signals [&lt;ulink linkType="reference" linkID="455008"&gt;455008&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="455010"&gt;455010&lt;/ulink&gt;]. Ras/mitogen-activated protein kinase (Ras/MAPK) serves as a primary signaling conduit. Activated EGFR promotes the formation of the Grb2-SOS-Shc complex that affects Ras [&lt;ulink linkType="reference" linkID="455012"&gt;455012&lt;/ulink&gt;] with further activation of MAPK, phosphorylation of MAPK kinase (MEK) and, ultimately, activation of transcription factors leading to stimulation of cellular proliferation. Other pathways activated by EGFR include phospholipase C-g, phosphatidylinositol-3 kinase, protein kinase B/Akt, Src, the stress-activated MAPK, c-Jun N terminal kinase and signal transducers and activators of transcription [&lt;ulink linkType="reference" linkID="454905"&gt;454905&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="455345"&gt;455345&lt;/ulink&gt;]. This is a highly dynamic and complex network with interplay of factors dependent upon binding ligand and membrane concentrations, and the affinity of the potential co-receptors, HER2, HER3 and HER4. The specificity and potency of the cytoplasmic signal relates to the extent and nature of EGFR dimerization. Thus, EGFR binding, activation and dimerization may result in cellular proliferation or differentiation, or have effects on angiogenesis, migration, adhesion, diminution of apoptosis and transformation.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;After the demonstration that murine monoclonal antibodies inhibited EGFR activation and receptor tyrosine kinase with subsequent antiproliferative effects on human tumor cell lines [&lt;ulink linkType="reference" linkID="455065"&gt;455065&lt;/ulink&gt;], a human murine chimera of mAb 225 was produced and called IMC-C225 (C225; &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt;).&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;This chimerized antibody targets the EGFR, and has a 10-fold greater affinity for EGFR than the natural ligand. It is associated with receptor dimerization but prevents receptor phosphorylation [&lt;ulink linkType="reference" linkID="455056"&gt;455056&lt;/ulink&gt;]. In light of the potential integral role of EGFR in signaling pathways related to cell-cycle progression and tumor cell proliferation, it was hypothesized that anti-EGFR treatment may potentiate traditional cytotoxic therapies (chemotherapy and/or radiation) with additive or synergistic antitumor effects [&lt;ulink linkType="reference" linkID="455063"&gt;455063&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="455495"&gt;455495&lt;/ulink&gt;]. In targeting the extracellular EGFR domain, anti-EGFR monoclonal antibodies affect EGFR pathways in a highly specific manner. Ligand binding is blocked and activation of the receptor is inhibited.&lt;/para&gt;&lt;para&gt; &lt;ulink linkType="Drug" linkID="10388"&gt;Cetuximab&lt;/ulink&gt; has been studied in a variety of tumor types and animal models [&lt;ulink linkType="reference" linkID="455063"&gt;455063&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="455495"&gt;455495&lt;/ulink&gt;]. It competes with the natural ligand for the receptor, leading to internalization of the antibody-receptor complex. This complex does not participate in signal transduction, and the Fc region of the antibody may initiate complement-mediated cytotoxicity or antibody-dependant cell-mediated cytotoxicity. &lt;ulink linkType="Drug" linkID="10388"&gt;Cetuximab&lt;/ulink&gt; inhibits cell-cycle progression, enhances apoptosis, inhibits angiogenesis and diminishes recovery after cytotoxic therapy. Huang and Harari [&lt;ulink linkType="reference" linkID="455099"&gt;455099&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="455142"&gt;455142&lt;/ulink&gt;] have demonstrated that molecular blockade of EGFR enhances in vitro radiosensitivity of SCCHN. They further demonstrated the capacity of &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; to modulate the in vitro and in vivo radiation response of human squamous cell carcinoma (SCC) tumor cells and xenografts. &lt;ulink linkType="Drug" linkID="10388"&gt;Cetuximab&lt;/ulink&gt; has a strong inhibitory effect on post-radiation damage repair in cultured tumor cells. Tumor xenograft studies demonstrated complete regression in athymic mice treated with a combination of &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; and radiation. The authors concluded that in addition to antiproliferative growth inhibition, EGFR blockade with &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; appears to influence the capacity of human SCCs to effect DNA repair after exposure to radiation.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism&lt;/subtitle&gt;Baselga and colleagues [&lt;ulink linkType="reference" linkID="455146"&gt;455146&lt;/ulink&gt;] have evaluated the pharmacokinetics and toxicity of &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; in patients with advanced tumors overexpressing EGFR. In three successive phase I trials, 52 patients were treated using a conventional dose-escalation format. In one of these protocols, &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; was combined with cisplatin and the patient population was limited to those with head/neck or non-small-cell lung cancer (NSCLC) with dose-escalation to 400 mg/m2 administered weekly. Cisplatin was administered at 60 mg/m2 every 28 days. &lt;ulink linkType="Drug" linkID="10388"&gt;Cetuximab&lt;/ulink&gt; displayed non-linear pharmacokinetics, and with antibody doses in the range of 200 to 400 mg/m2, complete saturation of systemic clearance occurred. The sera of 19 patients were analyzed for the presence of human antichimeric IgG antibodies, and anti-&lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; antibodies were detected in only one patient. Of 13 patients receiving &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; and cisplatin, nine patients completed 12 weeks of therapy and two partial tumor responses were observed.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity &lt;/subtitle&gt;No data are currently available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;Several phase I clinical studies have been reported, offering promising early results after combining &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; with radiotherapy and cisplatin in patients with SCCHN. Of the 13 patients receiving &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; and cisplatin in phase I trials, nine patients completed 12 weeks of therapy and two partial tumor responses were observed.&lt;/para&gt;&lt;para&gt;Robert et al [&lt;ulink linkType="reference" linkID="422335"&gt;422335&lt;/ulink&gt;] evaluated the pharmacokinetics, toxicity profile and efficacy of &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; with radiation therapy in therapy-naive patients with locally advanced SCCHN. This group treated 16 patients (one following surgery) in a standard dose-escalation trial with most patients receiving conventional once-daily radiotherapy. The last three patients in this study were treated with a hyperfractionated schedule. &lt;ulink linkType="Drug" linkID="10388"&gt;Cetuximab&lt;/ulink&gt; was delivered as a loading dose in the range of 100 to 500 mg/m2 followed by weekly infusions of 100 to 250 mg/m2 for 7 to 8 weeks during the radiation treatment course. Circulating levels of &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; and antichimeric antibody response were determined. Of the 15 previously untreated patients, 13 achieved complete disease remission with two partial responders. At the time of publication, six locoregional recurrences had been observed, with 65% of patients attaining two-year disease-free survival. The recommended dose for phase II/III studies is a loading dose of 400 to 500 mg/m2 and a maintenance weekly dose of 250 mg/m2.&lt;/para&gt;&lt;para&gt;Shin and coworkers [&lt;ulink linkType="reference" linkID="424746"&gt;424746&lt;/ulink&gt;], from the &lt;ulink linkType="Company" linkID="23382"&gt;MD Anderson Cancer Center&lt;/ulink&gt;, have reported intriguing results of a phase Ib trial in patients with recurrent SCCHN. &lt;ulink linkType="Drug" linkID="10388"&gt;Cetuximab&lt;/ulink&gt; was given in combination with cisplatin. Using tumor samples, the authors assessed EGFR saturation with immunohistochemistry, the EGFR tyrosine kinase assay, and detection of EGFR/&lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; complex formation by immunoblot assay. Twelve patients were entered and all expressed high levels of EGFR concentration. Three different dose levels of &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; with a fixed dose of cisplatin were studied. The loading dose of &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; at 400 mg/m2 with a weekly maintenance dose of 250 mg/m2 achieved a high percentage of EGFR saturation in tumor tissue and these doses were recommended for phase III trials. Six of the nine evaluable patients achieved major responses, including two considered to be clinically complete. Three of these responding patients received previous therapy with cisplatin, and in four patients, the indicator lesions were located within previous radiotherapy treatment volumes.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;The MD Anderson experience led to a multi-institutional trial [&lt;ulink linkType="reference" linkID="436928"&gt;436928&lt;/ulink&gt;]. After demonstration of recurrent or metastatic SCCHN, patients were treated with either cisplatin and paclitaxel, or cisplatin and infusional 5-fluorouracil. After two treatment cycles, responding patients continued the initial treatment regimen at the discretion of managing physicians. Patients with either stable disease or progressive disease then proceeded to therapy with &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; and cisplatin. &lt;ulink linkType="Drug" linkID="10388"&gt;Cetuximab&lt;/ulink&gt; was administered at a loading dose of 400 mg/m2,followed by a weekly administration at 250 mg/m2. Cisplatin therapy would conclude after four cycles and &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; could be continued until disease progression.&lt;/para&gt;&lt;para&gt;With 125 patients entered into the trial, the median age was 59 years with a range of 29 to 89 years. Males predominated, 99 versus 26 females. The median Karnofsky performance status was 80. The initial disease site was relatively evenly spread among oral cavity, oro/hypopharynx and larynx. Ten of 41 patients (24%) in the stable-disease cohort achieved an objective response to the experimental cisplatin and &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; therapy. Disease stabilization was maintained in 25 patients (61%). Five of 22 patients (23%), in the progressive-disease cohort, achieved a partial response to therapy and six (27%) patients achieved disease stabilization. This study was modified in the Spring of 2001 to enter patients with documented disease progression after cisplatin-based chemotherapy to the progressive-disease group and was presented at this year's American Society of Clinical Oncology meeting [&lt;ulink linkType="reference" linkID="455485"&gt;455485&lt;/ulink&gt;]. Of an overall total of 78 patients with disease considered refractory to cisplatin, 12% responded to the &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt;-cisplatin regimen. Early impressions are that &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; administered in combination with cisplatin appears to be generally well tolerated. Moreover, molecular inhibition of EGFR signaling with &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; appears to convert a percentage of cisplatin non-responders to responders, which provides a potentially valuable new therapy option for this challenging patient cohort.&lt;/para&gt;&lt;para&gt;A number of additional trials examining &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; in head and neck cancer patients are ongoing or have just recently completed accrual. The &lt;ulink linkType="Company" linkID="22122"&gt;Memorial Sloan-Kettering Cancer Center&lt;/ulink&gt; group has conducted a phase II study with concomitant cisplatin/&lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; and intensified radiotherapy in 20 patients with locally advanced, nonresectable SCCHNs. A report of this experience is eagerly awaited.&lt;/para&gt;&lt;para&gt;Baselga and colleagues [&lt;ulink linkType="reference" linkID="455491"&gt;455491&lt;/ulink&gt;], in a parallel study with the &lt;ulink linkType="Company" linkID="23382"&gt;MD Anderson Cancer Center&lt;/ulink&gt; group described above [&lt;ulink linkType="reference" linkID="436928"&gt;436928&lt;/ulink&gt;], conducted a phase II study with cisplatin and &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; in patients with recurrent and refractory SCCs. Patients eligible for this trial had recurrent disease which was progressive after cisplatin-based chemotherapy. Ninety-six patients with a mean age of 57.4 years were entered into the trial. The overall response rate was 14.6%. Median survival time was 269 days in responders and 178 days for the entire group.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;Accrual has recently been completed for two phase III studies. Burtness and colleagues from the &lt;ulink linkType="Company" linkID="24771"&gt;Eastern Cooperative Oncology Group&lt;/ulink&gt; (ECOG) [&lt;ulink linkType="reference" linkID="451801"&gt;451801&lt;/ulink&gt;] have completed a randomized, double-blind, placebo-controlled trial for patients with recurrent head and neck cancer. No prior therapy for metastatic disease was allowed. Patients were randomized to receive cisplatin at a dose of 100 mg/m2 every 28 days and placebo, or the same schedule with weekly &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt;. A test dose of &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; was given on day 1, and if no hypersensitivity was demonstrated, 400 mg/m2 were infused over 2 h prior to cisplatin. In subsequent weeks, &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; (250 mg/m2) was administered. A total of 121 patients were entered. The primary endpoint of this study was time-to-tumor-progression and no clear difference was evident: 4.1 months median versus 3.4 months for the experimental and control arms, respectively. Both response rate (23 versus 9%) and overall survival (9.2 versus 8.0 months median, p = 0.18), however, favored &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt;-cisplatin treatment.&lt;/para&gt;&lt;para&gt;A multinational trial has recently completed enrolment of 416 patients treated definitively with radiotherapy for advanced SCCHN [Harari, personal communication]. Patients received either high-dose radiation alone (the majority with modern hyperfractionation or concomitant boost radiation schedules) or radiation plus weekly infusions of &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; during a 7-week course of radiotherapy. This trial will provide an unencumbered assessment of the capacity of EGFR inhibition to modulate radiation response, in a large cohort of advanced cancer patients treated with curative intent. Locoregional tumor control and overall survival will be analyzed in this randomized trial. Correlative studies will also be forthcoming from tumor materials gathered, as tissue specimens have been collected from all patients for quantitative EGFR analysis. Although EGFR status was not a prospective trial entry criterion, data will be available to uncover potential correlations with tumor response, locoregional control, and ultimate survival outcome.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side Effects and Contraindications&lt;/subtitle&gt;In a phase I dose-escalation trial in 52 patients with head/neck or NSCLC, &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; (up to 400 mg/m2 administered weekly) was combined with cisplatin. This dose range was well tolerated with most frequent adverse effects consisting of asthenia, transaminase elevation, nausea and skin rash. Toxic effects were most often of mild or moderate grade. There were four instances of severe (or higher) grade toxicity with solitary occurrences of aseptic meningitis, diarrhea and epiglottitis. A serious allergic reaction was seen in one patient [&lt;ulink linkType="reference" linkID="455146"&gt;455146&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a phase I trial of &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; in combination with radiation, toxicity was characteristic of high-dose radiation studies for head and neck cancer. In-field, moderate-to-severe grade mucocutaneous effects were observed in all patients. Grade I or II acneiform rash was also evident in 13 patients. One patient had a life-threatening allergic reaction and no antibodies against &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; were detected [&lt;ulink linkType="reference" linkID="422335"&gt;422335&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a phase II trial of &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; in combination with cisplatin, toxicity was considered manageable, with grade I/II skin rash being frequent but severe in &amp;lt; 5% of patients. Serious allergic reactions were observed in four (5%) patients treated with &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="453851"&gt;453851&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a phase II study in patients with recurrent and refractory SCCs treated with cisplatin and &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; therapy, drug-related toxicity consisted of grade I/II rash (45%), acne (25%), asthenia (16%), fever (13%) and vomiting (10%) [&lt;ulink linkType="reference" linkID="455491"&gt;455491&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a phase III trial in 64 patients with recurrent head and neck cancer, a preliminary report of toxicity for 64 patients revealed that grade III/IV hypersensitivity was observed in four (6%), neutropenia in 11 (17%), and rash in seven (11%) patients [&lt;ulink linkType="reference" linkID="451801"&gt;451801&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;Early impressions are that &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; represents a highly promising new anticancer agent, one of a class of chimeric monoclonal antibodies (like herceptin and rituxan) that show great promise in cancer therapy. Preclinical and phase I/II clinical data suggest that inhibition of EGFR signaling can increase tumor cell vulnerability to conventional cytotoxic chemotherapy and radiation therapy. The randomized ECOG study was possibly flawed by a small patient number and selection of cisplatin alone as the chemotherapy component of the study. Use of cisplatin and paclitaxel could have been considered. Nonetheless, these trials set the stage for more definitive clinical investigations. To more precisely determine independent activity and associated toxicity, &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; single-agent trials may be of value in the setting of recurrent disease. Many questions remain regarding EGFR biology and the specific mechanisms by which compounds, such as &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt;, may exert their anticancer activity. Should we use EGFR expression to guide selection of patients for therapy? Does conventional treatment affect receptor activation? Should monoclonal antibodies, which compete with extracellular ligand for receptor binding, be used in concert with small-molecule receptor tyrosine kinase inhibitors? Will the recently completed phase III radiotherapy trial provide pivotal outcome data? Certainly the integration of targeted molecular treatment approaches in combined therapy strategies for the treatment of SCCHN is at hand. These new approaches provide real opportunities to enhance outcomes for advanced head and neck cancer patients.&lt;/para&gt;&lt;para&gt;Dr Matt Lohmeyer is a senior scientist specializing in anticancer drug development, and is based in the UK&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Submission date: 15 September 1997&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;The C225 antibody was designed to inactivate the human epidermal growth factor receptor (EGFR) by blocking the interaction between the natural ligand and its receptor. The EGFR is overexpressed in about one third of all human cancers and has been directly implicated in tumor growth and progression.&lt;/para&gt;&lt;para&gt;C225 is a chimeric antibody and was derived from the 225 mouse monoclonal antibody, by combining the variable region of 225 with the constant region of human IgG1. This was in order to reduce the chances of generating human anti-mouse antibodies in patients treated with the agent, thus potentially enhancing the clinical utility of the antibody [&lt;ulink linkType="reference" linkID="250810"&gt;250810&lt;/ulink&gt;]. Both 225 and C225 bind to the human EGFR with high specificity and with an affinity equal to its natural ligand. Thus, they compete with the EGFR ligand for binding and block ligand-mediated activation of EGFR [&lt;ulink linkType="reference" linkID="250810"&gt;250810&lt;/ulink&gt;]. Interestingly, the chimeric antibody is somewhat better at interacting with EGFR, as its dissociation constant is approximately five-fold lower than that of 225 [&lt;ulink linkType="reference" linkID="250810"&gt;250810&lt;/ulink&gt;] and it is suggested that this advantage is reflected in the improved pre-clinical performance of C225 [&lt;ulink linkType="reference" linkID="250810"&gt;250810&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;C225 is highly specific for its antigen, the EGF receptor, and there are no reported cross-reactions with other cellular proteins. C225 binds to EGFR with an apparent Kd of 0.147 / 0.201 nM, as determined by ELISA / surface plasmon resonance, respectively [&lt;ulink linkType="reference" linkID="250810"&gt;250810&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;On binding EGFR, C225 blocks ligand-mediated receptor activation in a wide range of prostate carcinoma cell lines [&lt;ulink linkType="reference" linkID="250806"&gt;250806&lt;/ulink&gt;] and a range of other cell lines of various origins [&lt;ulink linkType="reference" linkID="250810"&gt;250810&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="250802"&gt;250802&lt;/ulink&gt;]. C225 also induces the downregulation of EGFR by receptor internalization [&lt;ulink linkType="reference" linkID="250806"&gt;250806&lt;/ulink&gt;]. In some in vitro models, C225 alone is sufficient to inhibit tumor cell proliferation [&lt;ulink linkType="reference" linkID="250802"&gt;250802&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="250810"&gt;250810&lt;/ulink&gt;]. In vivo, a number of single agent C225 studies have also shown dose-dependent antitumor efficacy [&lt;ulink linkType="reference" linkID="250806"&gt;250806&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="250810"&gt;250810&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="250802"&gt;250802&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="242505"&gt;242505&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="250804"&gt;250804&lt;/ulink&gt;]. However, C225 alone is not universally effective, having failed to produce significant inhibition of tumor growth in KB cell xenograft studies [&lt;ulink linkType="reference" linkID="207446"&gt;207446&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="250807"&gt;250807&lt;/ulink&gt;]. Both the in vitro and in vivo efficacy of C225 can be boosted significantly by combining the antibody with other cytotoxic treatments, including doxorubicin [&lt;ulink linkType="reference" linkID="267002"&gt;267002&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="250806"&gt;250806&lt;/ulink&gt;], cisplatin [&lt;ulink linkType="reference" linkID="207446"&gt;207446&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="250807"&gt;250807&lt;/ulink&gt;] and the protein kinase A inhibitor, 8-Cl-cAMP (ICN) [&lt;ulink linkType="reference" linkID="250804"&gt;250804&lt;/ulink&gt;]. The proposed mechanism of action of C225, when used in combination with other agents, is the selective induction of apoptosis. A marked downregulation of cell cycle regulatory proteins, including p53, pRb, cyclin D1, cdk-2, cdk-4 and cdc-2 was also noted, when A431 human epidermoid carcinoma cells were exposed to doxorubicin and C225 [&lt;ulink linkType="reference" linkID="267002"&gt;267002&lt;/ulink&gt;]. Similar results were obtained for the combination of C225 and cisplatin in KB cells [&lt;ulink linkType="reference" linkID="207446"&gt;207446&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="250807"&gt;250807&lt;/ulink&gt;], although the relevance of such findings remains unclear.&lt;/para&gt;&lt;para&gt;The effect of C225 treatment on growth factor levels in tumors has also been investigated. After twice weekly treatment with C225, GEO human colon carcinoma xenografts were immunostained with antibodies against basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), &lt;ulink linkType="Drug" linkID="5932"&gt;amphiregulin&lt;/ulink&gt;, transforming growth factor-alpha (TGF-alpha) and cripto. C225 alone resulted in some decrease in growth factor levels, but combination treatment with C225 and 8-Cl-cAMP resulted in a dramatic decrease which was likely to affect the autocrine growth factor environment of the tumor.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism&lt;/subtitle&gt;Given the proteinaceous nature of this antibody, there is no available data on the in vivo metabolism of C225. Pharmacokinetic studies performed as part of a 13 patient phase Ib/IIa clinical trial, indicate that C225 follows single-compartment kinetics, with a serum half-life of 32.8 h +/- 9% at dose levels of 50 - 100 mg/m2. At these doses, the distribution volume was determined as Vd = 50.6 ml/kg +/- 16% with average clearance rates of 1.07 ml/h/kg +/- 14% [&lt;ulink linkType="reference" linkID="207500"&gt;207500&lt;/ulink&gt;]. In a separate report about the same study, the serum half-life, following a 100 mg/m2 dose of C225, was 36 h [&lt;ulink linkType="reference" linkID="211524"&gt;211524&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The minimal serum level of C225, at which the EGFR is saturated, was determined to be approximately 20 nM. In clinical trials, a single dose of 100 mg/m2 was sufficient to maintain C225 levels above 20 nM for over seven days [&lt;ulink linkType="reference" linkID="211524"&gt;211524&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="207500"&gt;207500&lt;/ulink&gt;]. With weekly dosing, stable trough levels of C225 could be maintained above 20 nM [&lt;ulink linkType="reference" linkID="211524"&gt;211524&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;Results from phase I studies in a variety of EGFR overexpressing cancers show that iv infusions of C225 at doses ,between 5 mg/m2 and 100 mg/m2, do not result in any major toxicities [&lt;ulink linkType="reference" linkID="211524"&gt;211524&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="207500"&gt;207500&lt;/ulink&gt;]. In one study, minor toxicities of fever (&gt; 38 degC), fatigue and nausea were observed in three different patients [&lt;ulink linkType="reference" linkID="211524"&gt;211524&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A preliminary report from the phase Ib/IIa study in head and neck and non-small cell lung cancer (NSCLC) using C225 in combination with cisplatin, confirms that dose-limiting toxicity had not been reached at doses of up to 400 mg/m2 [&lt;ulink linkType="reference" linkID="246979"&gt;246979&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;Given iv as 30 min infusions, C225 was well tolerated at doses between 5 and 100 mg/m2, given either as a single or weekly dose [&lt;ulink linkType="reference" linkID="211524"&gt;211524&lt;/ulink&gt;]. The two studies comprised a total of 25 patients with a variety of EGFR overexpressing malignancies, including head and neck (nine), prostate (five), kidney (four), ovary (two), pancreas (two), lung, esophagus, and breast cancer.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In 1996, ImClone announced the initiation of three phase Ib/IIa studies, testing C225 in combination with cisplatin (head and neck and non-small cell lung cancer), doxorubicin (prostate) and taxol (breast) [&lt;ulink linkType="reference" linkID="242505"&gt;242505&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="196311"&gt;196311&lt;/ulink&gt;]. Preliminary results for the C225 plus cisplatin study were released by ImClone in May 1997, reporting 'evidence strongly suggestive of biological activity' for some of the 22 patients in the study [&lt;ulink linkType="reference" linkID="246979"&gt;246979&lt;/ulink&gt;]. Of the nine patients treated with doses in excess of 100 mg/m2, one showed progressive disease, while six demonstrated stable disease and two achieved partial responses [&lt;ulink linkType="reference" linkID="246979"&gt;246979&lt;/ulink&gt;]. In the same press-release, ImClone reported that the phase Ib/IIa study in prostate cancer showed encouraging results and that additional patients were being recruited for dose levels of 200 mg/m2 to extend the study beyond the initial group of 30 patients [&lt;ulink linkType="reference" linkID="246979"&gt;246979&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;ImClone is planning to extend the evaluation of C225 for head and neck cancers further by starting more trials to test the efficacy of C225 in combination with radiotherapy and as a single agent in conjunction with surgery [&lt;ulink linkType="reference" linkID="246979"&gt;246979&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;At the time of writing phase III studies had not been initiated.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side-effects and Contraindications&lt;/subtitle&gt;No side-effects have been reported.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;A significant proportion of human tumors overexpress EGFR and this has been linked to enhanced autocrine stimulation and tumor progression. EGFR is, therefore, a legitimate target for an antiligand approach. There is even greater evidence for selective overexpression of another member of the EGF receptor family, namely HER2/neu. Although potentially not as selective as an anti-HER2 approach, the C225 chimeric monoclonal antibody shows good clinical potential, particularly where studies are performed in conjunction with established cytotoxic agents, such as cisplatin or doxorubicin. Whether ImClone's anti-EGFR antibody C225 will be superior to &lt;ulink linkType="Company" linkID="19453"&gt;Genentech&lt;/ulink&gt;'s anti- HER2/neu antibody remains to be established. The &lt;ulink linkType="Company" linkID="19453"&gt;Genentech&lt;/ulink&gt; antibody is currently in phase III clinical evaluation. Both antibodies appear to be of clinical benefit without significant toxicity against a range of different human solid tumors.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="IN">India</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-10-29T00:00:00.000Z</StatusDate><Source id="957229" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="X2">Asia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="XE">South America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="XJ">Middle East</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-06-30T00:00:00.000Z</StatusDate><Source id="1461669" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="FI">Finland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-09-19T00:00:00.000Z</StatusDate><Source id="944606" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="GT">Guatemala</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="IL">Israel</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="CL">Chile</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="PA">Panama</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-10-29T00:00:00.000Z</StatusDate><Source id="957229" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="IN">India</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="AT">Austria</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="XF">Central America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="EC">Ecuador</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="PE">Peru</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="MY">Malaysia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-03-11T00:00:00.000Z</StatusDate><Source id="653235" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-06-30T00:00:00.000Z</StatusDate><Source id="1461669" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-03-11T00:00:00.000Z</StatusDate><Source id="653235" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-09-19T00:00:00.000Z</StatusDate><Source id="944606" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-03-04T00:00:00.000Z</StatusDate><Source id="591298" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="CL">Chile</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2939">Thymoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-10-22T00:00:00.000Z</StatusDate><Source id="1705698" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="NO">Norway</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2193">Anal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2193">Anal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-03-08T00:00:00.000Z</StatusDate><Source id="1268927" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-03-08T00:00:00.000Z</StatusDate><Source id="1268927" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-10-22T00:00:00.000Z</StatusDate><Source id="1705698" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="FR">France</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="EC">Ecuador</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="PA">Panama</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="CL">Chile</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-10-22T00:00:00.000Z</StatusDate><Source id="1705698" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="EU">EU</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="MY">Malaysia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="NO">Norway</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="2380">Bladder cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-10-22T00:00:00.000Z</StatusDate><Source id="1705698" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="AT">Austria</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-04-25T00:00:00.000Z</StatusDate><Source id="1283502" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-09-18T00:00:00.000Z</StatusDate><Source id="1324154" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="FI">Finland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3666">Metastatic stomach cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-03-21T00:00:00.000Z</StatusDate><Source id="1389621" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-03-08T00:00:00.000Z</StatusDate><Source id="1268927" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="XE">South America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-10-22T00:00:00.000Z</StatusDate><Source id="1705698" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="NO">Norway</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="EU">EU</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-09-18T00:00:00.000Z</StatusDate><Source id="1324154" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-05-01T00:00:00.000Z</StatusDate><Source id="1663105" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-04-25T00:00:00.000Z</StatusDate><Source id="1283502" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3666">Metastatic stomach cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-03-21T00:00:00.000Z</StatusDate><Source id="1389621" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3666">Metastatic stomach cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-03-21T00:00:00.000Z</StatusDate><Source id="1389621" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="2939">Thymoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-10-22T00:00:00.000Z</StatusDate><Source id="1705698" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="127">Stomach tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-03-21T00:00:00.000Z</StatusDate><Source id="1389621" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-10-22T00:00:00.000Z</StatusDate><Source id="1705698" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="XF">Central America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="IN">India</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="127">Stomach tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-03-21T00:00:00.000Z</StatusDate><Source id="1389621" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="XJ">Middle East</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="CN">China</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="XE">South America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3666">Metastatic stomach cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-03-21T00:00:00.000Z</StatusDate><Source id="1389621" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="CN">China</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="EU">EU</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="X2">Asia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="989">Colorectal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-03-06T00:00:00.000Z</StatusDate><Source id="1389621" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="NO">Norway</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="2193">Anal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="XH">Far East</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3666">Metastatic stomach cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-03-21T00:00:00.000Z</StatusDate><Source id="1389621" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18101">Merck KGaA</Company><Country id="FR">France</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="989">Colorectal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-03-06T00:00:00.000Z</StatusDate><Source id="1389621" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="GT">Guatemala</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="IN">India</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="2193">Anal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-09-18T00:00:00.000Z</StatusDate><Source id="1324154" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-10-22T00:00:00.000Z</StatusDate><Source id="1705698" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="CL">Chile</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="ES">Spain</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="PE">Peru</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2121188" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="194">Sarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-03-13T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="NO">Norway</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-04-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1240">Mesothelioma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-06-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="FR">France</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1516">Biliary cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-03-13T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-03-13T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="194">Sarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-03-13T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2380">Bladder cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-11-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="427">Uterine cervix tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-11-11T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3669">Metastatic pancreas cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-03-08T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-10-06T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19862">Merck Serono SA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-03-03T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="427">Uterine cervix tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-11-11T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-06-05T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3669">Metastatic pancreas cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-03-08T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-04-25T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062214">Inven2</Company><Country id="NO">Norway</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-11-27T00:00:00.000Z</StatusDate><Source id="1541914" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-12-30T00:00:00.000Z</StatusDate><Source id="1264140" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3669">Metastatic pancreas cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-12-09T00:00:00.000Z</StatusDate><Source id="349626" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3669">Metastatic pancreas cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-12-09T00:00:00.000Z</StatusDate><Source id="422557" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1996-01-01T00:00:00.000Z</StatusDate><Source id="199214" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-10-24T00:00:00.000Z</StatusDate><Source id="858345" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-07-31T00:00:00.000Z</StatusDate><Source id="843752" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="194">Sarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-03-31T00:00:00.000Z</StatusDate><Source id="1025518" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="194">Sarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-03-31T00:00:00.000Z</StatusDate><Source id="1025518" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="FR">France</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1516">Biliary cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-10-31T00:00:00.000Z</StatusDate><Source id="981857" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1108">Glioma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-06-18T00:00:00.000Z</StatusDate><Source id="911055" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-06-13T00:00:00.000Z</StatusDate><Source id="796228" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-03-11T00:00:00.000Z</StatusDate><Source id="653235" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-03-11T00:00:00.000Z</StatusDate><Source id="653235" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-06-14T00:00:00.000Z</StatusDate><Source id="1125158" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-12-31T00:00:00.000Z</StatusDate><Source id="1230193" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-12-31T00:00:00.000Z</StatusDate><Source id="1230193" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-07-21T00:00:00.000Z</StatusDate><Source id="1211987" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-07-21T00:00:00.000Z</StatusDate><Source id="1211987" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-01-31T00:00:00.000Z</StatusDate><Source id="1284128" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-01-31T00:00:00.000Z</StatusDate><Source id="1284128" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-09-11T00:00:00.000Z</StatusDate><Source id="942513" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="IN">India</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-10-24T00:00:00.000Z</StatusDate><Source id="738760" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="IN">India</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-02-16T00:00:00.000Z</StatusDate><Source id="734112" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-06-28T00:00:00.000Z</StatusDate><Source id="1311084" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="XH">Far East</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3666">Metastatic stomach cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-07-09T00:00:00.000Z</StatusDate><Source id="923604" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3666">Metastatic stomach cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-07-09T00:00:00.000Z</StatusDate><Source id="923604" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3666">Metastatic stomach cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-07-09T00:00:00.000Z</StatusDate><Source id="923604" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3666">Metastatic stomach cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-07-09T00:00:00.000Z</StatusDate><Source id="923604" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3666">Metastatic stomach cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1234184" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="547104" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-12-21T00:00:00.000Z</StatusDate><Source id="1352207" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-11-10T00:00:00.000Z</StatusDate><Source id="1517763" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-11-10T00:00:00.000Z</StatusDate><Source id="1517763" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-08-31T00:00:00.000Z</StatusDate><Source id="646378" type="CONFERENCE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-08-31T00:00:00.000Z</StatusDate><Source id="646378" type="CONFERENCE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-12-31T00:00:00.000Z</StatusDate><Source id="734112" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-07-27T00:00:00.000Z</StatusDate><Source id="591970" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-04-03T00:00:00.000Z</StatusDate><Source id="660930" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-07-27T00:00:00.000Z</StatusDate><Source id="591970" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-01-31T00:00:00.000Z</StatusDate><Source id="616326" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-12-31T00:00:00.000Z</StatusDate><Source id="1517763" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-12-31T00:00:00.000Z</StatusDate><Source id="1517763" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-07-27T00:00:00.000Z</StatusDate><Source id="591970" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="AT">Austria</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-07-27T00:00:00.000Z</StatusDate><Source id="591970" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-07-27T00:00:00.000Z</StatusDate><Source id="591970" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="FI">Finland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-07-27T00:00:00.000Z</StatusDate><Source id="591970" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-07-27T00:00:00.000Z</StatusDate><Source id="591970" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-07-27T00:00:00.000Z</StatusDate><Source id="591970" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-10-27T00:00:00.000Z</StatusDate><Source id="579610" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-10-27T00:00:00.000Z</StatusDate><Source id="579610" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-10-27T00:00:00.000Z</StatusDate><Source id="579610" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-12-01T00:00:00.000Z</StatusDate><Source id="515542" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="CL">Chile</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-07-27T00:00:00.000Z</StatusDate><Source id="591970" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-07-27T00:00:00.000Z</StatusDate><Source id="591970" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-10-24T00:00:00.000Z</StatusDate><Source id="738760" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-10-24T00:00:00.000Z</StatusDate><Source id="738760" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="CL">Chile</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-10-24T00:00:00.000Z</StatusDate><Source id="738760" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="IL">Israel</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-10-24T00:00:00.000Z</StatusDate><Source id="738760" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="GT">Guatemala</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-07-31T00:00:00.000Z</StatusDate><Source id="734111" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="PA">Panama</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-07-31T00:00:00.000Z</StatusDate><Source id="734111" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="EC">Ecuador</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-09-30T00:00:00.000Z</StatusDate><Source id="734111" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-09-30T00:00:00.000Z</StatusDate><Source id="734111" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="MY">Malaysia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-09-30T00:00:00.000Z</StatusDate><Source id="734111" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-07-27T00:00:00.000Z</StatusDate><Source id="591970" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-12-31T00:00:00.000Z</StatusDate><Source id="734112" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-10-25T00:00:00.000Z</StatusDate><Source id="1025523" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="427">Uterine cervix tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-02-08T00:00:00.000Z</StatusDate><Source id="1025513" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="427">Uterine cervix tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-02-08T00:00:00.000Z</StatusDate><Source id="1025513" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1996-01-01T00:00:00.000Z</StatusDate><Source id="199214" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3666">Metastatic stomach cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-03-05T00:00:00.000Z</StatusDate><Source id="1642851" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="NO">Norway</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-11-27T00:00:00.000Z</StatusDate><Source id="1541914" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2380">Bladder cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-03-13T00:00:00.000Z</StatusDate><Source id="1025510" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2939">Thymoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-12-02T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-03-04T00:00:00.000Z</StatusDate><Source id="591298" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-10-30T00:00:00.000Z</StatusDate><Source id="957229" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-10-29T00:00:00.000Z</StatusDate><Source id="957229" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-09-19T00:00:00.000Z</StatusDate><Source id="944606" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2380">Bladder cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-03-13T00:00:00.000Z</StatusDate><Source id="1025510" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1240">Mesothelioma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-05-07T00:00:00.000Z</StatusDate><Source id="1657523" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-02-29T00:00:00.000Z</StatusDate><Source id="1106380" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="FR">France</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-11-30T00:00:00.000Z</StatusDate><Source id="1042763" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-03-10T00:00:00.000Z</StatusDate><Source id="317654" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-03-10T00:00:00.000Z</StatusDate><Source id="317654" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-07-31T00:00:00.000Z</StatusDate><Source id="1466397" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-12-21T00:00:00.000Z</StatusDate><Source id="1352207" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-03-11T00:00:00.000Z</StatusDate><Source id="653235" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-03-11T00:00:00.000Z</StatusDate><Source id="653235" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-03-11T00:00:00.000Z</StatusDate><Source id="653235" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-03-11T00:00:00.000Z</StatusDate><Source id="653235" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-06-19T00:00:00.000Z</StatusDate><Source id="918824" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-12-01T00:00:00.000Z</StatusDate><Source id="967526" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="127">Stomach tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-03-31T00:00:00.000Z</StatusDate><Source id="1642851" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="127">Stomach tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-03-31T00:00:00.000Z</StatusDate><Source id="1642851" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="NO">Norway</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-10-20T00:00:00.000Z</StatusDate><Source id="1676056" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-09-15T00:00:00.000Z</StatusDate><Source id="943610" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-10-22T00:00:00.000Z</StatusDate><Source id="957229" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="XE">South America</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-09-15T00:00:00.000Z</StatusDate><Source id="943610" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="XJ">Middle East</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-09-15T00:00:00.000Z</StatusDate><Source id="943610" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="XF">Central America</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-09-15T00:00:00.000Z</StatusDate><Source id="943610" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="X2">Asia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-09-15T00:00:00.000Z</StatusDate><Source id="943610" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="PE">Peru</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-09-15T00:00:00.000Z</StatusDate><Source id="943610" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="GT">Guatemala</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="PA">Panama</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="EC">Ecuador</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-09-15T00:00:00.000Z</StatusDate><Source id="943610" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="MY">Malaysia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-09-15T00:00:00.000Z</StatusDate><Source id="943610" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="CL">Chile</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="IL">Israel</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-06-27T00:00:00.000Z</StatusDate><Source id="496093" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-06-30T00:00:00.000Z</StatusDate><Source id="496093" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-05-31T00:00:00.000Z</StatusDate><Source id="885966" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2193">Anal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-06-30T00:00:00.000Z</StatusDate><Source id="1446832" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-12-01T00:00:00.000Z</StatusDate><Source id="967526" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="IN">India</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-03-01T00:00:00.000Z</StatusDate><Source id="772792" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-07-31T00:00:00.000Z</StatusDate><Source id="1806941" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-03-01T00:00:00.000Z</StatusDate><Source id="772792" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="XJ">Middle East</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-09-15T00:00:00.000Z</StatusDate><Source id="943610" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="XE">South America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-09-15T00:00:00.000Z</StatusDate><Source id="943610" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="XF">Central America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-09-15T00:00:00.000Z</StatusDate><Source id="943610" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="X2">Asia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-09-15T00:00:00.000Z</StatusDate><Source id="943610" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-03-01T00:00:00.000Z</StatusDate><Source id="772792" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="AT">Austria</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="FI">Finland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-03-01T00:00:00.000Z</StatusDate><Source id="772792" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-03-01T00:00:00.000Z</StatusDate><Source id="772792" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="CL">Chile</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="PE">Peru</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-09-15T00:00:00.000Z</StatusDate><Source id="943610" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="GT">Guatemala</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="PA">Panama</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="EC">Ecuador</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-09-15T00:00:00.000Z</StatusDate><Source id="943610" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="MY">Malaysia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-02-21T00:00:00.000Z</StatusDate><Source id="1450511" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="NO">Norway</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2193">Anal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-06-30T00:00:00.000Z</StatusDate><Source id="1446832" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-03-01T00:00:00.000Z</StatusDate><Source id="772792" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="CL">Chile</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="IN">India</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-03-01T00:00:00.000Z</StatusDate><Source id="772792" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="IL">Israel</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-01-14T00:00:00.000Z</StatusDate><Source id="1348676" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-09-15T00:00:00.000Z</StatusDate><Source id="943610" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-02-12T00:00:00.000Z</StatusDate><Source id="523128" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-08-14T00:00:00.000Z</StatusDate><Source id="501075" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-10-28T00:00:00.000Z</StatusDate><Source id="510896" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="CA">Canada</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-11-24T00:00:00.000Z</StatusDate><Source id="514622" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-11-24T00:00:00.000Z</StatusDate><Source id="514622" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="AU">Australia</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-11-03T00:00:00.000Z</StatusDate><Source id="511321" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-03-31T00:00:00.000Z</StatusDate><Source id="591967" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-05-31T00:00:00.000Z</StatusDate><Source id="542377" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-03-31T00:00:00.000Z</StatusDate><Source id="591967" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-05-11T00:00:00.000Z</StatusDate><Source id="324314" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-05-11T00:00:00.000Z</StatusDate><Source id="324314" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3669">Metastatic pancreas cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-12-09T00:00:00.000Z</StatusDate><Source id="349626" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3669">Metastatic pancreas cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-09-19T00:00:00.000Z</StatusDate><Source id="422557" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-10-07T00:00:00.000Z</StatusDate><Source id="563334" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="CN">China</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3666">Metastatic stomach cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-03-31T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="547104" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-31T00:00:00.000Z</StatusDate><Source id="763073" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-31T00:00:00.000Z</StatusDate><Source id="763073" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-08T00:00:00.000Z</StatusDate><Source id="755711" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-04-26T00:00:00.000Z</StatusDate><Source id="616326" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="PE">Peru</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-04-26T00:00:00.000Z</StatusDate><Source id="616326" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-11-06T00:00:00.000Z</StatusDate><Source id="739247" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="CL">Chile</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-03-31T00:00:00.000Z</StatusDate><Source id="591967" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-07-15T00:00:00.000Z</StatusDate><Source id="925595" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-07-15T00:00:00.000Z</StatusDate><Source id="925595" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-09-15T00:00:00.000Z</StatusDate><Source id="885914" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-09-15T00:00:00.000Z</StatusDate><Source id="885914" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-04-03T00:00:00.000Z</StatusDate><Source id="660930" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-03-10T00:00:00.000Z</StatusDate><Source id="317654" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-09-19T00:00:00.000Z</StatusDate><Source id="422557" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-09-19T00:00:00.000Z</StatusDate><Source id="422557" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1997-12-05T00:00:00.000Z</StatusDate><Source id="271226" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-03-01T00:00:00.000Z</StatusDate><Source id="772792" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19862">Merck Serono SA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-06-03T00:00:00.000Z</StatusDate><Source id="796228" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-08-14T00:00:00.000Z</StatusDate><Source id="501075" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-02-12T00:00:00.000Z</StatusDate><Source id="523128" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2002-08-28T00:00:00.000Z</StatusDate><Source id="468726" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3669">Metastatic pancreas cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-04-01T00:00:00.000Z</StatusDate><Source id="321259" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1995-06-16T14:37:59.000Z</StatusDate><Source id="179103" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-09-19T00:00:00.000Z</StatusDate><Source id="422557" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-07-18T00:00:00.000Z</StatusDate><Source id="398068" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="5">Accelerated Approval</RegulatoryDesignation><OwnerCompany id="17193">Imclone LLC</OwnerCompany><Country id="US">US</Country><Indication id="3658">Metastatic colorectal cancer</Indication><AwardedIndication>Treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are intolerant to irinotencan-based chemotherapy</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-02-12T00:00:00.000Z</MileStoneDate><Source id="523128" type="PR"></Source></Row><Row><RegulatoryDesignation id="5">Accelerated Approval</RegulatoryDesignation><OwnerCompany id="17193">Imclone LLC</OwnerCompany><Country id="US">US</Country><Indication id="3658">Metastatic colorectal cancer</Indication><AwardedIndication>Treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are refractory to irinotecan-based chemotherapy, in combination with irinotecan</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-02-12T00:00:00.000Z</MileStoneDate><Source id="523128" type="PR"></Source></Row><Row><RegulatoryDesignation id="5">Accelerated Approval</RegulatoryDesignation><OwnerCompany id="17193">Imclone LLC</OwnerCompany><Country id="US">US</Country><Indication id="3658">Metastatic colorectal cancer</Indication><AwardedIndication>Treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are refractory to irinotecan-based chemotherapy, in combination with irinotecan</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="3">Filed</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-08-14T00:00:00.000Z</MileStoneDate><Source id="501075" type="PR"></Source></Row><Row><RegulatoryDesignation id="5">Accelerated Approval</RegulatoryDesignation><OwnerCompany id="17193">Imclone LLC</OwnerCompany><Country id="US">US</Country><Indication id="3658">Metastatic colorectal cancer</Indication><AwardedIndication>Treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are intolerant to irinotencan-based chemotherapy</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="3">Filed</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-08-14T00:00:00.000Z</MileStoneDate><Source id="501075" type="PR"></Source></Row><Row><RegulatoryDesignation id="3">Breakthrough Therapy</RegulatoryDesignation><OwnerCompany id="17810">Eli Lilly &amp; Co</OwnerCompany><Country id="US">US</Country><Indication id="3658">Metastatic colorectal cancer</Indication><AwardedIndication>Treatment with encorafenib in combination with binimetinib and cetuximab for patients with BRAF-mutant metastatic colorectal carcinoma after failure of one to two prior lines of therapy</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-08-07T00:00:00.000Z</MileStoneDate><Source id="2060639" type="PR"></Source></Row><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="17810">Eli Lilly &amp; Co</OwnerCompany><Country id="US">US</Country><Indication id="3658">Metastatic colorectal cancer</Indication><AwardedIndication>Treatment of refractory CRC (Colorectal Cancer)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-02-01T00:00:00.000Z</MileStoneDate><Source id="397656" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="17193">Imclone LLC</OwnerCompany><Country id="US">US</Country><Indication id="249">Pancreas tumor</Indication><AwardedIndication>Treatment of pancreatic cancer</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-06-15T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="17193">Imclone LLC</OwnerCompany><Country id="US">US</Country><Indication id="623">Head and neck tumor</Indication><AwardedIndication>Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2000-07-03T00:00:00.000Z</MileStoneDate></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00682"><Name>Epidermal growth factor receptor</Name><SwissprotNumbers><Swissprot>P00533</Swissprot><Swissprot>P04412</Swissprot><Swissprot>P13387</Swissprot><Swissprot>P55245</Swissprot><Swissprot>Q01279</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1052050">SFJ Pharmaceuticals Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1061229">Cancer Prevention and Research Institute of Texas</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1062214">Inven2</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1120033">Forty Seven Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="15065">Bristol-Myers Squibb Co</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="15489">Weizmann Institute of Science</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="17810">Eli Lilly &amp; Co</Company><CountAsPrincipalActive>3</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>3</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>6</CountTotal></Company><Company><Company id="18101">Merck KGaA</Company><CountAsPrincipalActive>4</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>4</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>6</CountTotal></Company><Company><Company id="20527">University of Arizona</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="21081">Institut Gustave Roussy</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="21864">University of Texas System</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="22122">Memorial Sloan-Kettering Cancer Center</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="22690">Lonza Group AG</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="28430">Alchemia Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="29820">AVEO Oncology</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="DOL1000637">Sheba Medical Center</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="11">Patent - Exclusive Rights</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="2">Drug - Screening/Evaluation</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="21">Patent - Litigation Settlement</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>4</CountActive><CountInactive>0</CountInactive><CountTotal>4</CountTotal></Type><Type><Type sortOrder="6">Drug - Manufacturing/Supply</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>3</CountActive><CountInactive>0</CountInactive><CountTotal>3</CountTotal></Type></CountsByTypes><Deals><Deal id="117095" title="BMS to develop ImClone's cetuximab and related compounds in US, Canada and Japan       "></Deal><Deal id="117099" title="Merck KGaA to develop ImClone's cetuximab outside of North America  "></Deal><Deal id="117101" title="Lonza to manufacture ImClone's cetuximab"></Deal><Deal id="117299" title="ImClone and Merck KGaA to codevelop and market cetuximab in Japan "></Deal><Deal id="120698" title="Institut Gustave Roussy and Merck Serono to conduct cetuximab trial"></Deal><Deal id="145215" title="Alchemia and Merck Serono to collaborate on phase II trial of HA-Irinotecan in combination with Erbitux for metastatic colorectal cancer "></Deal><Deal id="148998" title="Merck KGaA to obtain exclusive worldwide rights to Inven2’s patents related to EGFR inhibitors for the treatment of neuropathic pain"></Deal><Deal id="153452" title="Memorial Sloan-Kettering to conduct phase II trial of BMS' cetuximab against thymoma "></Deal><Deal id="165583" title="Erbitux Cetuximab Litigation Settlement"></Deal><Deal id="246759" title="SFJ Pharmaceuticals to collaborate on development of Merck KGaA's abituzumab combination with Erbitux for mCRC"></Deal><Deal id="248004" title="AVEO Oncology and University of Arizona to conduct phase II trial of ficlatuzumab and cetuximab for HNSCC"></Deal><Deal id="248548" title="CPRIT to award MD Anderson Cancer Center funding to support the research on advancing the fight against cancer"></Deal><Deal id="248619" title="Forty Seven and Eli Lilly to evaluate safety, tolerability and clinical activity of combination of 5F9 and cetuximab for solid tumors and CRC"></Deal><Deal id="248716" title="Weizmann Institute of Science and Chaim Sheba Medical Center to test Tagrisso in combination with Erbitux and Herceptin against lung tumor"></Deal></Deals><PatentFamilies><PatentFamily id="1000629" number="WO-2009040426" title="Immunoliposomes for treatment of cancer"></PatentFamily><PatentFamily id="1013900" number="WO-2009085262" title="Method of treating cancer with immunomodulatory compounds and IgG"></PatentFamily><PatentFamily id="1031371" number="WO-2008101177" title="IgE antibodies to chimeric or humanized IgG therapeutic monoclonal antibodies as a screening test for anaphylaxis."></PatentFamily><PatentFamily id="1035717" number="WO-2008077171" title="Treatment of diabetes by at least one epidermal growth factor receptor specific antibody or a derivative thereof"></PatentFamily><PatentFamily id="1040904" number="WO-2012018260" title="Epidermal growth factor receptor targeted immune therapy"></PatentFamily><PatentFamily id="1046420" number="WO-2012123755" title="Re-directed immunotherapy"></PatentFamily><PatentFamily id="1070395" number="WO-2007008338" title="Egfr inhibitors promote axon regeneration"></PatentFamily><PatentFamily id="1070551" number="WO-2007028196" title="Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment"></PatentFamily><PatentFamily id="108407" number="WO-2007064957" title="Fcγ polymorphisms for predicting disease and treatment outcome"></PatentFamily><PatentFamily id="1097392" number="WO-00211677" title="Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists"></PatentFamily><PatentFamily id="1110799" number="WO-2011063309" title="Methods and compositions for treating hedgehog-associated cancers"></PatentFamily><PatentFamily id="1114074" number="WO-2009150255" title="Markers for predicting response and survival in anti-egfr treated patients"></PatentFamily><PatentFamily id="1141374" number="WO-2010124239" title="Genetic polymorphisms associated with clinical outcomes of topoisomerase inhibitor therapy for cancer"></PatentFamily><PatentFamily id="1145694" number="WO-2008051363" title="Stable polypeptide formulations"></PatentFamily><PatentFamily id="1170967" number="WO-2007147001" title="Lyophilized formulations of anti-egfr antibodies"></PatentFamily><PatentFamily id="1189342" number="WO-2011107664" title="Method for selecting patients for treatment with an EGFR inhibitor"></PatentFamily><PatentFamily id="1244776" number="WO-2008036254" title="Autophagic compounds and tyrosine kinase inhibitors for treating cancer"></PatentFamily><PatentFamily id="1247437" number="WO-2008104183" title="Recombinant anti-epidermal growth factor receptor antibody compositions"></PatentFamily><PatentFamily id="1251948" number="CN-101077334" title="Anticancer composition containing tyrosine kinase inhibitor"></PatentFamily><PatentFamily id="1258420" number="WO-2010131080" title="A method for predicting the therapeutic responsiveness of a patient to a medical treatment with an EGFR inhibitor"></PatentFamily><PatentFamily id="1294090" number="WO-2008079976" title="Dimeric high affinity EGFR constructs and uses thereof"></PatentFamily><PatentFamily id="1310670" number="WO-2005089372" title="Therapeutic synergy of anti-cancer compounds"></PatentFamily><PatentFamily id="1334614" number="WO-2011159004" title="SNP for predicting the sensitivity to anticancer targeted therapeutic formulation"></PatentFamily><PatentFamily id="1336846" number="US-20110177068" title="Pharmaceutical preparation comprising an antibody against the egf receptor"></PatentFamily><PatentFamily id="1455166" number="WO-2010022736" title="Recombinant anti-epidermal growth factor receptor antibody compositions"></PatentFamily><PatentFamily id="1464625" number="WO-2004021994" title="Cancer therapy using whole glucan particles and antibodies"></PatentFamily><PatentFamily id="1482487" number="WO-2012022724" title="Combination anti - cancer therapy"></PatentFamily><PatentFamily id="148745" number="WO-2011087548" title="Therapeutic compositions and methods for targeted delivery of active agents"></PatentFamily><PatentFamily id="1488596" number="WO-2012084173" title="Methods and compositions for detecting mutation in the human epidermal growth factor receptor gene"></PatentFamily><PatentFamily id="153609" number="WO-2010080804" title="Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators"></PatentFamily><PatentFamily id="1549309" number="WO-2009021149" title="Detection of extracellular tumor-associated JAK2 nucleic acids in blood plasma or serum"></PatentFamily><PatentFamily id="1564312" number="WO-2012138739" title="Compositions and methods for treating cancer"></PatentFamily><PatentFamily id="157986" number="WO-2012138694" title="Compositions comprising saccharide binding moieties and methods for targeted therapy"></PatentFamily><PatentFamily id="1584433" number="WO-03007988" title="Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan"></PatentFamily><PatentFamily id="1589899" number="WO-2008045373" title="Stable formulations"></PatentFamily><PatentFamily id="1590979" number="WO-2009030239" title="Novel methods and antibodies for treating cancer"></PatentFamily><PatentFamily id="1612429" number="WO-2010073119" title="Stable pharmaceutical composition containing at least one monoclonal antibody and at least one amphiphilic polysaccharide comprising hydrophobic substituents"></PatentFamily><PatentFamily id="1629826" number="WO-2011056894" title="Truncated epiderimal growth factor receptor (EGFRt) for transduced T-cell selection"></PatentFamily><PatentFamily id="1635325" number="WO-2012130141" title="Method and composition for enhancing target cells uptake of therapeutic agents"></PatentFamily><PatentFamily id="1657553" number="WO-00205791" title="Antitumor combined therapy"></PatentFamily><PatentFamily id="1661506" number="WO-2006119395" title="Therapeutic combination compositions and methods of using same"></PatentFamily><PatentFamily id="1695584" number="WO-2010077643" title="Masking ligands for reversible inhibition of multivalent compounds"></PatentFamily><PatentFamily id="1696113" number="WO-2007047235" title="Compositions and methods for treatment of airway hypersecretion"></PatentFamily><PatentFamily id="1712972" number="WO-2011059762" title="Anti-EGFR antibodies and their uses"></PatentFamily><PatentFamily id="1762870" number="WO-2009012175" title="Antibodies specific for the C-terminal regulatory domain of EGFR and their use"></PatentFamily><PatentFamily id="1780615" number="WO-2012018609" title="Mig6 and therapeutic efficacy"></PatentFamily><PatentFamily id="1782608" number="WO-2011127061" title="Enhancement of radiation therapy by targeted high-Z nanoparticles"></PatentFamily><PatentFamily id="1807797" number="WO-2005077414" title="Highly concentrated liquid formulations of anti-EGFR antibodies"></PatentFamily><PatentFamily id="1828269" number="WO-03053465" title="Lyophilized preparation containing antibodies to the EGF receptor"></PatentFamily><PatentFamily id="1847157" number="WO-2011011617" title="Therapeutic compositions and methods"></PatentFamily><PatentFamily id="1856922" number="WO-2011001276" title="Immunocytokines in combination with anti-ErbB antibodies for the treatment of cancer"></PatentFamily><PatentFamily id="1861299" number="WO-2012075679" title="Methods of metabolic targeting cancer cells using chemo- and immunotherapy for treating cancer"></PatentFamily><PatentFamily id="1866120" number="EP-00359282" title="Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic compositions containing same."></PatentFamily><PatentFamily id="1898903" number="WO-2010051552" title="Methods of simulating chemotherapy for a patient"></PatentFamily><PatentFamily id="1906232" number="WO-2006124689" title="Combination therapy"></PatentFamily><PatentFamily id="1932114" number="WO-2005118876" title="EGFR mutations"></PatentFamily><PatentFamily id="1934413" number="WO-2011059752" title="Methods and compositions for anti-EGFR treatment"></PatentFamily><PatentFamily id="1956696" number="WO-2006042313" title="Method of treating the accumulation of serous fluid in serous body cavities"></PatentFamily><PatentFamily id="1958724" number="WO-2007067500" title="Predictors of patient response to treatment with egfr inhibitors"></PatentFamily><PatentFamily id="1959291" number="WO-2008014386" title="Treatment of tumors in pediatric patients with epidermal growth factor receptor antagonists"></PatentFamily><PatentFamily id="1995547" number="EP-00125023" title="Recombinant immunoglobulin preparations"></PatentFamily><PatentFamily id="2001979" number="WO-2011109625" title="Methods for determining responsiveness to a drug based upon determination of Ras mutation and/or Ras amplification"></PatentFamily><PatentFamily id="2003457" number="WO-2010028288" title="Methods for stratifying and annotating cancer drug treatment options"></PatentFamily><PatentFamily id="2034614" number="WO-2009023172" title="Predictions of responsiveness to EGFR inhibitors"></PatentFamily><PatentFamily id="2069375" number="US-08137919" title="Method of determining the sensitivity of cancer cells to egfr inhibitors including cetuximab, panitumumab and erlotinib"></PatentFamily><PatentFamily id="2074893" number="WO-2011130265" title="KRAS primers and probes"></PatentFamily><PatentFamily id="2122405" number="WO-2006017317" title="Method for the treatment of disease"></PatentFamily><PatentFamily id="2124632" number="WO-2008103920" title="Targeted protein cages"></PatentFamily><PatentFamily id="2139910" number="WO-2010141543" title="Methods for the detection and quantitation of the p95 component of HER2/neu (ERbB2)"></PatentFamily><PatentFamily id="2147981" number="WO-2012065705" title="Novel complex mutation in the epidermal growth factor receptor kinase domain"></PatentFamily><PatentFamily id="2148415" number="WO-2012049112" title="EGFR aptamer inhibitor for use in therapy and diagnosis"></PatentFamily><PatentFamily id="2153383" number="WO-2012129352" title="The KRAS variant and tumor biology"></PatentFamily><PatentFamily id="2180507" number="WO-2007025044" title="Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators"></PatentFamily><PatentFamily id="2211281" number="WO-2006108627" title="Anti-EGFR antibody therapy based on an increased copy number of the EGFR gene in tumor tissues"></PatentFamily><PatentFamily id="2222687" number="WO-2009140508" title="Methods for predicting a patient's response to EGFR inhibitors"></PatentFamily><PatentFamily id="2229273" number="WO-2010081173" title="Modified antibody compositions, methods of making and using thereof"></PatentFamily><PatentFamily id="225532" number="WO-2011133819" title="Methods of enhancing antibody-dependent cellular cytotoxicity"></PatentFamily><PatentFamily id="226187" number="WO-2011015918" title="Vectors and compounds for expression of recombinant cetuximab"></PatentFamily><PatentFamily id="2271398" number="WO-2011120870" title="EGFR inhibitor and antiviral agent for simultaneous, separate or sequential use in the treatment and/or prevention and/or palliation of cancer"></PatentFamily><PatentFamily id="2286518" number="WO-2008079973" title="EGFR binding peptides and uses thereof"></PatentFamily><PatentFamily id="229769" number="WO-2012042009" title="Means and methods for diagnosing cancer using an antibody which specifically binds to BRAF V600E"></PatentFamily><PatentFamily id="2355457" number="WO-2007146959" title="Pan-cell surface receptor-specific therapeutics"></PatentFamily><PatentFamily id="2370615" number="WO-2011020033" title="Engineered proteins including mutant fibronectin domains"></PatentFamily><PatentFamily id="2370892" number="WO-2012022677" title="Novel combination therapy for the treatment of cancer"></PatentFamily><PatentFamily id="2376239" number="WO-2012131092" title="Method and kits for the prediction of response/nonresponse to the treatment with an anti-EGFR antibody in patients with colorectal cancer of all UICC stages"></PatentFamily><PatentFamily id="2382657" number="WO-2012145682" title="A method for culturing mammalian cells to improve recombinant protein production"></PatentFamily><PatentFamily id="2382991" number="WO-2012143495" title="Novel binder-drug conjugates (ADCs) and their use"></PatentFamily><PatentFamily id="2384473" number="US-20120269818" title="Methods for treating infection by HPV"></PatentFamily><PatentFamily id="2388409" number="WO-2012146919" title="CXCR1 as a predictor of response to treatment with epidermal growth factor receptor therapeutic"></PatentFamily><PatentFamily id="2399544" number="WO-2012154680" title="Modified and derivatized β-glucan compounds, compositions, and methods"></PatentFamily><PatentFamily id="2404026" number="WO-2012156437" title="Method for EGFR directed combination treatment of cancer"></PatentFamily><PatentFamily id="2421860" number="WO-2012164497" title="Synergistic pharmaceutical combination for the treatment of squamous cell carcinoma of head and neck"></PatentFamily><PatentFamily id="2423029" number="EP-02530462" title="Methods and kits for predicting tumor responses to antibodies against epidermal growth factor receptor (EGFR) and uses thereof"></PatentFamily><PatentFamily id="2424817" number="CN-102796815" title="Kit and method of using pyrophosphoric acid sequencing method to detect k-ras gene polymorphism"></PatentFamily><PatentFamily id="2431340" number="WO-2012135360" title="Binding proteins specific for EGFR expressed on tumor and uses thereof"></PatentFamily><PatentFamily id="2447398" number="WO-2013006547" title="Antibodies against epidermal growth factor receptor (egfr) and uses thereof"></PatentFamily><PatentFamily id="2447527" number="WO-2013005108" title="EGFR targeted therapy"></PatentFamily><PatentFamily id="2462835" number="WO-2013016714" title="Sur-binding proteins against ErbB3"></PatentFamily><PatentFamily id="2466186" number="WO-2013017645" title="Mutations in the epidermal growth factor receptor gene"></PatentFamily><PatentFamily id="2469520" number="WO-2013023043" title="Treatment of advanced solid tumors using combination of anti-ErbB3 immunotherapy and selected chemotherapy"></PatentFamily><PatentFamily id="2469594" number="WO-2013022738" title="P97 fragments with transfer activity"></PatentFamily><PatentFamily id="2475923" number="WO-2010085234" title="Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway"></PatentFamily><PatentFamily id="2475924" number="WO-2010085235" title="Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway"></PatentFamily><PatentFamily id="2478904" number="WO-2007126758" title="Method and system for determining whether a drug will be effective on a patient with a disease"></PatentFamily><PatentFamily id="2485761" number="WO-2013033380" title="Diagnostic markers"></PatentFamily><PatentFamily id="2494854" number="WO-2013037824" title="Endoglycosidase from &lt;i&gt;Streptococcus pyogenes&lt;/i&gt; and methods using it"></PatentFamily><PatentFamily id="2497557" number="EP-02574680" title="Probe, polymorphism detection method, method of evaluating drug efficacy or tolerance, and reagent kit"></PatentFamily><PatentFamily id="2499064" number="WO-2013048883" title="Anti-ErbB3 antibodies and uses thereof"></PatentFamily><PatentFamily id="2499908" number="WO-2013055530" title="Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells"></PatentFamily><PatentFamily id="2519336" number="WO-2013063510" title="Protein formulations containing amino acids"></PatentFamily><PatentFamily id="2528534" number="WO-2013068103" title="Novel complex mutations in the epidermal growth factor receptor kinase domain"></PatentFamily><PatentFamily id="2532543" number="WO-2013076282" title="A method for predicting responsiveness to a treatment with an EGFR inhibitor"></PatentFamily><PatentFamily id="2556913" number="WO-2013102096" title="Aptamers and diagnostic methods for detecting the EGF receptor"></PatentFamily><PatentFamily id="2563389" number="WO-2013105013" title="Mutant antibodies and conjugation thereof"></PatentFamily><PatentFamily id="2565402" number="WO-2013107883" title="Tetrahydrofolates in combination with EGFR-inhibitors"></PatentFamily><PatentFamily id="2568667" number="WO-2013112856" title="Multifunctional nanomaterials for the treatment of cancer"></PatentFamily><PatentFamily id="2577982" number="WO-2013118073" title="SERPINB4, as a marker for an early evaluation of the response to anti-EGFR therapies by a non-invasive method"></PatentFamily><PatentFamily id="2580194" number="US-20130216523" title="Methods for facilitating diagnosis, prognosis and treatment of cancer by detecting HER1 expression"></PatentFamily><PatentFamily id="2590782" number="WO-2013134743" title="Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof"></PatentFamily><PatentFamily id="2592871" number="WO-2013138310" title="An antibody array used for the analysis of the three-dimensional structure of protein therapeutics and its production"></PatentFamily><PatentFamily id="2594511" number="WO-2013139423" title="Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with other anti-tumor compounds"></PatentFamily><PatentFamily id="2594984" number="WO-2013140074" title="Method for determining the ability of an antibody to keep cells close to one another"></PatentFamily><PatentFamily id="2605830" number="WO-2013151774" title="Combination therapy with an anti-hyaluronan agent and a tumor-targeted taxane"></PatentFamily><PatentFamily id="2622545" number="WO-2013159155" title="Oncolytic &lt;i&gt;Clostridium ghonii&lt;/i&gt; strains, and methods of production and use"></PatentFamily><PatentFamily id="2626466" number="WO-2013164095" title="Production of secreted therapeutic antibodies in microalgae"></PatentFamily><PatentFamily id="2637621" number="CN-103254311" title="Preparation method of antibody-maytansinoid conjugate"></PatentFamily><PatentFamily id="2646198" number="WO-2015055841" title="Method"></PatentFamily><PatentFamily id="2651299" number="WO-2013188500" title="Whole cell assays and methods"></PatentFamily><PatentFamily id="2658454" number="WO-2013192546" title="Activatable antibodies having non-binding steric moieties and mehtods of using the same"></PatentFamily><PatentFamily id="2677958" number="WO-2014020152" title="Ligands for apheresis and immunoabsorption"></PatentFamily><PatentFamily id="2679636" number="WO-2014025688" title="Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor"></PatentFamily><PatentFamily id="2682656" number="WO-2014028221" title="Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-EGFR drug"></PatentFamily><PatentFamily id="2683421" number="US-08653448" title="Method for analyzing glycan structure"></PatentFamily><PatentFamily id="2720096" number="WO-2012048332" title="A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use"></PatentFamily><PatentFamily id="2725904" number="WO-2014066606" title="Combination"></PatentFamily><PatentFamily id="2726045" number="WO-2014065661" title="Modified antibody, antibody-conjugate and process for the preparation thereof"></PatentFamily><PatentFamily id="2726490" number="WO-2014064682" title="Combinations of epidermal growth factor receptor targeting antibodies for treating cancer"></PatentFamily><PatentFamily id="272737" number="WO-2009082485" title="Anti-C35 antibody combination therapies and methods"></PatentFamily><PatentFamily id="2734621" number="US-20140134158" title="KRAS mutations and resistance to anti-EGFR treatment"></PatentFamily><PatentFamily id="2735009" number="JP-05809125" title="Anti-inflammatory agent"></PatentFamily><PatentFamily id="2744265" number="WO-2014081944" title="Egfr and c-met-fibronectin type iii domain binding molecules"></PatentFamily><PatentFamily id="2744480" number="WO-2014080381" title="Colorectal cancer classification with differential prognosis and personalized therapeutic responses"></PatentFamily><PatentFamily id="2744527" number="WO-2014080020" title="Auto-injector assembly"></PatentFamily><PatentFamily id="2756236" number="WO-2014091486" title="Combination therapy for cancer"></PatentFamily><PatentFamily id="2758076" number="WO-2014096551" title="Linker-payload molecule conjugates"></PatentFamily><PatentFamily id="2758371" number="WO-2014100565" title="Methods and compositions relating to treatment of cancer"></PatentFamily><PatentFamily id="2758525" number="WO-2014095088" title="EGFR targeted therapy of neurological disorders and pain"></PatentFamily><PatentFamily id="2758770" number="WO-2014095766" title="Prediction of the treatment response to an anti-EGFR molecule in colorectal cancer patients"></PatentFamily><PatentFamily id="2759011" number="WO-2014094957" title="Copolymers for protein precipitation"></PatentFamily><PatentFamily id="2767241" number="WO-2014106527" title="Method for producing secretable antibodies by expression in &lt;i&gt;Saccharomyces cerevisiae&lt;/i&gt;"></PatentFamily><PatentFamily id="2768513" number="CN-103898198" title="Panitumumab, cetuximab targeted medicine gene of method and the primer"></PatentFamily><PatentFamily id="2768779" number="CN-103897061" title="Blocking cetuximab and egfr-binding antibody, kit and hybridoma cell thereof"></PatentFamily><PatentFamily id="2782915" number="WO-2014122600" title="Methods of selecting combination therapy for colorectal cancer patients"></PatentFamily><PatentFamily id="2782941" number="WO-2014122582" title="Drug selection for non-small cell lung cancer therapy"></PatentFamily><PatentFamily id="2790737" number="WO-2014133950" title="Particle compositions and methods related thereto"></PatentFamily><PatentFamily id="2796393" number="WO-2014135655" title="Compositions and methods for treating muscle-invasive bladder cancer"></PatentFamily><PatentFamily id="2798624" number="WO-2014139131" title="Use of EGFR biomarkers for the treatment of gastric cancer with anti-EGFR agents"></PatentFamily><PatentFamily id="2808417" number="US-09572878" title="Method of combination therapy using an egfr antagonist and anti-c-met antibody"></PatentFamily><PatentFamily id="2811647" number="WO-2014164427" title="Fusion immunomodulatory proteins and methods for making same"></PatentFamily><PatentFamily id="2824714" number="WO-2014177771" title="Conjugates of a glycoprotein or a glycan with a toxic payload"></PatentFamily><PatentFamily id="2826576" number="WO-2014182970" title="Bispecific HER2 and HER3 antigen binding constructs"></PatentFamily><PatentFamily id="2830407" number="WO-2014185752" title="Method for analyzing pattern of live intercellular membrane protein binding"></PatentFamily><PatentFamily id="2834340" number="WO-2014189303" title="Trans-tumoral peptide specific to neuropilin and fusion protein having same peptide fused therein"></PatentFamily><PatentFamily id="2834503" number="WO-2014188363" title="Methods for predicting and improving the survival of colorectal cancer patients"></PatentFamily><PatentFamily id="2835800" number="WO-2014193937" title="The KRAS variant and response to cancer therapy"></PatentFamily><PatentFamily id="2836985" number="EP-02808035" title="Composition for target membrane protein depletion"></PatentFamily><PatentFamily id="2839499" number="WO-2016067013" title="Method of synthesising adcs using affinity resins"></PatentFamily><PatentFamily id="2842547" number="WO-2015172708" title="Monoclonal antibody against human PrPc and use thereof"></PatentFamily><PatentFamily id="2857584" number="WO-2015000062" title="EGFR antibody conjugates"></PatentFamily><PatentFamily id="2857677" number="WO-2015001015" title="Actively transported and protease-resistant peptides as BBB shuttles and shuttle-cargo constructs"></PatentFamily><PatentFamily id="2869657" number="WO-2016089888" title="Antibodies to ADAM17 and uses thereof"></PatentFamily><PatentFamily id="2908916" number="WO-2015038755" title="Methods and compositions for treatment of &lt;i&gt;Chlamydial&lt;/i&gt; infection and related diseases and disorders"></PatentFamily><PatentFamily id="2913321" number="WO-2015048008" title="Binding molecules specific for HER3 and uses thereof"></PatentFamily><PatentFamily id="2921438" number="WO-2016082677" title="Proteinaceous heterodimer and use thereof"></PatentFamily><PatentFamily id="2927070" number="WO-2016074589" title="Kit for detecting drug resistance of cetuximab used for metastatic colorectal cancer treatment"></PatentFamily><PatentFamily id="2928892" number="WO-2015063244" title="Epithelial-mesenchymal transition in circulating tumor cells (CTCs) negatives for cytokeratin (CK) expression in patients with non-metastatic breast cancer"></PatentFamily><PatentFamily id="2940893" number="WO-2015077342" title="Detection of arginine methylation of EGFR for prediction of resistance to therapy"></PatentFamily><PatentFamily id="2949070" number="WO-2015081117" title="Therapeutic metal complexes"></PatentFamily><PatentFamily id="294934" number="WO-2008109105" title="Methods and compositions for improved therapeutic effects with siRNA"></PatentFamily><PatentFamily id="2949371" number="WO-2015078906" title="A method for predicting responsiveness to a treatment with an EGFR inhibitor"></PatentFamily><PatentFamily id="2956878" number="CN-104622794" title="A combined molecular targeted drugs and cytotoxic drugs of gel injection"></PatentFamily><PatentFamily id="2966749" number="WO-2015096982" title="Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP)"></PatentFamily><PatentFamily id="2970520" number="WO-2015103128" title="Methods for the detection of esophageal adenocarcinoma"></PatentFamily><PatentFamily id="2971097" number="JP-06320040" title="The treatment of the colon cancer by anti- prok1 antibody and anti- vegf antibody combined use"></PatentFamily><PatentFamily id="2974087" number="WO-2015103987" title="Compounds and compositions for treating HER2 positive tumors"></PatentFamily><PatentFamily id="2994733" number="US-09789214" title="Radiolabeled active targeting pharmaceutical composition and the use thereof"></PatentFamily><PatentFamily id="2996306" number="WO-2015123754" title="Methods to produce single glycoform antibodies"></PatentFamily><PatentFamily id="299680" number="WO-2011153488" title="Combination cancer therapies with wortmannin analogs"></PatentFamily><PatentFamily id="3024428" number="WO-2015134411" title="Bi-specific antibodies and uses thereof"></PatentFamily><PatentFamily id="3038459" number="WO-2015144184" title="Use of TIMP-1 as a biomarker in the EGF-receptor inhibitor treatment of metastatic colorectal cancer"></PatentFamily><PatentFamily id="3038465" number="WO-2015145388" title="Methods of treating colorectal cancers harboring upstream Wnt pathway mutations"></PatentFamily><PatentFamily id="3046741" number="US-20150283271" title="Method for mimicking human clinical trial by using non-human animals"></PatentFamily><PatentFamily id="3046884" number="US-09743646" title="Method of establishing isogenic multi-xenograft model and the use thereof"></PatentFamily><PatentFamily id="3049740" number="CZ-00028636" title="Kit for prediction of therapeutic response to cetuximab"></PatentFamily><PatentFamily id="3050843" number="WO-2015155998" title="Anti-HER3 antibody-drug conjugate"></PatentFamily><PatentFamily id="3050904" number="WO-2015157213" title="EGFR-targeted nanoparticles"></PatentFamily><PatentFamily id="3058173" number="WO-2015164594" title="Chimeric antigen receptors (CAR) for use in therapy and methods for making the same"></PatentFamily><PatentFamily id="3063080" number="WO-2015166288" title="Needle safety shield"></PatentFamily><PatentFamily id="3065629" number="WO-2015171907" title="Isotopic identification and tracing of biologic products"></PatentFamily><PatentFamily id="3065975" number="US-10022451" title="Encapsulated agents and methods of making and using thereof"></PatentFamily><PatentFamily id="3067260" number="WO-2015175705" title="Gene mutations and copy number alterations of EGFR, KRAS, and MET"></PatentFamily><PatentFamily id="3071370" number="WO-2015177266" title="Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists"></PatentFamily><PatentFamily id="3071521" number="WO-2015177349" title="Anti-EGFR conformational single domain antibodies and uses thereof"></PatentFamily><PatentFamily id="3091787" number="WO-2015189106" title="A method for monitoring the treatment of patients with tumors expressing EGFR"></PatentFamily><PatentFamily id="3102418" number="WO-2015197919" title="Antibody drug conjugates binding to high-mannose n-glycan"></PatentFamily><PatentFamily id="3102763" number="WO-2015197510" title="Near-infrared fluorogenic porphycene derivatives as fluorescent labels for photodiagnosis and phototherapeutic use"></PatentFamily><PatentFamily id="3103112" number="WO-2015198332" title="Compositions and methods for treating cancer"></PatentFamily><PatentFamily id="3105110" number="WO-2016000721" title="Identifying compounds modifying a cellular phenotype"></PatentFamily><PatentFamily id="3115917" number="WO-2016011167" title="Her3 inhibition in low-grade serous ovarian cancers"></PatentFamily><PatentFamily id="3120879" number="WO-2016011658" title="Combination therapy"></PatentFamily><PatentFamily id="3123398" number="WO-2016015788" title="Mutations in the extracellular domain III of epidermal growth factor receptor gene"></PatentFamily><PatentFamily id="3123860" number="WO-2016018087" title="Novel biomarker for predicting sensitivity to EGFR-targeting agent, and use thereof"></PatentFamily><PatentFamily id="3131732" number="WO-2016025641" title="Combinations of an ERK inhibitor and an EGFR inhibitor and related methods"></PatentFamily><PatentFamily id="3133238" number="CN-105315376" title="Single-chain antibody of collagen-specific binding, encoding gene and application thereof"></PatentFamily><PatentFamily id="3140281" number="US-20160058863" title="Low viscosity concentrated protein dispersions"></PatentFamily><PatentFamily id="3145915" number="WO-2016040622" title="Uses of anti-Her3 antibodies for treating cancer"></PatentFamily><PatentFamily id="3146210" number="WO-2016038609" title="Anti-HER3 antibodies and uses of same"></PatentFamily><PatentFamily id="3152484" number="WO-2016046365" title="A method for predicting responsiveness to a treatment with an EGFR inhibitor"></PatentFamily><PatentFamily id="3158329" number="WO-2017067188" title="Pharmaceutical composition and applications thereof"></PatentFamily><PatentFamily id="3160420" number="WO-2016054603" title="Multivalent meditopes, meditope-binding antibodies and uses thereof"></PatentFamily><PatentFamily id="3166600" number="WO-2016055380" title="Mutations in the epidermal growth factor receptor kinase domain"></PatentFamily><PatentFamily id="3170248" number="WO-2016060278" title="Method for estimating sensitivity to drug therapy for colorectal cancer"></PatentFamily><PatentFamily id="3170487" number="WO-2016058056" title="Novel imaging composition and uses thereof"></PatentFamily><PatentFamily id="3173724" number="WO-2016062851" title="Treatment of cancers using anti-nkg2a agents"></PatentFamily><PatentFamily id="3181241" number="WO-2016065456" title="EGFR antibody-based combination therapy"></PatentFamily><PatentFamily id="3181661" number="WO-2016069764" title="Methods for the rapid preparation of labeled glycosylamines and for the analysis of glycosylated biomolecules producing the same"></PatentFamily><PatentFamily id="3202065" number="WO-2016087648" title="Immunoglobulins with incorporated heterologous CH3 domains resulting in a prolonged half-life"></PatentFamily><PatentFamily id="3212316" number="WO-2016104794" title="Prediction of effect of EGFR inhibitor by detecting BRAF mutation"></PatentFamily><PatentFamily id="3236704" number="WO-2016112064" title="Response to EGFR blockade"></PatentFamily><PatentFamily id="3237298" number="US-20160201131" title="Method for identifying drug resistance related mutations"></PatentFamily><PatentFamily id="3268267" number="CN-105796594" title="Composition in the manufacture of a medicament for the treatment of cancer"></PatentFamily><PatentFamily id="3277958" number="WO-2016125169" title="Combinations of IRS/STAT3 dual modulators and anti-cancer agents for treating cancer"></PatentFamily><PatentFamily id="3313572" number="CN-105838778" title="Method of ddPCR technique monitoring colorectal cancer patient to panitumumab or cetuximab drug resistance"></PatentFamily><PatentFamily id="3318208" number="WO-2016135041" title="Fusion proteins and antibodies comprising thereof for promoting apoptosis"></PatentFamily><PatentFamily id="3353458" number="WO-2016140624" title="Cytotoxic HEXIM1 peptides and uses thereof"></PatentFamily><PatentFamily id="33816" number="WO-2007014335" title="Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer"></PatentFamily><PatentFamily id="3408548" number="WO-2016164843" title="Site-specific covalent chemical ligation to monoclonal and polyclonal immunoglobulin"></PatentFamily><PatentFamily id="3409094" number="WO-2012020065" title="Fab-glycosylated antibodies"></PatentFamily><PatentFamily id="3416918" number="WO-2016168634" title="Biomarkers related to treatment of cancer with HER3 and EGFR inhibitors"></PatentFamily><PatentFamily id="3427645" number="WO-2016171365" title="Fab fragment specifically binding to EGFR"></PatentFamily><PatentFamily id="343968" number="WO-2009099634" title="Picoplatin and amrubicin to treat lung cancer"></PatentFamily><PatentFamily id="3440520" number="WO-2016179399" title="High affinity CD47 analogs"></PatentFamily><PatentFamily id="3445386" number="WO-2016187158" title="Chimeric antigen receptor compositions"></PatentFamily><PatentFamily id="3459905" number="WO-2016191556" title="Liposomal nanoconstructs and methods of making and using the same"></PatentFamily><PatentFamily id="3470917" number="WO-2016192621" title="Tumor treatment method using full-length cetuximab expressed based on adenovirus carrier"></PatentFamily><PatentFamily id="3471218" number="WO-2016193955" title="Combinations of kinase inhibitors for treating colorectal cancer"></PatentFamily><PatentFamily id="3471812" number="WO-2016196682" title="β-1,6-glucan cetuximab antibody conjugates"></PatentFamily><PatentFamily id="3479641" number="US-20160363587" title="Magnetic nanoparticle conjugate and use thereof"></PatentFamily><PatentFamily id="3514262" number="CN-106267368" title="Cetuximab comprising collagen scaffold in application of preparing medicine for repairing spinal cord injury"></PatentFamily><PatentFamily id="3515529" number="CN-106265607" title="A method for pulmonary inhalation chitosan nano-polymeric particle and preparation method thereof"></PatentFamily><PatentFamily id="3522545" number="WO-2017012944" title="Method for individualized cancer therapy"></PatentFamily><PatentFamily id="3522596" number="WO-2017013129" title="Her2 binding proteins based on di-ubiquitin muteins"></PatentFamily><PatentFamily id="3522815" number="WO-2017014177" title="Method for evaluating health state and method for predicting long-term efficacy of anticancer agent"></PatentFamily><PatentFamily id="3522955" number="WO-2017015008" title="Her3 antibodies"></PatentFamily><PatentFamily id="3533561" number="WO-2017018474" title="Method for preparing core fucose-containing antibody"></PatentFamily><PatentFamily id="3534090" number="WO-2017023815" title="Bruton's tyrosine kinase inhibitor combinations and uses thereof"></PatentFamily><PatentFamily id="3536576" number="WO-2017021631" title="Ig1 and the therapeutic use thereof"></PatentFamily><PatentFamily id="35368" number="WO-2008095015" title="Method of treating recurrent tumors"></PatentFamily><PatentFamily id="3542084" number="WO-2017025179" title="A transglutamine tag for efficient site-specific bioconjugation"></PatentFamily><PatentFamily id="3555110" number="CN-106399582" title="A detection and colorectal cancer targeted medicine cetuximab treatment sensitivity related gene polymorphism kit and application thereof"></PatentFamily><PatentFamily id="3560574" number="US-10072065" title="Peptide-mediated delivery of immunoglobulins across the blood-brain barrier"></PatentFamily><PatentFamily id="3562842" number="WO-2017037634" title="TGF-β-receptor ectodomain fusion molecules and uses thereof"></PatentFamily><PatentFamily id="3577106" number="WO-2017048944" title="High-Z nanoparticles and the use thereof in radiation therapy"></PatentFamily><PatentFamily id="3579713" number="CN-106474483" title="Graphene oxide modified by cetuximab, preparation method and application"></PatentFamily><PatentFamily id="3595715" number="CN-106546676" title="Function of fibrin of modifying and open tubular column and application in the monoclonal antibody isomer separation"></PatentFamily><PatentFamily id="3600842" number="WO-2017066132" title="Synthetic antibody mimic peptides"></PatentFamily><PatentFamily id="3604950" number="WO-2017066664" title="Combination therapy including a raf inhibitor for the treatment of colorectal cancer"></PatentFamily><PatentFamily id="3605565" number="WO-2017070133" title="Intracellular delivery compounds"></PatentFamily><PatentFamily id="3611802" number="WO-2016038610" title="Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI)"></PatentFamily><PatentFamily id="3617718" number="EP-03165237" title="Antibody-drug conjugate (adc) and method for forming the same"></PatentFamily><PatentFamily id="3625861" number="WO-2017079283" title="Use of TLR-8 agonists to treat cancer"></PatentFamily><PatentFamily id="3683372" number="WO-2017100462" title="Treatment of cancer with dual targeting of CD47 and EGFR"></PatentFamily><PatentFamily id="3691582" number="WO-2017106462" title="Bispecific antibody platform"></PatentFamily><PatentFamily id="3718400" number="WO-2017118406" title="Anti-EGFR combinations for treating tumors"></PatentFamily><PatentFamily id="3719589" number="WO-2018215656" title="Protease and binding polypeptide for o-glycoproteins"></PatentFamily><PatentFamily id="3730797" number="CN-106913868" title="An immune liposome and its preparation method and application"></PatentFamily><PatentFamily id="3738134" number="WO-2017127703" title="Quantifying KRAS for optimal cancer therapy"></PatentFamily><PatentFamily id="374346" number="WO-2012007137" title="Peptide for use in the treatment of breast cancer and/or bone metastases"></PatentFamily><PatentFamily id="3749935" number="WO-2017136581" title="Anti-EGFR antibody drug conjugate"></PatentFamily><PatentFamily id="3749942" number="WO-2017136603" title="Cancer evolution detection and diagnostic"></PatentFamily><PatentFamily id="376411" number="WO-09640210" title="Antibody and antibody fragments for inhibiting the growth of tumors."></PatentFamily><PatentFamily id="3765121" number="WO-2017140845" title="Polypeptides for preparing drug conjugates capable of promoting apoptosis in a cell expressing an orexin receptor"></PatentFamily><PatentFamily id="3765484" number="WO-2017143026" title="Sortase-modified molecules and uses thereof"></PatentFamily><PatentFamily id="3767400" number="CN-107064513" title="A tumour diagnostic reagent kit"></PatentFamily><PatentFamily id="378400" number="WO-2011022335" title="Methods of using CD44 fusion proteins to treat cancer"></PatentFamily><PatentFamily id="3787094" number="WO-2017155281" title="Complex of adenovirus and PAMAM-PEG-Erbitux, and use thereof"></PatentFamily><PatentFamily id="3795077" number="WO-2017156594" title="Use of laminins as biomarkers for cancer diagnosis and prognosis"></PatentFamily><PatentFamily id="3795966" number="WO-2017161206" title="Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use"></PatentFamily><PatentFamily id="3799346" number="WO-2017162663" title="Prodrugs of cytotoxic active agents having enzymatically cleavable groups"></PatentFamily><PatentFamily id="3799375" number="WO-2017162733" title="IgA antibodies with enhanced stability"></PatentFamily><PatentFamily id="3808731" number="WO-2017170846" title="Pharmaceutical polymer micelle composition"></PatentFamily><PatentFamily id="381536" number="WO-2011064319" title="Pyrosequencing method for predicting the response of a patient towards anti-cancer treatment"></PatentFamily><PatentFamily id="3821065" number="WO-2017179660" title="MicroRNA-143 derivative"></PatentFamily><PatentFamily id="3828663" number="WO-2017183675" title="Method for preparing cell exhibiting drug resistance, method for screening anti-cancer drug, and anti-cancer drug screening kit"></PatentFamily><PatentFamily id="3829010" number="WO-2017185063" title="Polymorphisms toll like receptor genes predicts clinical outcomes of colorectal cancer patients"></PatentFamily><PatentFamily id="3834599" number="WO-2017186928" title="RNA encoding an antibody"></PatentFamily><PatentFamily id="3834608" number="WO-2017186950" title="Bispecific antibodies targeting EGFR and HER2"></PatentFamily><PatentFamily id="3835224" number="WO-2017189906" title="Immune-based treatment of &lt;i&gt;KRAS&lt;/i&gt;-variant cancer patients"></PatentFamily><PatentFamily id="3840919" number="WO-2017191759" title="Ophthalmic drug sustained release device"></PatentFamily><PatentFamily id="3841089" number="WO-2017192598" title="Pre-targeting strategies for molecular imaging and/or radioimmunotherapy"></PatentFamily><PatentFamily id="3841563" number="US-20170319723" title="Radioimmune complex, theranostic agent and kit"></PatentFamily><PatentFamily id="3851247" number="CN-107325184" title="A targeting EGFR and HER2 double specific antibody and its application"></PatentFamily><PatentFamily id="3855704" number="WO-2017200016" title="Therapeutic agent for lung cancer that has acquired egfr-tki resistance"></PatentFamily><PatentFamily id="3855912" number="WO-2017201089" title="Fluorochemical targeted therapies"></PatentFamily><PatentFamily id="3857858" number="WO-2018124538" title="Nano-liposomal carrier composition with complex inclusive of cas9 protein, kras gene expression-inhibiting guide RNA and cationic polymer loaded therein and therapeutic agent comprising same for colorectal cancer resistant to anticancer agent due to KRAS gene mutation"></PatentFamily><PatentFamily id="3863704" number="WO-2017205465" title="Antibodies and methods of making same"></PatentFamily><PatentFamily id="3874294" number="WO-2017210538" title="Pharmaceutical combinations"></PatentFamily><PatentFamily id="3887485" number="WO-2017217344" title="Molecular targeting drug bubble and method for manufacturing same"></PatentFamily><PatentFamily id="3887828" number="WO-2017218891" title="Site-specific crosslinking of antibodies"></PatentFamily><PatentFamily id="3894679" number="WO-2017220767" title="Preparation of &lt;sup&gt;212&lt;/sup&gt;Pb abeled monoclonal antibodies"></PatentFamily><PatentFamily id="3894979" number="WO-2017222310" title="Antibody-drug composite platform using bispecific antibody"></PatentFamily><PatentFamily id="3921114" number="WO-2018013673" title="Stabilizing excipients for therapeutic protein formulations"></PatentFamily><PatentFamily id="3927084" number="WO-2018017649" title="Use of antibody-coupled T-cell receptor (ACTR) with multiple anti-cancer antibodies in cancer treatment"></PatentFamily><PatentFamily id="3945258" number="WO-2018048063" title="Method for quantitatively measuring interaction between membrane proteins in living cells"></PatentFamily><PatentFamily id="3951013" number="WO-2018031734" title="Designer α1,6-fucosidase mutants enable direct core fucosylation of intact N-glycopeptides and N-glycoproteins"></PatentFamily><PatentFamily id="3957918" number="WO-2018034301" title="Combination drug of anti-epiregulin antibody and anti-EGFR antibody"></PatentFamily><PatentFamily id="3960362" number="CN-107670033" title="Antitumor drug compound and application thereof"></PatentFamily><PatentFamily id="3963415" number="WO-2018036403" title="Oligosaccharide linker and antibody-drug conjugate with site-specific linkage prepared using the oligosaccharide linker"></PatentFamily><PatentFamily id="3975164" number="WO-2018044540" title="Compositions and methods for detecting protein trafficking"></PatentFamily><PatentFamily id="4000812" number="WO-2015181805" title="Modified antigen binding polypeptide constructs and uses thereof"></PatentFamily><PatentFamily id="4003575" number="WO-2016041945" title="Neutralization of inhibitory pathways in lymphocytes"></PatentFamily><PatentFamily id="4004083" number="CN-107857817" title="Collagen specific binding ability of egfr antibody and application in spinal cord injury repair"></PatentFamily><PatentFamily id="4013669" number="WO-2015188157" title="Library of pH responsive polymers and nanoprobes thereof"></PatentFamily><PatentFamily id="402878" number="WO-2006045991" title="Method to predict whether a tumor will react to a chemotherapeutic treatment"></PatentFamily><PatentFamily id="4039790" number="WO-2018078143" title="Means and methods for determining efficacy of anti-EGFR inhibitors in colorectal cancer (CRC) therapy"></PatentFamily><PatentFamily id="4040104" number="WO-2018079859" title="Cell labeling method"></PatentFamily><PatentFamily id="4060981" number="US-20180140703" title="Tumor radiosensitization with antibody conjugates"></PatentFamily><PatentFamily id="4088204" number="WO-2018106645" title="Β-1,6-glucan therapeutic antibody conjugates"></PatentFamily><PatentFamily id="4095959" number="WO-2018112027" title="Antibody-drug conjugates and uses thereof"></PatentFamily><PatentFamily id="4104412" number="WO-2018114447" title="Method for functionalizing nanoparticles"></PatentFamily><PatentFamily id="4122297" number="WO-2018127916" title="A PD1-CD70 fusion protein and methods of use thereof"></PatentFamily><PatentFamily id="4122298" number="WO-2018127917" title="A PD1-41BBL fusion protein and methods of use thereof"></PatentFamily><PatentFamily id="4122299" number="WO-2018127918" title="A SIRPα-CD70 fusion protein and methods of use thereof"></PatentFamily><PatentFamily id="4122300" number="WO-2018127919" title="A SIRP1α-41BBL fusion protein and methods of use thereof"></PatentFamily><PatentFamily id="4126298" number="WO-2018131705" title="Method of detecting somatic mutations in tumor marker genes, and tumor status evaluation method"></PatentFamily><PatentFamily id="4137438" number="WO-2018138113" title="Anti-cancer treatments with an anti-MUC1 antibody and an ErbB inhibitor"></PatentFamily><PatentFamily id="4146196" number="WO-2018148489" title="Analyte detection immunoassay"></PatentFamily><PatentFamily id="41688" number="WO-2009050143" title="Combinations of (1R,2R,3S,4S)-N4-(3-aminocarbonylbicyclo[2.2.1]hept-5-ene-2-yl)-5-fluoro-N2-[(3-methyl-4-(4-methylpiperazin-1-yl]phenyl-2,4-pyrimidineamine"></PatentFamily><PatentFamily id="4171861" number="WO-2018156815" title="Therapeutic compositions and related methods for photoimmunotherapy"></PatentFamily><PatentFamily id="418343" number="WO-2009136352" title="Anti-angiogenic compounds"></PatentFamily><PatentFamily id="4183651" number="WO-2018160675" title="Methods for diagnosing, prognosing, and treating colorectal cancer using biomarker expression"></PatentFamily><PatentFamily id="4183739" number="WO-2018160987" title="MAP kinase pathway targets for the treatment of Marfan syndrome"></PatentFamily><PatentFamily id="4200053" number="WO-2018166542" title="Method for the treatment of patients with carcinomas"></PatentFamily><PatentFamily id="4200362" number="WO-2018167847" title="Method for simultaneous quantification of monoclonal antibody"></PatentFamily><PatentFamily id="421199" number="WO-2010101916" title="Methods for predicting cancer response to EGFR inhibitors"></PatentFamily><PatentFamily id="4218063" number="WO-2018177325" title="System and method for determining cetuximab sensitivity on gastric cancer"></PatentFamily><PatentFamily id="4218195" number="WO-2018178060" title="HDAC inhibitors-based antibody drug conjugates (ADCs) and use in therapy"></PatentFamily><PatentFamily id="4218732" number="WO-2018181276" title="Human tissue stem cell and use thereof"></PatentFamily><PatentFamily id="4218850" number="WO-2018181863" title="Method for evaluating multiple different genes of interest"></PatentFamily><PatentFamily id="4219769" number="US-20180280423" title="Compositions and methods for combating drug-resistant cancers"></PatentFamily><PatentFamily id="4220654" number="WO-2018196581" title="Dihydroartemisinin-steroid conjugate and preparation method and use thereof"></PatentFamily><PatentFamily id="4224762" number="CN-108588201" title="Method and device for detecting cetuximab resistance-resistant trace DNA mutation in colorectal cancer"></PatentFamily><PatentFamily id="4261908" number="WO-2018209208" title="Anti-EGFR/high affinity NK-cells compositions and methods for chordoma treatment"></PatentFamily><PatentFamily id="4275414" number="WO-2018211517" title="High concentration protein formulations with reduced viscosity"></PatentFamily><PatentFamily id="4280588" number="CN-108795868" title="A human colorectal cancer cetuximab resistant cell strain and application thereof"></PatentFamily><PatentFamily id="4286764" number="WO-2018218097" title="Glucose oxidase-nanoparticle bioconjugates for cancer treatment and uses thereof"></PatentFamily><PatentFamily id="429620" number="WO-2011022472" title="Methods and compositions for the treatment of proliferative and pathogenic diseases"></PatentFamily><PatentFamily id="429665" number="WO-2005051355" title="Solid forms of anti-EGFR-antibodies"></PatentFamily><PatentFamily id="4299213" number="WO-2019034177" title="Antibody drug conjugate having two different drugs"></PatentFamily><PatentFamily id="4303946" number="WO-2018226897" title="Expression of novel cell tags"></PatentFamily><PatentFamily id="4304115" number="WO-2018231762" title="Systems and methods for identifying cancer treatments from normalized biomarker scores"></PatentFamily><PatentFamily id="4312783" number="WO-2018228464" title="Tumour-targeted nanocapsule, preparation method therefor and use thereof"></PatentFamily><PatentFamily id="4313546" number="WO-2018232164" title="Antibody drug conjugates that bind LGR5"></PatentFamily><PatentFamily id="4321466" number="WO-2018236065" title="Marker for predicting therapeutic response of anticancer agent in colorectal cancer patient"></PatentFamily><PatentFamily id="4328961" number="WO-2019004799" title="Conjugate of VEGF-grab protein and drug, and use thereof"></PatentFamily><PatentFamily id="4379738" number="WO-2019023347" title="Anti-SIRP-α antibodies and related methods"></PatentFamily><PatentFamily id="4379753" number="WO-2019023396" title="Enhanced chimeric antigen receptors and use thereof"></PatentFamily><PatentFamily id="4382832" number="CN-109260470" title="Application of natural killer t cell combined with cetuximab in preparing antitumor drug"></PatentFamily><PatentFamily id="4388758" number="WO-2019028191" title="Systems and methods for performing a real-time glycan assay of a sample"></PatentFamily><PatentFamily id="4390959" number="WO-2019030156" title="Fc binding proteins with cysteine in the C-terminal helical region"></PatentFamily><PatentFamily id="4398179" number="WO-2019036619" title="Stabilizing excipients for therapeutic protein formulations"></PatentFamily><PatentFamily id="4435077" number="EP-03457139" title="Antibody-like peptides for quantifying therapeutic antibodies"></PatentFamily><PatentFamily id="4455502" number="WO-2019066621" title="Composition for detecting Ras/BRAF mutations, and kit comprising same"></PatentFamily><PatentFamily id="445907" number="WO-2011053779" title="Methods for treating cancer in patients having IGF-1R inhibitor resistance"></PatentFamily><PatentFamily id="4461436" number="WO-2019068756" title="Cysteine engineered antigen-binding molecules"></PatentFamily><PatentFamily id="4461895" number="WO-2019070856" title="Modified epidermal growth factor receptor peptides for use in genetically-modified cells"></PatentFamily><PatentFamily id="4495968" number="WO-2019088348" title="EGFR inhibitor-resistant cancer treatment agent"></PatentFamily><PatentFamily id="4496416" number="WO-2019090284" title="Methods and materials for identifying and treating cancers having elevated levels of phosphorylated ubiquitin"></PatentFamily><PatentFamily id="4505357" number="WO-2019090424" title="Antibody glycoconjugates and methods of production and use"></PatentFamily><PatentFamily id="451583" number="WO-2012044167" title="Methods and means for typing a sample comprising cancer cells based on oncogenic signal transduction pathways"></PatentFamily><PatentFamily id="4516064" number="WO-2019100005" title="Product and process for employing GC7 (N1-guanyl-1,7-diaminoheptane) based antigen binding conjugates in cancer therapy"></PatentFamily><PatentFamily id="4516081" number="WO-2019100052" title="CD137 antibodies and tumor antigen-targeting antibodies and uses thereof"></PatentFamily><PatentFamily id="4537733" number="WO-2019107962" title="Method for conjugating antibody and physiologically active substance"></PatentFamily><PatentFamily id="4542150" number="WO-2019109188" title="Acyl hydrazone linkers, methods and uses thereof"></PatentFamily><PatentFamily id="4542550" number="WO-2019111998" title="Cancer spheroid production method and method for selecting colon cancer patients"></PatentFamily><PatentFamily id="454437" number="WO-2012125573" title="Use of inhibitors of EGFR-family receptors in the treatment of hormone refractory breast cancers"></PatentFamily><PatentFamily id="455333" number="WO-2012076688" title="Combination comprising a derivative of the family of the combretastatins and cetuximab"></PatentFamily><PatentFamily id="4562794" number="WO-2019126565" title="Lipid derivatives for &lt;i&gt;in vitro or in vivo&lt;/i&gt; delivery"></PatentFamily><PatentFamily id="4563319" number="US-20190192701" title="Method for tumor-targeting treatment and diagnosis, conjugates used for the same, and preparation method thereof"></PatentFamily><PatentFamily id="480610" number="WO-2009015233" title="Gefitinib sensitivity-related gene expression and products and methods related thereto"></PatentFamily><PatentFamily id="494324" number="WO-2004085474" title="Method of producing an antibody to epidermal growth factor receptor"></PatentFamily><PatentFamily id="504172" number="WO-2009126834" title="Combination of HGF inhibitor and EGF inhibitor to treat cancer"></PatentFamily><PatentFamily id="51601" number="WO-2009070328" title="Modulators of the epidermal growth factor receptor (EGFR) pathway for use in the treatment or prevention of substance abuse"></PatentFamily><PatentFamily id="516490" number="WO-2009156584" title="Assessing risk of metastases and/or ddfs of patients with neoplasms, screening of patients responding to cancer therapy and such therapy"></PatentFamily><PatentFamily id="526890" number="WO-2010103056" title="Improvement of tumor treatment"></PatentFamily><PatentFamily id="527893" number="WO-2012136829" title="Novel combination treatment of cancer"></PatentFamily><PatentFamily id="574108" number="WO-2009062199" title="EGFR/NEDD9/TGF-β lnteractome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders"></PatentFamily><PatentFamily id="585358" number="CN-101077335" title="Anticancer composition containing tyrosine kinase inhibitor"></PatentFamily><PatentFamily id="591705" number="WO-2009006301" title="Protein stabilization"></PatentFamily><PatentFamily id="592608" number="WO-2010145796" title="Biomarkers and methods for determining efficacy of anti-EFGR antibodies in cancer therapy"></PatentFamily><PatentFamily id="594145" number="WO-2010043050" title="Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab"></PatentFamily><PatentFamily id="603306" number="US-20120252748" title="Methods and compositions for determining the responsiveness of cancer therapeutics"></PatentFamily><PatentFamily id="623225" number="WO-2010124236" title="Polymorphism in K-ras 3' untranslated region associated with clinical outcomes of cancer treatments independent of K-ras mutation status"></PatentFamily><PatentFamily id="644824" number="WO-2004032961" title="Bispecific anti-Erb-B antibodies and their use in tumor therapy"></PatentFamily><PatentFamily id="658514" number="WO-2008148546" title="Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a NIR fluorescence label"></PatentFamily><PatentFamily id="670891" number="WO-2012071648" title="EGFR antagonist for the treatment of heart disease"></PatentFamily><PatentFamily id="696151" number="WO-2011031840" title="Methods and compositions for the treatment of receptor tyrosine kinase mediated diseases or disorders"></PatentFamily><PatentFamily id="697819" number="WO-2006009694" title="Crystal of EGFR extracellular domain and cetuximab fab fragment and uses thereof"></PatentFamily><PatentFamily id="744127" number="US-09193791" title="Development of masked therapeutic antibodies to limit off-target effects"></PatentFamily><PatentFamily id="747019" number="WO-2012024659" title="Antibody-based constructs directed against tyrosine kinase receptors"></PatentFamily><PatentFamily id="75839" number="WO-2011119553" title="Materials and methods related to modulation of mismatch repair and genomic stability by miR-155"></PatentFamily><PatentFamily id="75906" number="WO-2012033953" title="Methods for assessing and identifying or evolving conditionally active therapeutic proteins"></PatentFamily><PatentFamily id="771092" number="WO-2005049829" title="Process"></PatentFamily><PatentFamily id="771253" number="WO-2005075003" title="Implantable medical devices for treating or preventing restenosis"></PatentFamily><PatentFamily id="77712" number="WO-2011015921" title="Highly efficient process of purification and production of recombinant cetuximab"></PatentFamily><PatentFamily id="779089" number="WO-2009044273" title="Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response"></PatentFamily><PatentFamily id="79749" number="WO-2011146405" title="EGF +61G/A and TS 5'UTR 2R/3R polymorphisms predict clinical outcomes in cancer patients undergoing anti-EGFR therapy"></PatentFamily><PatentFamily id="807630" number="WO-2007023307" title="Combinations comprising dmxaa for the treatment of cancer"></PatentFamily><PatentFamily id="816131" number="WO-2010022017" title="Method and composition for enhancing hematopoietic stem cell mobilization"></PatentFamily><PatentFamily id="81748" number="WO-2012009425" title="In vitro pharmacokinetics/pharmacodynamics bellows perfusion system for enhancing effectiveness of cancer chemotherapy"></PatentFamily><PatentFamily id="829200" number="US-04943533" title="Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor"></PatentFamily><PatentFamily id="848252" number="WO-2007070784" title="Fluorescent detection of cancer and fluorescent guided surgical removal"></PatentFamily><PatentFamily id="873105" number="WO-2007013950" title="Combination therapy of HER expressing tumors"></PatentFamily><PatentFamily id="890229" number="WO-2009140542" title="Biomarkers for the identification, monitoring, and treatment of head and neck cancer"></PatentFamily><PatentFamily id="891678" number="WO-2012028703" title="Method for the prognosis of the progression of cancer"></PatentFamily><PatentFamily id="922750" number="WO-2007128557" title="Combination of an anti-EDB fibronectin domain antibody L19-SIP and an anti-EGFR antibody"></PatentFamily><PatentFamily id="945078" number="WO-2010039248" title="Methods for the treatment of cancer"></PatentFamily><PatentFamily id="950206" number="WO-2004030625" title="Synergistic methods and compositions for treating cancer"></PatentFamily><PatentFamily id="951733" number="WO-2005113018" title="Cancer treatment using viruses and camptothecins"></PatentFamily><PatentFamily id="968986" number="WO-2010120506" title="Combination treatment of cancer with cetuximab and tetrac"></PatentFamily><PatentFamily id="972981" number="WO-2012082841" title="Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer"></PatentFamily><PatentFamily id="973627" number="US-04663281" title="Enhanced Production Of Proteinaceous Materials In Eucaryotic Cells"></PatentFamily><PatentFamily id="985919" number="WO-00069459" title="Treatment of refractory human tumors with epidermal growth factor receptor antagonists"></PatentFamily><PatentFamily id="993156" number="WO-2005058365" title="Pharmaceutical preparation containing an antibody for the EGF receptor"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="1">Analyte</Type><Count>6</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>10</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="2">Drug Target</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>131</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="4">Delivery device</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>112</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>154</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>39</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sharp KK" id="1002418"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Agilent Technologies Inc" id="1002429"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Avesthagen Ltd" id="1002448"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="National Yang Ming University" id="1002709"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hospital Vall D'Hebron" id="1003065"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Laboratory Corporation of America Holdings" id="1003399"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Receptor BioLogix Inc" id="1003710"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Genomic Health Inc" id="1003812"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universitat de Barcelona" id="1003992"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shizuoka Prefectural Government" id="1004082"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="OncoTherapy Science Inc" id="1004292"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="London Health Sciences Centre Research Inc" id="1004826"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Biogen Inc" id="1005244"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tsinghua University" id="1005253"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="IntegraGen" id="1005525"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Genovis AB" id="1006059"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universitat Ramon Llull" id="1006144"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Alabama" id="1006257"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nippon Medical School Foundation" id="1006387"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Agency For Science Technology &amp; Research" id="1006569"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Qilu Pharmaceutical Co Ltd" id="1006577"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nanjing University" id="1007090"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Glycotope GmbH" id="1007207"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jazz Pharmaceuticals plc" id="1007377"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Aix-Marseille Université" id="1007956"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Peking University" id="1009044"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universität zu Köln" id="1009493"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universite Francois Rabelais de Tours" id="1009897"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Institute Of Nuclear Energy Research Taiwan Roc" id="1010559"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Halozyme Therapeutics Inc" id="1010825"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Akela Pharma Inc" id="1011141"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universitat fur Bodenkultur Wien" id="1012927"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tunghai University" id="1013139"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ordway Research Institute" id="1013222"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Glykos Finland Oy" id="1013782"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Translational Genomics Research Institute" id="1013832"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="NantKwest Inc" id="1015036"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Medical University of Vienna" id="1015721"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Fukui" id="1016096"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Flagship Ventures" id="1016494"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Precision Therapeutics Inc" id="1016810"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Daiichi Sankyo Co Ltd" id="1017506"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Fukuoka University" id="1017688"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Galaxy Biotech LLC" id="1017833"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Symyx Technologies Inc" id="1017945"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novelix Pharmaceuticals Inc" id="1018290"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Formurex Inc" id="1020445"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="BIOalternatives" id="1021508"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Intec Pharma Ltd" id="1021548"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Intrexon Corp" id="1021778"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Masaryk University" id="1022154"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nagoya City University" id="1022846"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Protgen Ltd" id="1024338"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="West Penn Allegheny Health System Inc" id="1026278"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="VentiRx Pharmaceuticals Inc" id="1031136"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Arrowhead Pharmaceuticals Inc" id="1031474"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Adocia SAS" id="1031509"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Precision BioSciences Inc" id="1032090"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="SpeciGen Inc" id="1032372"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Thermo Fisher Scientific Inc" id="1032764"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Korea Institute of Radiological and Medical Sciences" id="1032959"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Central South University" id="1033512"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sea Lane Biotechnologies LLC" id="1034967"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Biodesix Inc" id="1035096"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sirnaomics Inc" id="1036675"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shin-il Pharmaceutical Co Ltd" id="1036998"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Piramal Phytocare Ltd" id="1037717"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Adam Mickiewicz University" id="1037762"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Agendia BV" id="1038503"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zymeworks Inc" id="1038924"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="KAHR Medical Ltd" id="1039221"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Signature Diagnostics Ag" id="1039809"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="The DNA Repair Company" id="1039937"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ifo-Regina Elena Cancer Institute" id="1041458"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Beckman Research Institute" id="1041736"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>3</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes" id="1041755"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ontario Institute for Cancer Research" id="1042038"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Copenhagen Hospital Corp" id="1042412"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Medical University of Graz" id="1042520"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Institut Regional Du Cancer De Montpellier" id="1043305"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Adimab LLC" id="1043519"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sankara Nethralaya" id="1044084"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="2cureX" id="1045589"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="CytomX Therapeutics Inc" id="1045603"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis" id="1046025"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cancer Genetics Inc" id="1047178"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="biOasis Technologies Inc" id="1047492"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Waters Technologies Corp" id="1047801"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Oncoceutics Inc" id="1048147"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sorrento Therapeutics Inc" id="1048574"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="WntResearch AB" id="1048731"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nanoparticle Biochem Inc" id="1049532"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Asan Foundation" id="1049605"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="ImmuneXcite Inc" id="1050535"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sesen Bio Inc" id="1052472"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Wellstat Management Company LLC" id="1052587"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Aueon Inc" id="1052875"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hainan Honz Pharmaceutical Co Ltd" id="1053496"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Institut Municipal D'Investigació Mèdica (Imim)" id="1053701"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tegopharm Corp" id="1055310"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Trackfive Diagnostics Inc" id="1056694"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Eddingpharm Inc" id="1056888"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Servicio Andaluz De Salud" id="1058089"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Institute for Research in Biomedicine Barcelona" id="1059628"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bio-Bedst Aps" id="1061133"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jiangsu Cancer Hospital" id="1061241"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="EPO Experimentelle Pharmakologie &amp; Onkologie Berlin-Buch Gmbh" id="1061572"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Rakuten Medical Inc" id="1063426"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="MultiVir Inc" id="1063558"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Isofol Medical AB" id="1063821"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="South China Normal University" id="1064262"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kitov Pharmaceuticals Ltd" id="1064310"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hospital District Of Southwest Finland" id="1064697"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dunne Consultancy Services Ltd" id="1065747"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chinese Academy of Medical Sciences &amp; Peking Union Medical College" id="1066199"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai Biotecan Pharmaceuticals Co Ltd" id="1066487"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sciencons Ltd" id="1067098"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mtm Research Llc" id="1067276"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alacris Theranostics Gmbh" id="1067409"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Algenics" id="1067859"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of the Pacific" id="1068350"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Abpro Inc" id="1069081"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Promise Advanced Proteomics" id="1069083"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sichuan Baili Pharmaceutical Co Ltd" id="1069227"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cure Cancer Worldwide Corp" id="1070859"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Echogen Inc" id="1071611"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AbbVie Inc" id="1072507"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tianjin University of Traditional Chinese Medicine" id="1073035"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chemo-Enhanced Llc" id="1073896"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lipotarg GmbH" id="1073913"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang Provincial People's Hospital" id="1074063"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jinan Kytril Medical Science and Technology Co Ltd" id="1074133"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="ADC Biotechnology Ltd" id="1074186"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dingfu Biotarget Co Ltd" id="1075462"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sykehuset Sorlandet Hf" id="1077343"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Region Southern Denmark" id="1077790"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Forbius" id="1078063"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Weill Cornell Medical College, USA" id="1084617"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Istituto di Ricovero e Cura a Carattere Scientico" id="1084821"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Fondazione del Piemonte per l'Oncologia [FPO]" id="1085743"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dragonfly Sciences Ltd" id="1086182"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Meditope Biosciences Inc" id="1086605"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Anhui University" id="1086889"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mosaic Biosciences Inc" id="1086971"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="National University Health System" id="1087042"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Array Bridge Inc" id="1088261"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Weifang Medical University" id="1089229"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="TOMA Biosciences Inc" id="1089898"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="SynAffix BV" id="1090283"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Celcuity LLC" id="1091022"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Guardant Health Inc" id="1093870"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Medtronic plc" id="1097361"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Iso Istituto Superiore Di Oncologia" id="1097684"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Medeina Cell Technologies" id="1097856"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="NanoPharmaceuticals LLC" id="1101432"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="MiraKind" id="1101462"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Donglongmai (Shanghai) Health Management Service Co Ltd" id="1101749"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="IQVIA Holdings Inc" id="1101929"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Unum Therapeutics Inc" id="1101952"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Gencurix Inc" id="1101980"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Centre Scientifique de Monaco" id="1103204"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="NantWorks LLC" id="1103920"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="NantOmics LLC" id="1104426"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Symic Biomedical Inc" id="1104536"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Excelse Bio" id="1109149"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Compass Therapeutics LLC" id="1111234"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Corvus Pharmaceuticals Inc" id="1112757"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="OncoResponse Inc" id="1114689"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="BIOMUNEX Pharmaceuticals" id="1114963"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Fundació Institut Mar D’Investigacions Mèdiques  (Imim)" id="1117253"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="ReForm Biologics LLC" id="1117633"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hunan Jingfeng Pharmaceutical Co Ltd" id="1119640"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Forty Seven Inc" id="1120033"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Seven and Eight Biopharmaceuticals Inc" id="1120662"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Beijing Tongjian Regeneration Medicine Technology Co Ltd" id="1121797"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Miradx" id="1125402"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="G&amp;G Science Co Ltd" id="1126031"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nature's Fingerprint Authentication" id="1126541"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Akriveia Therapeutics LLC" id="1131227"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sonocore Inc" id="1131300"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Precipio Diagnostics LLC" id="1131345"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cambridge Healthtech Institute" id="1131859"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="UV-Cap GmbH &amp; Co KG" id="1143306"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alliance Medical Group" id="1148001"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Wellmarker Bio Co Ltd" id="1150555"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nanoview Diagnostics Inc" id="1152154"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alfasigma SpA" id="1153354"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tianjin Nanuo Bio-Technology Co Ltd" id="1153562"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pierian Holdings Inc" id="1154893"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bostongene LLC" id="1155159"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bhami's Research Laboratory Pvt Ltd" id="1156261"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Moogene Medi Co Ltd" id="1157840"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shandong Xinchuang Biotechnology Co Ltd" id="1158005"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Washington University School of Medicine, US" id="1160134"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bloom Science Inc" id="1165307"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Innate Biotherapeutics LLC" id="1166032"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="CER Group" id="1167674"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Logone Bio Convergence Research Foundation" id="1172878"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Abenex" id="1183089"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Akrevia Therapeutics LLC" id="1183789"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kyo Diagnostics KK" id="1188328"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Abbott Laboratories" id="13601"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Amgen Inc" id="14109"></CompanyLink><CountAsOwner>6</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>8</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chinese Academy of Medical Military Sciences" id="14168"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AstraZeneca plc" id="14190"></CompanyLink><CountAsOwner>5</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Antisoma plc" id="14239"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Battelle" id="14405"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bayer AG" id="14455"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Boehringer Ingelheim International GmbH" id="14881"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ecole Polytechnique Federale de Lausanne" id="14901"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bristol-Myers Squibb Co" id="15065"></CompanyLink><CountAsOwner>10</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>11</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Celgene Corp" id="15331"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Weizmann Institute of Science" id="15489"></CompanyLink><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Baylor University" id="15500"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Centre National de la Recherche Scientifique (CNRS)" id="15511"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Consiglio Nazionale delle Ricerche" id="15534"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Development Center for Biotechnology" id="15669"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Eisai Co Ltd" id="15872"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Fred Hutchinson Cancer Research Center" id="16218"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Fushimi Pharmaceutical Co Ltd" id="16259"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Gilead Sciences Inc" id="16450"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Gifu University" id="16831"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Industrial Technology Research Institute" id="17218"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="INSERM" id="17229"></CompanyLink><CountAsOwner>9</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>9</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Institut Pasteur" id="17237"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johnson &amp; Johnson" id="17332"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="La Jolla Institute of Allergy &amp; Immunology" id="17747"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Eli Lilly &amp; Co" id="17810"></CompanyLink><CountAsOwner>15</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>16</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Max-Planck Gesellschaft Zur Förderung Der Wissenschaften Ev" id="17962"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck &amp; Co Inc" id="18077"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck KGaA" id="18101"></CompanyLink><CountAsOwner>18</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>18</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Massachusetts Institute of Technology" id="18225"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Medical Research Council" id="18438"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mylan NV" id="18439"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Myriad Genetics Inc" id="18440"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Poniard Pharmaceuticals Inc" id="18472"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nestle SA" id="18477"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="National Research Council of Canada" id="18632"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pall Corp" id="18732"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pfizer Inc" id="18767"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Promega Corp" id="19157"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="PDL BioPharma Inc" id="19162"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Regeneron Pharmaceuticals Inc" id="19214"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Repligen Corp" id="19220"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="RIKEN" id="19442"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Roche Holding AG" id="19446"></CompanyLink><CountAsOwner>14</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>15</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shimadzu Corp" id="19888"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shionogi &amp; Co Ltd" id="19898"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Takeda Pharmaceutical Co Ltd" id="20300"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Toppan Insatsu KK" id="20405"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="UCB SA" id="20452"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="US Government" id="20516"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Arizona" id="20527"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bar-Ilan University" id="20531"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="The University of Birmingham" id="20537"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of California" id="20547"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>7</CountAsThirdParty><CountTotal>10</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="City of Hope" id="20558"></CompanyLink><CountAsOwner>7</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>7</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dartmouth College" id="20565"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Emory University" id="20573"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Georgia" id="20579"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Harvard University" id="20584"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johns Hopkins University" id="20596"></CompanyLink><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Kansas" id="20597"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Kentucky" id="20600"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Maryland" id="20611"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Manitoba" id="20614"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="McGill University" id="20617"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Melbourne" id="20620"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Montpellier" id="20630"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mount Sinai School of Medicine" id="20631"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of New Mexico" id="20639"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universite de Nice Sophia Antipolis" id="20644"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="New York University" id="20646"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ohio State University" id="20649"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Pennsylvania" id="20658"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Pittsburgh" id="20659"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Southern California" id="20673"></CompanyLink><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Seoul National University" id="20676"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Stanford University" id="20679"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Thomas Jefferson University" id="20685"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>3</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Tokyo" id="20686"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universiteit Utrecht" id="20692"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Vanderbilt University" id="20693"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Virginia" id="20695"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Wake Forest University" id="20699"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Washington" id="20701"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Yale University" id="20703"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Yeshiva University" id="20704"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="XOMA Corp" id="20954"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="California Institute of Technology" id="21070"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Institute of Cancer Research UK" id="21072"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Institut Gustave Roussy" id="21081"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Howard Hughes Medical Institute" id="21084"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ludwig Institute for Cancer Research" id="21091"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Scripps Research Institute" id="21102"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mayo Clinic Foundation" id="21111"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Fox Chase Cancer Center" id="21112"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>37</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>37</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Louisville" id="21246"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Rice University" id="21247"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universite Paris Sud XI" id="21281"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Valtion Teknillinen Tutkimuskeskus" id="21454"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Turin" id="21709"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Texas System" id="21864"></CompanyLink><CountAsOwner>6</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>8</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Qiagen NV" id="21996"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Oregon Health Sciences University" id="22708"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universita di Bologna" id="22726"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Institut Curie" id="22740"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Georgetown University" id="22821"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Japanese Foundation For Cancer Research" id="23138"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Texas A&amp;M University System" id="23290"></CompanyLink><CountAsOwner>7</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>7</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cardiff University" id="23495"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Griffith University" id="23770"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Deutsches Krebsforschungszentrum" id="23844"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chinese Academy of Sciences" id="23863"></CompanyLink><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Assistance Publique Hopitaux de Paris" id="23948"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Albany Medical College" id="24139"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Keio University" id="24183"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Boston Children's Hospital" id="24334"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kaohsiung Medical University" id="24415"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Koebenhavns Universitet" id="24588"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Harvard Medical School" id="24839"></CompanyLink><CountAsOwner>6</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>8</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tohoku University" id="25025"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pohang University of Science &amp; Technology" id="25083"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Korea Research Institute of Bioscience and Biotechnology" id="25145"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Palermo" id="25176"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Basel" id="25177"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ajou University" id="25185"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Lund" id="25208"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pennsylvania State University" id="25251"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Japanese National Cancer Center" id="25425"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Odense University" id="25449"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Granada" id="25460"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Colorado System" id="25520"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kennedy Krieger Institute" id="25533"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Korea Advanced Institute of Science and Technology" id="25540"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Seattle Genetics Inc" id="25554"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kyushu University" id="25556"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Splash Pharmaceuticals Inc" id="25616"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cincinnati Children's Hospital Medical Center" id="25631"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Celldex Therapeutics Inc" id="25726"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Namur" id="25794"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universite Denis Diderot" id="25808"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Array BioPharma Inc" id="25902"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Centre Hospitalier Universitaire Vaudois" id="25992"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Georgia Institute of Technology" id="26046"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Genmab A/S" id="26469"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hanyang University" id="26824"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Queens University of Belfast" id="27130"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Xencor Inc" id="27617"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merrimack Pharmaceuticals Inc" id="27954"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Samsung Electronics Co Ltd" id="28039"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Heidelberg" id="28348"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="GlaxoSmithKline plc" id="28355"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Academia Sinica" id="28429"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alchemia Ltd" id="28430"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Symphogen A/S" id="28600"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Graffinity Pharmaceuticals AG" id="28668"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Biocon Ltd" id="28769"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Innate Pharma SA" id="28788"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Microbiotix Inc" id="28907"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Affitech A/S" id="28936"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Philogen SpA" id="29032"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="NanoCarrier Co Ltd" id="29050"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bionomics Ltd" id="29256"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Immuno Research" id="29406"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="The Center of Molecular Immunology" id="29496"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Immutep Ltd" id="29539"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Samsung Life Public Welfare Foundation" id="29568"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Vaccinex Inc" id="29595"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Infinity Pharmaceuticals Inc" id="29753"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universite de Bordeaux" id="29872"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="l’Universite Paris Descartes" id="30170"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Clayton Foundation For Research" id="30619"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="VU University Medical Center" id="30810"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nanospectra Biosciences Inc" id="31210"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="The Noguchi Institute" id="31402"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="CureVac GmbH" id="31507"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="SomaLogic Inc" id="CM27979"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="JSR Corp" id="CM28169"></CompanyLink><CountAsOwner>5</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Arkray Inc" id="CM28186"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Texas Children's Hospital" id="DOL1000129"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Southern Denmark" id="DOL1000153"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="European Security Partnership" id="DOL1000355"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Quest Diagnostics Inc" id="DOL1000590"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput>